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Abstract
B Cells at the Interface of Innate and Adaptive Immunity 
in Systemic Lupus Erythematosus:
Requirements for the Activation of Autoreactive B Cells 
in Autoimmune Disease 
Sean Ryan Christensen 
2005
Systemic autoimmune disease is characterized by loss of immunologic tolerance 
to a restricted set of self-nuclear antigens. These macromolecular complexes can be 
grouped into two categories: DNA-containing autoantigens such as chromatin, and RNA- 
containing autoantigens such as Smith antigen (Sm) and related ribonucleoprotein 
complexes. Elucidating the mechanism for selective targeting of these molecules in 
systemic lupus erythematosus (SLE) may provide clues to the etiology of disease. We 
hypothesized that Toll-like receptors (TLRs), germline-encoded pattern-recognition 
receptors of the innate immune system, could dictate target antigen specificity in SLE. 
Using genetic ablation of various TLRs in murine models of SLE, we have demonstrated 
that TLRs are critical for directing the autoimmune response against canonical nuclear 
autoantigens.
In the absence of TLR9, a receptor for CpG sequence motifs in DNA, the 
generation of autoantibodies to DNA-containing antigens was specifically inhibited. 
Other autoantibodies specific for RNA-containing antigens were maintained or even 
increased in TLR9-deficient autoimmune mice. We then investigated whether TLR3, a
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receptor for double-stranded RNA, orTLR7, a receptor for single-stranded RNA, were 
required for the generation of autoantibodies to RNA-containing antigens. While TLR3 
did not appear to affect autoantibody production, the absence of TLR7 led to a reduction 
in anti-ribonucleoprotein antibodies. Genetic deletion of these receptors also had 
dramatic, but opposing, effects on disease progression. TLR9-deficient mice developed 
exacerbated disease and systemic inflammation with accelerated mortality, while TLR7- 
deficient mice had ameliorated clinical disease and decreased immune activation. A 
critical component of disease pathogenesis in these mice appeared to be the activation of 
type I interferon-producing plasmacytoid dendritic cells (pDCs), which was increased in 
the absence of TLR9, but decreased in the absence of TLR7.
Further studies on the mechanism of autoantibody production and pDC activation 
revealed that TLR9 expression within B cells was required for anti-DNA antibody 
production, and that circulating serum factors generated in the absence of TLR9 could 
induce interferon production by pDCs. We have also shown that costimulation by CD4+ 
helper T cells contributes to autoantibody production in SLE. Integration of innate and 
adaptive activation signals is thus central to B cell autoantibody production and clinical 
disease progression in SLE.
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Chapter 1: Introduction
Systemic Autoimmune Disease
The mammalian immune system is a powerful defense against infection by a wide 
variety of invading microbes from viruses to multicellular parasites. The immune arsenal 
of molecular and cellular effectors must be carefully regulated, however, to prevent 
immune attack of the host’s own tissues. Indeed, this concept of “tolerance to se lf’ is 
central to the function of the immune system, and is enforced by multiple cooperative and 
redundant mechanisms (1). Nevertheless, the destructive power of the immune system 
can, in certain circumstances, be misdirected towards endogenous molecules, cells and 
organs, with disastrous results for the individual.
Autoimmunity is a condition in which an individual’s immune system mounts a 
response against the body of its host. When this response leads to tissue damage or 
pathology, it is characterized as autoimmune disease (2). Because the clonally rearranged 
receptors of B and T lymphocytes can recognize an almost limitless array of molecular 
targets, nearly any organ system can be affected by the failure of immune regulation. 
Clinical entities as diverse as diabetes, Graves disease, rheumatoid arthritis, psoriasis, and 
Sjogren’s syndrome can all be classified under the broad heading of autoimmune disease. 
Perhaps the most intriguing of human autoimmune diseases is systemic lupus 
erythematosus (SLE). As suggested by its name, the disease is not focused upon a 
specific organ system or molecular target, but can have a diverse array of clinical 
manifestations affecting nearly any organ system. Among the most common and
6
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debilitating consequences of lupus are dermatitis, arthritis, generalized fatigue, 
neuropsychiatric complications, cardiovascular disease, and a progressive nephritis (3).
Although SLE has been extensively studied for over a century, the underlying 
causes of disease remain unknown. Twin studies have demonstrated that genetic factors 
are clearly involved, but are not the only causative agents, as appropriate interactions 
with the environment are also required for disease pathogenesis (4). Commensurate with 
our lack of understanding of lupus etiology is the lack of effective, specific treatments for 
the disease. Although therapy for lupus patients has improved with time and 10-year 
survival rates now approach 90%, there remains no cure, and affected patients have a 3- 
fold increased risk of early death compared to the general population (5). These figures 
become particularly tragic when examined in light of the fact that lupus tends to affect 
patients in the prime of their lives, between the ages of 25 and 55. Elucidation of the 
mechanisms of disease initiation and pathogenesis could lead to more effective therapies 
for lupus as well as a host of related autoimmune conditions.
B Cells are Central to SLE Pathogenesis
Several lines of evidence point towards B lymphocytes and their antibody 
products as critical mediators of lupus pathogenesis. The initial description of the “LE” 
cell in 1948 (6) set the stage for the notion that antibodies reactive with self nuclear 
components could lead to tissue damage. It then became clear that 
hypergammaglobulinemia and the production of a defined set of circulating 
autoantibodies were central features of disease (7). Of particular interest were antibodies 
to endogenous DNA, which are present in the vast majority of SLE patients, tend to rise
7
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and fall according to disease activity, and were proposed to be primary mediators of 
disease (8, 9). The importance of autoantibodies was reinforced by the observation that 
anti-nuclear antibodies are deposited in diseased kidneys (10), and the demonstration that 
anti-DNA antibodies could mediate nephritis in adoptive transfer experiments (11).
Definitive experiments in mouse models of autoimmune disease further clarified 
the role of B cells in pathogenesis. In MRL/MpJ mice—which develop characteristic 
autoantibodies, nephritis, and dermatitis—a complete lack of B cells due to genetic 
disruption of the JH locus abrogated the development of renal disease and increased 
survival in both Fas-intact and Fas-deficient Ipr/lpr animals (12, 13). In addition to the 
secretion pathogenic autoantibodies, B cells can also serve as potent antigen-presenting 
cells (APCs) in the activation of autoreactive T cells. This has been demonstrated by the 
ability of self-reactive B cells to break T cell tolerance to self cytochrome-c and snRNP 
antigens in vivo in normal mice (14, 15). The separation of APC function from 
autoantibody secretion was formally demonstrated in lupus-prone mice with an IgM H 
chain transgene lacking the exons required for secretion. In the presence of B cells but 
the absence of serum antibody, these mice developed interstitial nephritis and vasculitis, 
as well as the accumulation of activated and memory T cells, at a level comparable to 
mice with intact antibody production (16). Finally, recent clinical trials in human lupus 
patients have shown a beneficial effect of B cell depletion with anti-CD20 monoclonal 
antibody therapy, providing direct evidence that B cells, either as antibody-secreting cells 
or APCs, are central to lupus pathogenesis in humans (17-19).
8
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Selective Targeting of Self Antigens in SLE
Despite the protean clinical manifestations of lupus, a common feature shared by 
nearly all patients is the presence of a highly restricted set of autoantibodies (20). These 
antibodies were initially characterized by their ability to bind to nuclear antigens of fixed 
epithelial cells, and thus the fluorescent anti-nuclear antibody (ANA) test became a staple 
in the laboratory diagnosis of SLE (7). Further study showed that the various staining 
patterns of the ANA produced by serum from lupus patients could be correlated with 
autoantibodies to specific nuclear components (21-23). Surprisingly, of the tens of 
thousands of potential self antigens, the autoantibodies of SLE recognize a small subset 
of only a few dozen. Understanding the basis for this selective targeting could provide 
clues to the etiology of SLE and autoimmune disease in general (24).
Antibodies to single- and double-stranded DNA, to histones, and to the complexes 
of DNA and histones (either isolated nucleosomes or chromatin en masse) comprise one 
major subset of autoantibodies in SLE (9). As discussed above, the anti-DNA specificity 
is found in the majority of lupus patients, and thus is often cited as a primary mediator of 
pathogenesis. However, when studying multiple interacting factors in a complex disease, 
causality can be difficult to determine. The other major subset of autoantibodies in SLE, 
comprised of antibodies that recognize RNA-containing antigens, may be equally or even 
more important. These antigens include the Smith (Sm) and ribonucleoprotein (RNP) 
complexes involved in processing of nuclear RNA (25), the Ro/SSA and La/SSB 
antigens involved in processing of ribosomal RNA and transfer RNA in both the nucleus 
and cytoplasm, as well as ribosomal P proteins and even naked RNA molecules (23, 26). 
Because these autoantibodies are found in only a minority of lupus patients and can
9
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occasionally arise in related autoimmune conditions such as Sjogren’s syndrome, and 
because they can produce cytoplasmic rather than the characteristic nuclear ANA staining 
patterns, their role in disease is less well established. However, the presence of the anti- 
Ro specificity is clearly associated with distinct pathology such as vasculitis and 
congenital heart block, antibodies to ribosomal P proteins are correlated with nephritis 
and neuropsychiatric disease (26), and anti-Sm antibodies have also been linked to 
nephritis independently of anti-DNA (27). Thus, it has become increasingly clear that 
antibodies to both DNA- and RNA-containing antigens can contribute to autoimmune 
pathogenesis.
Although the effects of autoantibodies in lupus are becoming clearer, their 
etiology remains the focus of much speculation (28). Fairly conclusive evidence has 
shown, however, that the canonical autoantigens of SLE can be derived from endogenous 
apoptotic cells. Genomic DNA is cleaved into nucleosome fragments during the process 
of apoptotic cell death, and there is evidence that residual fragments of apoptotic DNA 
have a greater immune stimulatory capacity than native genomic DNA (29). In addition, 
both DNA- and RNA-containing antigens translocate from the nucleus to membrane 
blebs on the surface of apoptotic cells, where they presumably become available for 
immune recognition (30). Moreover, autoantibodies derived from lupus-prone mice have 
been shown to directly bind to these clusters of nuclear antigens on apoptotic blebs (31).
Autoantibodies can also be induced in otherwise normal individuals when a heavy 
burden of apoptotic and necrotic cells is created. In non-autoimmune mice, 
immunization with syngeneic apoptotic cells in the absence of any adjuvant can lead to 
ANA production (32), as can similar immunization with purified DNA from lymphocytes
10
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stimulated to undergo activation-induced cell death (33). Interestingly, immunization 
with total genomic DNA is much less effective at inducing autoantibody production (34, 
35). In a more physiologic setting, apoptotic and necrotic debris can accumulate when 
normal pathways of clearance are inhibited or overwhelmed. This failure of disposal 
results in autoimmunity in mice deficient in SAP (36), DNase I (37), or Mer (38), and in 
humans and mice lacking the early components of complement (39). Such a mechanism 
may also explain the increased incidence of anti-nuclear antibodies in circumstances of 
heightened cell death such as chronic viral infection (40).
Thus, it appears that the selectively targeted antigens in SLE are the products of 
cell death derived from endogenous cells. In addition, the oligoclonal nature and pattern 
of mutation and selection in autoreactive B cells indicate that autoimmune disease 
represents a specific and robust response to self antigens, not a chance byproduct of 
polyclonal activation or cross-reactivity (41,42). Why then should a sparse collection of 
DNA- and RNA-containing antigens be targeted while thousands of others are ignored? 
The answer may lie in the autoantigens themselves. It is possible that a receptor 
expressed either directly by B cells or by accessory immune cells is specifically activated 
by molecular patterns present within the canonical lupus autoantigens. Such activation 
would lead to the induction of autoimmunity directed only against the antigens containing 
these putative patterns. Because essentially all the targeted antigens of lupus contain 
some form of nucleic acid, we hypothesized that a class of receptors activated by nucleic 
acid ligands could be fundamentally responsible for the generation of anti-nuclear 
antibodies in lupus. Moreover, if such a family of receptors could be activated by 
endogenous antigens, it would be central to the etiology and pathogenesis of SLE.
11
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Toll-like Receptors and Innate Recognition of Endogenous Antigens
The adaptive immune system, composed of B and T lymphocytes and their 
somatically-rearranged antigen receptors, can recognize virtually any antigen, including 
self antigens. Although the majority of autoreactive lymphocytes are purged from the 
repertoire during development, this negative selection is not complete (43). There must 
be a mechanism in place to prevent these self-reactive cells from inducing autoimmunity, 
as well as a mechanism to instruct the adaptive immune system when to mount a 
protective response to invading microbes. In 1989, Charles Janeway predicted the 
existence of an “innate” immune system, intrinsically capable of the discrimination of 
self from non-self antigen (44). Activation of innate immunity in response to foreign 
antigens inherent in viruses and bacteria (coined pathogen associated molecular patterns) 
would result in induction of an adaptive immune response, while innate tolerance to self 
antigens would prevent the development of autoimmunity. Under this hypothesis, an 
effective immune response cannot be initiated without activation of innate immunity.
A central concept of innate immunity is that microbes are recognized by a small 
number of germline-encoded pattern-recognition receptors. Unlike B and T cell 
receptors, which are generated during the lifetime of the organism, innate receptors are 
selected over an evolutionary time scale, and thus have been purged of gene products that 
pose an unacceptable risk of autoimmunity (45). The discovery of a human homolog of 
the Drosophila innate immune receptor Toll, (46), followed by the demonstration that this 
receptor is required for the immune response to bacterial lipopolysaccharide (47, 48), 
proved the existence of innate pattem-recognition receptors. It has since been shown that
12
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there are at least 11 different mammalian Toll-like Receptors (TLRs) activated by a wide 
range of microbial ligands, and that activation of this family of innate receptors is indeed 
critical for the induction of an adaptive immune response (49-53).
A subset of TLRs has evolved to recognize the nucleic acid ligands of invading 
bacteria and viruses. These include TLR9, a receptor for hypomethylated CpG sequence 
motifs in double-stranded DNA (dsDNA) (54), TLR3, a receptor for double-stranded 
RNA (dsRNA) (55), and TLR7, a receptor for single-stranded RNA (ssRNA) (56-58). 
TLR8 in humans can also be activated by ssRNA (58), but a role for TLR8 in the mouse 
immune system has not been identified (59). In addition, a TLR-independent pathway 
for recognition of RNA and DNA ligands has recently been described (60-63). The exact 
nature of the receptors in this pathway remains unclear, but it appears that these innate 
sensors complement the activity of TLRs in the defense against viral infection. Innate 
recognition of microbial nucleic acids, however, poses a unique problem for the 
discrimination of self from non-self antigens. Because pathogens and the host utilize the 
same nucleic acids to transmit genetic information, the risk of autoimmunity by 
activation of these receptors is high.
Several mechanisms have evolved to prevent activation of TLR3, -7, and -9 by 
endogenous nucleic acids. The most important appears to be sequestration of these 
receptors in intracellular compartments, where host-derived antigens are largely excluded 
(52, 64). The importance of this compartmentalization was shown by the demonstration 
that mammalian DNA could activate a chimeric TLR9 expressed on the cell surface, but 
not wild-type TLR9 contained in intracellular compartments (65). In addition, the fine 
specificity of these receptors appears to favor molecular determinants that are common in
13
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microbial nucleic acids, but underrepresented in endogenous cells. For example, the CpG 
motifs found in bacterial DNA are potent activators of TLR9, but GC sequences and 
mammalian genomic DNA are not, and can even inhibit activation of TLR9 by 
stimulatory DNA (66). Similarly, TLR3, -7, and -8 are preferentially activated by 
unmodified RNA present in bacteria, while methylation and other common modifications 
of eukaryotic RNA prevent its recognition by these receptors (67).
Despite these additional checkpoints in the discrimination of self versus non-self, 
innate immune activation by endogenous nucleic acids may yet occur in certain 
circumstances. Murine dendritic cells (DCs) can be induced to mature, express activation 
markers, and efficiently present antigen to T cells both in vitro and in vivo after exposure 
to dsDNA from lysed murine fibroblasts (68). Similarly, mRNA released from apoptotic 
cells can activate signaling pathways downstream of TLR3 (69), and RNA sequences 
derived from endogenous Sm/RNP complexes can lead to activation of TLR7 and TLR8 
(70). Weak or tolerizing signals induced by TLR recognition of endogenous ligands may 
be converted into overt inflammation and autoimmunity in cases of high ligand 
concentration or perseverance, such as when normal clearance mechanisms of apoptotic 
debris are overwhelmed (38, 39). A low level of activation by TLRs may also reach a 
critical threshold when cells simultaneously receive an additional stimulus. This 
phenomenon of costimulation is an inherent aspect of immune biology (1), and may be 
particularly relevant for the activation of autoreactive B cells.
14
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B Cells at the Interface of Innate and Adaptive Immunity in SLE
B lymphocytes occupy a unique niche in the immune system because they express 
both the germline encoded receptors of the innate immune system as well as a clonally 
derived receptor of the adaptive immune system: the somatically rearranged B cell 
receptor (BCR). B cells express TLR7 and TLR9, and are directly stimulated by 
synthetic ligands for these receptors (71, 72). After ligation of TLRs, B cells are 
stimulated to proliferate, express costimulatory molecules for antigen presentation to T 
cells, secrete modest amounts of cytokines, and most importantly, differentiate into 
antibody-secreting plasma cells (73, 74). TLR signaling is thus an essential aspect of B 
cell function. In fact, not only is the presence of TLR ligands required for an effective 
humoral immune response, but TLR activation must occur in a B cell-intrinsic manner for 
effective antibody production (75). Within a single B lymphocyte, therefore, signaling 
pathways generated by the innate and adaptive immune system cooperate to generate 
effective immunity.
The synergy of activation signals generated by innate and adaptive receptors may 
also facilitate the activation of autoreactive B cells in lupus. In the context of concurrent 
BCR stimulation, methylated non-stimulatory DNA can assume stimulatory capacity for 
B cell proliferation and antibody secretion (76). In addition, low concentrations of 
specific antigen can synergize with non-stimulatory mammalian DNA to induce B cell 
activation (77). This combination of two sub-optimal stimuli may be particularly 
relevant for autoreactive B cells, which are unlikely to have strong signals transmitted by 
the BCR due to the combination of central deletion of high-affinity clones and peripheral 
anergy of remaining cells (78). Conversely, additional regulatory mechanisms exist
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within anergic B cells to prevent their aberrant activation by TLR ligands (79). Whether 
this regulation can be overcome by simultaneous BCR and TLR signaling in vivo is 
unknown.
Seminal work on the role of TLRs in autoimmunity has shown that autoreactive 
rheumatoid factor B cells specifically proliferate in vitro in response to immune 
complexes of IgG and self DNA, but not IgG-protein complexes (80). This response is 
completely dependent upon TLR signaling, and requires TLR9 for full activation of the 
autoreactive B cells (81). Further study of the mechanism revealed that signaling through 
both the BCR and TLRs is essential, and indicated that BCR-medicated endocytosis and 
delivery of DNA complexes to TLR9-containing endosomal compartments is central to 
the response (29). An analogous response occurs in rheumatoid factor B cells stimulated 
with RNA-containing immune complexes, and signals through TLR7 instead of TLR9 
(82). Importantly, anti-dsDNA B cells are also stimulated by self DNA in vitro in a 
similar fashion, indicating that pre-existing complexes of IgG and nucleic acids are not 
required (29); anti-nuclear B cells may be directly stimulated by endogenous ligands.
Thus, by virtue of the integration of signals from the innate and adaptive 
immunity, autoreactive B cells with anti-nuclear specificity are uniquely poised to initiate 
autoimmune responses. Potentially weak activation signals transmitted by a low-affinity 
autoreactive BCR can be complemented by TLR signaling, allowing otherwise anergic B 
cells to break tolerance. Furthermore, the control mechanisms to prevent innate 
recognition of endogenous nucleic acids (intracellular sequestration and poor activation 
by mammalian sequence elements) can be overcome by BCR-mediated delivery of 
nucleic acid ligands to endosomal compartments and concurrent stimulation via the
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antigen receptor. This two-signal model of B cell activation emphasizes the importance 
of B cells at the interface of innate and adaptive immunity in the pathogenesis of SLE. 
Thus, several investigators have also proposed a role for innate immunity in the induction 
of autoimmune responses (83-85), and inhibition of TLR signaling has begun to emerge 
as an attractive therapeutic goal in the treatment of autoimmune disease (86, 87).
Type I Interferons in SLE
Type I interferons (IFN-I) encompass a family of more than twenty related gene 
products, of which the several interferon-alpha (IFN-a) genes and the single interferon- 
beta (IFN-|3) gene, are most pertinent for the function of the immune system (88). IFN-I 
have a panoply of effects on nearly every cell type in the immune system, and are critical 
mediators of resistance to viral infection. The complex biology and signaling pathways 
of interferons are gradually being elucidated, but it was three decades ago that the 
important role of IFN-I in SLE was first suggested. It was noted that human lupus 
patients have elevated circulating interferon titers, and that levels of serum interferon 
directly correlate with disease activity (89). More recently, gene expression analysis has 
identified characteristic gene expression patterns in blood cells of lupus patients, and 
these expression patterns were found to overlap with those genes induced by IFN-I (90, 
91). As with the original observation of circulating IFN-I, the level of expression of 
interferon-inducible genes in these studies correlated with disease severity. Genetic 
knockouts of the type I interferon receptor in mouse models have also highlighted the 
importance of these cytokines in autoimmunity. Inability to respond to IFN-a/|3 
dramatically improved symptoms and severity of autoimmune disease in two different
17
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lupus-prone mouse strains (92,93), although one conflicting report observed a negligible 
effect on disease in MRL/MpJ mice (94). These observations are supported by the fact 
that exogenous interferon can induce symptoms and laboratory findings of autoimmune 
disease in patients treated with IFN-a for unrelated conditions (95, 96).
Besides the clear association of interferon with autoimmunity, several of the 
known effects of IFN-a/(3 may directly contribute to autoimmune pathology or disease 
progression. Firstly, IFN-I facilitates B cell activation, leading to augmented antibody 
secretion, particularly of the inflammatory immunoglobulin isotypes IgG2a and IgG3 in 
the mouse (97, 98). The effect of these cytokines on B cells is such that in the presence 
of concurrent BCR and TLR9 stimulation (as is predicted to occur in B cells with anti- 
nuclear specificity), IFN-a can induce differentiation to antibody-secreting plasma cells 
in the absence of T cell costimulation (99). Secondly, IFN-I is a potent activator of 
monocytes and immature dendritic cells (88). Immature blood-derived monocytes 
assume the activated phenotype of mature DCs and acquire robust T cell stimulatory 
capacity when cultured in the presence of IFN-I (100). In the context of autoimmunity, 
circulating monocytes from lupus patients have an intrinsically high efficiency of antigen 
presentation, and this elevated APC activity is dependent upon IFN-a (101). Finally, 
IFN-I appears to polarize the T cell response toward the inflammatory Thl type (97,
100), and, by virtue of STAT4 activation, can directly prime T cells for production of the 
prototypical Thl cytokine, gamma interferon (102).
Although many cells of both hematopoietic and non-hematopoietic origin can 
produce IFN-I, it was not until recently that a specialized cell type primed for rapid 
production of high levels of IFN-I was clearly identified. Originally classified as
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plasmacytoid T cells for their prominent rough endoplasmic reticulum and histological 
location in T cell zones of the lymph node, plasmacytoid dendritic cells (pDCs) are now 
recognized as the central interferon producing cells of the immune system (103-105). 
Plasmacytoid DCs express TLR7 and TLR9, and upon recognition of viral nucleic acids 
by these receptors, rapidly produce high levels of IFN-I (52, 106, 107). It is interesting to 
note that while activation of TLR7 and TLR9 in B cells induces proliferation and 
antibody secretion, the same receptors lead to the elaboration of IFN-I in pDCs. This 
difference that has been attributed to expression of the signaling adaptor interferon- 
regulatory factor 7 (IRF7) in pDCs (108), and may also depend on intracellular sorting of 
TLR-containing endosomal compartments (109).
Because pDCs, like B cells, express nucleic acid-binding TLRs that may be 
activated by endogenous ligands, and because IFN-I is implicated in the pathogenesis of 
SLE, it is likely that activation of TLRs by self nuclear antigens can lead to IFN-I 
production by pDCs in autoimmune disease. For example, IFN-a produced by pDCs in 
the skin was found to be essential for the pathogenesis of psoriasis (110), and pDC- 
derived IFN-I has been similarly proposed to play a central role in lupus (111). Unlike 
autoreactive B cells, however, pDCs lack a specific antigen receptor capable of 
transmitting costimulatory signals and delivering endogenous nucleic acids to appropriate 
intracellular compartments for recognition by TLRs. How then can pDCs be stimulated 
by host-derived DNA/RNA ligands? Recent work focusing on IgG immune complexes 
from human lupus patients provides at least one answer, and reinforces the primary role 
of B cells at the interface of innate and adaptive immunity in SLE.
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Initial studies on serum from lupus patients revealed the presence of a circulating 
inducer of IFN-a production, which appeared to consist of DNA-containing immune 
complexes (112). Further work revealed that this interferon-inducer could be recreated 
by the mixture of purified lupus IgG and apoptotic cells or nucleic acids released into the 
supernatant of dying cell cultures (113, 114). Analogous to the dual signaling of the B 
cell response, this stimulation of pDCs requires both the ligation of the Fc receptor 
FcyRIIa by IgG at the cell surface and activation of TLR9 in endosomal compartments 
for efficient IFN-a production (115, 116). TLR7 also appears to be involved in the 
production of IFN-a in response to RNA-containing immune complexes (87). 
Interestingly, in several of these studies, RNA complexes activated more potent induction 
of IFN-a than DNA-containing complexes (87, 114). The stimulatory capacity of 
endogenous RNA is further supported by the fact that the presence of anti-RNA 
antibodies is independently associated with IFN-I production and clinical disease activity 
in lupus patients (117).
Thus, as is the case for autoreactive B cells with anti-nuclear specificity, a two 
signal model of activation can bypass the regulatory mechanisms of innate immunity and 
allow activation by endogenous nucleic acids. Unlike anti-nuclear B cells, however, 
pDCs require the presence of pre-existing immune complexes to permit TLR stimulation 
by endogenous ligands. The requirement of autoantibodies for dendritic cell activation 
positions B cells at the center of a positive feedback cycle in the pathogenesis of SLE: B 
cells produce autoantibodies, which induce IFN-I production, which promotes 
autoantibody formation by B cells. It is also important to note that this mechanism of Fc 
receptor-mediated activation of DCs can also be demonstrated in conventional myeloid
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dendritic cells (mDCs), which respond to DNA-containing immune complexes by 
producing inflammatory cytokines in a TLR9-dependent fashion (118). Stimulated 
mDCs in these experiments also elaborated the B cell activating factor BAFF, which has 
been linked to autoimmunity and could promote further expansion of autoreactive B cells 
(119).
Importance of Cognate T-B Interactions in SLE
Although interaction with dendritic cells can induce B cells to secrete antibodies 
in the absence of simultaneous T cell activation (99, 120), the provision of cognate help 
from CD4+ T cells is generally required for the effective generation of a humoral immune 
response. This central tenet of B cell activation appears to hold true in autoimmunity as 
well. Early experiments revealed that depletion of CD4+ T cells in lupus-prone mice 
could prevent disease in young animals as well as ameliorate advanced disease in aged 
animals (121, 122). It was subsequently shown that MHC-matched, cognate T cell help 
is required for the production of high titers of class-switched autoantibodies (123), and 
that the genetic absence of a(3 T cells in lupus-prone mice causes a reduction in 
rheumatoid factor and IgG anti-DNA titers (124). The availability of helper T cells is 
also critical in the 3H9 anti-DNA BCR transgene model, wherein anti-DNA B cells break 
peripheral tolerance only in the presence of cognate CD4+ T cells (125).
Cognate T-B interactions are mediated primarily through two costimulatory 
receptor-ligand families: the tumor necrosis factor (TNF)-TNF receptor (TNFR) family, 
and the B7-CD28 family. The TNF family member CD40L appears to play a central role 
in T cell-dependent B cell costimulation. CD40L-deficient mice are unable to form
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germinal centers or class-switched immunoglobulin to T-dependent antigens (126, 127), 
and deficiency of CD40L in lupus-prone mice causes a marked reduction in IgG anti- 
DNA titers (128). Although B7-1 and B7-2 costimulatory molecules are critical for the 
induction of appropriate humoral responses to immunized antigens (129), dual inhibition 
of these receptors in autoimmune mice produced only a minor decrease in autoantibody 
formation (130). Another B7 family member, inducible costimulator (ICOS), which is 
essential for germinal center formation and isotype switching in normal immune 
responses (131, 132), may be particularly relevant for autoimmune B cell activation. A 
recent report of lupus-like disease caused by a single gene mutation identified a primary 
defect in regulation of ICOS in helper T cells, which presumably allowed for 
inappropriate activation of autoreactive B cells (133). These various costimulatory 
molecules in cognate T-B interactions are expected to function cooperatively, as 
combined inhibition of the B7 and CD40 pathways leads to more profound suppression 
of autoimmune disease than either pathway alone (134, 135).
Besides the ability to costimulate B cell immune responses, certain subsets of 
CD4+ T cells can also actively suppress autoimmune responses. The inhibitory capacity 
of these CD25+ Foxp3-expressing regulatory T cells has been conclusively established, as 
has the critical importance of these cells in the prevention of overt autoimmune disease 
(136). Thus, the stimulatory effect of helper T cells on autoreactive B cells is balanced 
by the suppressive effect of regulatory T cells. This competition between activation and 
regulation of autoreactive B cells has been directly observed in the 3H9 anti-DNA 
transgene system (125). Similarly, selective depletion of regulatory T cells results in 
uncontrolled B cell activation and the production of autoantibodies in otherwise normal
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mice (137). The relative contribution regulatory and helper T cells in SLE remains 
unclear. Although it is likely that T cell inhibition could have therapeutic benefit, it 
remains possible that a blockade of all T cell function could free B cells from T cell- 
mediated suppression, potentially exacerbating autoantibody production.
Specific Aims of this Study
The ability of autoreactive B cells to be stimulated by the pattern-recognition 
receptors of the innate immune system and the somatically-rearranged antigen receptors 
of adaptive immunity places them in a unique position to respond to endogenous nuclear 
antigens. Moreover, the ability of B cells to prime autoreactive T cells, secrete cytokines, 
and produce autoantibodies, which can have direct pathogenic effects as well as mediate 
the activation of pDCs for efficient IFN-I production, positions these cells at the center of 
known pathogenic effector mechanisms in autoimmune disease. We have sought to 
define the factors necessary for the activation of autoreactive B cells, as well as the 
contribution of such B cell activation and autoantibody secretion to disease in a mouse 
model of SLE. The specific aims of this project are as follows:
1. Determine the importance of TLR3, -7, and -9 in dictating autoantibody target 
specificity and generalized autoimmune disease in murine lupus.
2. Determine the requirement for B cell-intrinsic expression of TLR9 in the 
generation of anti-DNA autoantibodies, and the contribution of TLR-mediated 
autoantibodies to pathogenesis in autoimmune disease.
3. Determine the phenotype and activation state of DNA-specific and non-specific 
autoreactive B cells in TLR9-deficient lupus-prone mice.
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4. Define the role of T cell help in the propagation of an established autoreactive 
B cell response.
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Chapter 2: Initial Analysis of TLR9 and TLR3 in Autoantibody 
Production in Murine Lupus
Systemic autoimmune disease in humans and mice is characterized by loss of 
immunologic tolerance to a restricted set of self nuclear antigens. Autoantigens such as 
double-stranded DNA (dsDNA) and the RNA-containing Smith antigen (Sm) may be 
selectively targeted in systemic lupus erythematosus because of their ability to activate a 
putative common receptor. TLR9, a receptor for hypomethylated CpG DNA motifs (54), 
has been implicated in the activation of autoreactive B cells in vitro (29, 80), but its role 
in promoting autoantibody production and disease in vivo has not been determined.
TLR3 is a receptor for dsRNA (55), and may be similarly activated by endogenous 
mRNA or the inherent stem-loop and double-stranded structures of Sm and Ul-snRNP 
autoantigens (69, 138). We have generated lupus-prone mice deficient in either TLR9 or 
TLR3 in order to investigate the requirements for these receptors in autoantibody 
production and clinical autoimmune disease in vivo.
Generation of Hybrid TLR-Deficient Lupus-Prone Mice
The inbred MRL/Mp mouse strain develops a lupus-like syndrome marked by 
characteristic autoantibodies, dermatitis, nephritis, and early mortality, which are 
accelerated in the presence o f  the F aslpr/,pr mutation (139). In order to investigate the role 
of TLR9 in autoimmune disease, we generated lupus-prone TLR9-deficient (TLR9 /_) 
mice by making F2 crosses of TLR9 ; mice and Fas-deficient MRLIMp>prllpr mice. We 
selected those TLR9; x MRL/Mp,pr/,/,r F2 littermates that were homozygous for Fas-
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deficiency and either TLR9-wild-type (TLR9+/+, n = 19) or TLR9 ' (n = 16). The 
heterogeneous genetic composition of the F2 generation was controlled with the use of 
large cohorts of littermate controls, such that background genes were evenly divided 
between the two groups of mice. Furthermore, the development of autoimmunity in Fas- 
deficient mice has been documented on multiple genetic backgrounds (140). Similar 
breeding strategies have been used previously to study the effects of single genes on 
autoimmune disease (12, 128).
ANA Profiles in Autoimmune TLR-Deficient Mice
Because the fluorescent anti-nuclear antibody (ANA) assay is the most sensitive 
detection method for antibodies to a variety of nuclear components in their native 
antigenic form (7, 141), we used it as an initial measure of autoantibody production in the 
serum of F2 mice. By classification of the ANA staining pattern, we were able to 
determine the specificity of the autoimmune response, and identify the dominant 
autoantigens targeted by individual mice. Homogenous nuclear staining is known to 
correlate with anti-dsDNA antibodies, while a coarsely speckled nuclear staining pattern 
corresponds to antibodies directed against RNA-containing antigens such as snRNPs or 
Sm (21, 22). Serum from 7 of 19 TLR9+/+ mice exhibited homogenous nuclear staining, 
whereas none of 16 TLR97 sera showed this pattern (Fig. 1, A and C, P = 0.009, Fisher’s 
exact test), suggesting an impairment in the generation of anti-dsDNA autoantibodies. 
Moreover, equatorial staining of chromosomes in metaphase cells, indicative of anti­
chromatin antibodies, was observed in 17 of 19 TLR9+/+ sera and 0 of 16 TLR9' sera 
(Fig. 1, A, B, and D, P < 0.0001). The high prevalence of metaphase chromatin staining
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in TLR9+/+ sera presumably reflects the presence of multiple different anti-DNA and anti- 
nucleosome antibody specificities. TLR9'7 mice were incapable of producing any of these 
autoantibodies.
In contrast to the lack of staining for anti-dsDNA and anti-chromatin 
autoantibodies in TLR9; sera, there was no decrease in the proportion of mice with 
predominantly speckled ANA patterns, although TLR9y sera had a qualitatively different 
speckled pattern compared to TLR9+/+ sera. While wild-type sera demonstrated mixed 
speckled and homogenous staining, TLR9_/ sera had exclusively speckled patterns in the 
absence of any superimposed homogenous staining (Fig. 1A and data not shown). In 
addition, TLR9y sera had an increased incidence of primarily cytoplasmic staining 
compared to wild-type littermates (Fig. 1, A and C, P = 0.013), although the sera with 
cytoplasmic patterns also stained nuclei in a faint speckled pattern. These findings 
indicate that TLR9'' mice were capable of targeting the typical RNA-containing 
autoantigens of lupus, and account for the equivalence of quantitative ANA titers in the 
two groups of mice (median titer greater than 1:2000, data not shown). Furthermore, the 
distribution of ANA patterns in TLR9 7 mice suggests that in the absence of anti-DNA 
antibodies, other autoantibody specificities are maintained and may even become more 
prominent.
TLR3-deficient lupus-prone mice were generated by F2 crosses with 
M R L /M p^^ mice in an analogous fashion to TLR9 mice. Unlike the TLR9 cohort, 
there was no difference in the distribution of either homogenous or speckled nuclear 
ANA patterns between TLR3+/+ (n = 15) and TLR3/_ (n = 17) littermates (Fig. 2, A and 
C). In addition, nearly all mice in both groups produced antibodies to chromatin, as
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evidenced by bright staining of metaphase chromosomes in mitotic cells (Fig. 2, A, B, 
and D). Because TLR3 is a receptor for dsRNA and may be involved in the generation of 
autoantibodies to RNA-containing antigens, we examined speckled ANA staining 
patterns in TLR37' sera, but could detect no difference in either the quality or intensity of 
staining for RNA-containing antigens. Both TLR3 7 and TLR3+/+ mice produced 
autoantibodies that stained nuclear substrates with fine speckled, discrete speckled, and 
mixed speckled/homogenous patterns (Fig. 2A and data not shown). Based on the ANA, 
the autoantibody profile of TLR37 mice was thus indistinguishable from wild-type 
littermates.
Reduced Anti-dsDNA Autoantibodies in TLR9-Deficient Mice
The loss of homogenous nuclear and mitotic chromatin staining in TLR97 sera 
implied a block in the generation of autoantibodies to DNA-containing antigens, so we 
sought to confirm this with a specific assay for anti-dsDNA antibodies. Indirect 
immunofluorescence on Crithidia luciliae substrates is an established assay for the 
detection of anti-dsDNA autoantibodies in SLE (142). Because the kinetoplast organelle 
of C. luciliae is composed exclusively of circular dsDNA in the absence of ssDNA,
RNA, or histones, the Crithidia assay is clinically the most specific test for antibodies to 
native dsDNA (143, 144). To further enhance the detection of anti-DNA antibodies, we 
co-stained the Crithidia DNA with 4 ’,6-diamidino-2-phenylindole (DAPI), thus 
permitting the differentiation of irrelevant cytoplasmic structures from true staining of 
kinetoplast and nuclear dsDNA (Fig. 2A).
28
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Among the TLR9 F2 mice, a subset of TLR9+/+ sera contained specific anti- 
dsDNA antibodies as detected by strong staining of the Crithidia kinetoplast, but these 
antibodies were absent in sera from TLR9_/ mice (Fig. 3A-B, P = 0.0121, Mann-Whitney 
U test). Seven of 19 wild-type and 3 of 16 TLR9'A sera were also found to have 
borderline staining of dsDNA, evidenced by a faint ring around the kinetoplast (Fig. 3A- 
B, intensity score of 1). It was unclear whether these staining patterns represented low- 
affinity anti-dsDNA or non-specific antibodies. We therefore analyzed the incidence of 
anti-dsDNA using intensity scores of either greater than zero or greater than one as 
positive. With both methods of analysis, we observed a significant reduction in anti- 
dsDNA antibodies in TLR9'; sera (P < 0.05, Fisher’s exact test). In contrast, TLR3 ; mice 
appeared to have no impairment in the generation of anti-dsDNA autoantibodies, as there 
was no difference in the incidence or intensity of kinetoplast staining between TLR3+/+ 
and TLR3'/_ sera (Fig. 3C). Thus, TLR9, but not TLR3, was required for the generation 
of specific autoantibodies to dsDNA in the context of murine lupus.
Anti-Sm and Anti-Cardiolipin Autoantibodies in TLR-Deficient Mice
Autoantibodies to Sm are exclusive to SLE and occur in approximately 25% of 
diseased humans and mice (25, 145). We performed Western blots to detect antibodies 
against the protein components of the Sm complex. Mice in both the TLR9 and TLR3 F2 
cohorts generated antibodies reacting with a cluster of bands in the 29-34 kD region of 
the gel, corresponding to the complex of B and B’ proteins (Fig. 4A-B). As expected, 
TLR9 / mice produced anti-Sm autoantibodies. In fact, there was a significant increase in 
the proportion of TLR9' ' mice with anti-Sm reactivity compared to TLR9+/+ littermates
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(Fig. 4, A and C, P = 0.0049, Fisher’s exact test). We confirmed these findings with a 
solid phase ELISA, using purified whole Sm antigen as the target, and again found higher 
levels of anti-Sm autoantibodies in TLR9'7 mice (Fig. 4D, P = 0.0014, Mann-Whitney U 
test). Consistent with the presence of speckled ANA patterns, TLR3; mice also 
generated anti-Sm autoantibodies at frequencies equivalent to their wild-type 
counterparts (Fig. 4, B, C, and E). Thus, neither TLR9 nor TLR3 were required for the 
production of autoantibodies to the RNA-containing Sm antigen, although, unexpectedly, 
there was a relative increase in anti-Sm autoantibodies in TLR9 ' mice.
Anti-phospholipid antibodies are also commonly found in autoimmune disease, 
and are associated with coagulation abnormalities and thrombosis (22). Because of the 
polyanionic nature of the lipid antigen, anti-phospholipid antibodies can cross-react with 
DNA, and anti-DNA antibodies can likewise have dual specificity for lipids such as 
phosphatidylserine (146). To determine if TLR9-deficiency or the loss of anti-dsDNA 
antibodies in TLR9 ' mice affected the generation of anti-phospholipid antibodies, we 
measured autoantibodies to cardiolipin, a prototypical phospholipid antigen. We found 
that TLR9; mice developed serum titers of anti-cardiolipin antibodies that were 
comparable to TLR9+/+ littermates (Fig. 4F), indicating that anti-dsDNA and anti­
phospholipid antibodies are controlled by separate mechanisms in these mice.
Global Immune Activation in TLR-Deficient Lupus-Prone Mice
Anti-chromatin and anti-ribonucleoprotein antibodies are among the earliest 
detectable autoantibodies in SLE, and are known to precede the appearance of overt 
clinical disease in both humans and mice (147, 148). The breakdown of tolerance to
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DNA-containing antigens may thus be a critical first step in systemic autoimmunity, and 
the early appearance of anti-chromatin autoantibodies may facilitate disease progression 
and epitope spreading to other nuclear autoantigens (149). We therefore determined 
whether the lack of TLR9 or TLR3 had any effect on several parameters of global 
autoimmune disease. TLR-intact and TLR-deficient mice from both the TLR9 and TLR3 
cohorts exhibited massive lymphadenopathy and splenomegaly (Fig. 5A), characteristic 
of the accumulation of activated lymphocytes in Fas-deficient autoimmunity. Both 
groups of mice also had elevated levels of total IgG and IgG2a in the serum relative to 
non-autoimmune C57BL/6 mice (Fig. 5B). To further define the autoimmune phenotype, 
we enumerated T cells, B cells, and CD4 /CD8' double-negative T cells, which 
accumulate with age in MRL/Mplpr/Ipr mice (139). These cell populations were not 
decreased in TLR-deficient mice in the spleen (Fig. 5C) or lymph nodes (data not 
shown), nor was there any block in the accumulation of activated and memory phenotype 
CD4+ T cells (Fig. 5D). Thus, neither deficiency of TLR9 or TLR3, nor the specific 
absence of anti-DNA autoantibodies in TLR9 /_ mice, inhibited the dysregulated immune 
activation and aberrant lymphocyte accumulation of systemic autoimmune disease.
There was, however, an unexpected increase in immune activation in TLR9'/_ 
animals compared to wild-type littermates. This was not observed for animals in the 
TLR3 cohort. Lymph node weight (P = 0.0016), splenic T cell count (P = 0.0277), 
double-negative T cell count (P = 0.0150), and activated CD4+ T cell count (P = 0.0327) 
were all significantly greater in TLR9 7 mice compared to TLR9+/+ littermates. Because 
the vast majority of the lymph node in these animals is composed of activated and
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double-negative T cells (data not shown), these findings all point toward an increased 
level of T cell activation in TLR9-deficient mice.
In addition to hypergammaglobulinemia and the accumulation of activated 
lymphocytes, increased production of type I interferons is associated with SLE in humans 
and mice (90, 91, 150). Moreover, genetic ablation of the type I interferon receptor 
markedly reduced clinical and immunologic signs of lupus in NZB mice (92), although 
this was not observed in other autoimmune strains (94). Because activation of TLR9 and 
TLR3 is known to stimulate the secretion of type I interferons (106, 151), we determined 
whether lack of either of these receptors influenced spontaneous interferon levels in 
autoimmune mice. Using an ELISA to detect serum IFN-a, we could not detect any 
impairment in interferon production by TLR97 or TLR37 F2 mice (Fig. 5E-F). Although 
the sensitivity of this assay was limited to IFN-a, it was clear that a subset of mice 
exhibited markedly elevated levels type I interferons even in the absence of TLR9 or 
TLR3.
Glomerulonephritis in the Absence of Anti-DNA Autoantibodies
To assess renal disease in TLR9- and TLR3-deficient autoimmune mice, we first 
measured spot proteinuria at the time of sacrifice. There was no difference between 
TLR97 or TLR37 mice and their wild-type counterparts, with most mice exhibiting mild 
to moderate levels of proteinuria (data not shown). Histologically, interstitial and 
perivascular lymphocytic infiltrates were present in the kidneys of all mice. There was a 
moderate increase in glomerular size and cellularity, with no detectable difference in any 
parameter between TLR9+/+ and TLR97 (Fig. 6, A, C, and E) or TLR3+/+ and TLR37 mice
32
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(Fig. 6, G, I, and K). PAS staining of kidney sections further revealed that TLR9_/ (Fig. 
6, B, D, and F) and TLR37 (Fig. 6, H, J, and L) mice developed significant glomerular 
protein deposition that was comparable to wild-type littermates, with marked thickening 
of capillary loops and obliteration of vessel lumens. These findings indicate that neither 
TLR9 nor TLR3 was essential for the induction of end organ disease in murine lupus.
Although interstitial renal disease and glomerulonephritis were not inhibited in 
TLR9-deficient mice, it was unclear whether this was due to direct glomerular deposition 
of immunoglobulin and complement-containing immune complexes. We therefore 
assessed renal IgG and complement deposition in TLR9; mice lacking anti-dsDNA and 
anti-chromatin autoantibodies. Both TLR9+/+ and TLR9 7 mice had immune deposits 
throughout the glomerulus, in contrast to non-autoimmune C57BL/6 mice (Fig. 7A). 
Although levels of IgG and C3 deposition varied among individuals, there was no 
difference in the mean glomerular fluorescence between the two groups of mice (Fig. 
7B). Thus, lupus nephritis and glomerular immune complex deposition were unaffected 
by the absence of anti-dsDNA and anti-chromatin autoantibodies in autoimmune TLR9'/_ 
mice.
Analysis of TLR3-Deficient Mice on Backcrossed MRL/Mp Background
Because TLR3 appeared to have no effect on autoantibody production, evidence 
of immune hyperactivation, or clinical disease in Fas-deficient mice in the F2 hybrid 
generation, we also analyzed a cohort of TLR3-deficient mice from a more homogenous 
and defined genetic background. Thus, TLR3+/ mice were backcrossed eight generations 
to MRL/Mp//,r/,pr mice, at which point over 99.8% of the genome was statistically derived
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from the MRL/Mp strain. We also verified that all TLR3' mice expressed the MHC1^  
and Ig^1 haplotypes derived from MRL/Mp (data not shown).
Analysis of TLR3+/+ and TLR3‘ ‘ littermates on the MRL/Mp'7"777"’ background 
confirmed that TLR3 did not directly impact autoantibody production or evidence of 
disease in these mice. Sera from T L R 3 m i c e  did not exhibit any significant differences 
in ANA patterns from wild-type serum, although there was an insignificant decrease in 
speckled ANA patterns in TLR3-deficient sera, which may have suggested a decrease in 
autoantibodies to RNA-containing antigens (Fig. 8A). Sera from the majority of mice in 
both groups contained anti-chromatin antibodies, as determined by specific staining of 
metaphase chromatin in mitotic cells (Fig. 8B). We also performed assays for anti-Sm 
antibodies to identify specific antibodies to RNA-containing antigens. Despite the 
potential decrease in speckled ANA staining patterns, TLR3 ' MRL/Mp'7"7'7"' mice 
produced anti-Sm autoantibodies at a level equal to or greater than their wild-type 
littermates (Fig 8D). Western blotting confirmed that mice in both groups generated 
antibodies recognizing both the Sm D and B/B’ proteins at 14 and 25-30 kD, respectively 
(Fig. 8E). We therefore conclude that TLR3 has no role in the generation of 
autoantibodies to the typical RNA-containing antigens of SLE. Circulating levels of total 
IgG and IgG2a, as well as spleen and lymph node weight and activated T and B cell 
counts were also not significantly different between TLR3+/+ and TLR3' mice (Fig. 8C 
and data not shown).
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Discussion
These results demonstrate that TLR9 is required for the generation of anti-dsDNA 
and anti-chromatin autoantibodies in lupus-prone mice. Although TLRs in general do not 
recognize endogenous antigens, this central tenet of self versus non-self discrimination 
appears to breakdown in autoreactive B cells in the context of SLE. This TLR-mediated 
activation of autoreactive B cells by endogenous nucleic acids has been observed in vitro 
(29, 80, 82), but had not been demonstrated in an in vivo system before. We speculate 
that the synergistic activation of anti-nuclear B cells by both the BCR and TLRs 
facilitates the specific activation of these cells by self antigens in autoimmunity. Such 
selective activation of B cells with antigen receptors capable of binding and internalizing 
endogenous nucleic acids could explain the highly restricted autoantibody repertoire 
observed in SLE in both humans and mice.
Although TLR9 can shape the autoantibody repertoire in SLE, lack of TLR9 did 
not ameliorate disease in lupus-prone mice. This was somewhat surprising given the 
historical association of anti-DNA antibodies with clinical disease activity (9). However, 
the presence of nephritis in TLR97' mice merely confirms previous observations that anti- 
DNA antibodies per se are not required for the development of disease in general or 
glomerulonephritis in particular (16, 152). In this sense, it is interesting that TLR9 A mice 
in this F2 cohort had both an increase in anti-Sm titers as well as an increase in several 
markers of immune activation. Because antibodies to RNA complexes may be associated 
with an increased production of IFN-I by pDCs (87, 114, 117), it is possible that the 
pathology observed in TLR9A mice could be directly attributed to these autoantibodies.
It is also possible, however, that either anti-DNA antibodies or TLR9 signaling in other
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cell types could have protective or regulatory roles in the context of autoimmune disease. 
We therefore will analyze the autoantibody repertoire and clinical disease phenotype of 
TLR9 ' on the homogenous genetic background of the MRL/Mp/pr/^  strain to further 
clarify these intriguing findings.
Unlike TLR9, TLR3 had no role in the generation of autoantibodies to DNA or 
the prototypical RNA-containing Sm antigen. TLR3 also did not affect the clinical 
development of SLE, either in the initial F2 cohort or in fully backcrossed MRL/Mp//,r//pr 
mice. One potential explanation for this is the highly restricted cellular expression of 
TLR3. TLR3 expression has only been detected in mature dendritic cells of the myeloid 
lineage (153), and was not observed in B cells by quantitative PCR (72). It is also 
possible that the specificity of TLR3 for dsRNA is not appropriate for the prototypical 
RNA-containing autoantigens of lupus, which are composed primarily of single-stranded 
RNA alternating with regions of intra-strand base pairing. Another candidate for the 
regulation of autoantibodies to RNA antigens is TLR7, an innate receptor for ssRNA (57, 
58). TLR7 is closely related to TLR9 in protein sequence and downstream signaling 
pathways (51), and, like TLR9, is expressed in endosomal compartments of B cells and 
pDCs (52, 72). Therefore, we will also analyze the effect of TLR7-deficiency on 
autoantibody production and disease development in the M R L /M p^ '' model of SLE.
Materials and Methods
Mice.
Heterozygous TLR9+/' mice (54) of a mixed genetic background (B6 and 129Sv) 
were generously provided by Shizuo Akira. These mice were bred to MRL/Mp//’r/,/7r mice
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in our colony under specific pathogen-free conditions. Intercrossing of FI offspring in 5 
mating pairs produced 22 Fas-deficient (Faslpr/lpr) F2 mice, 5 of which were TLR9+/+ and 4 
of which were T L R 9 \  Intercrossing of heterozygous TLR9+/ F2 mice in 4 additional 
mating pairs produced 56 Fas'pr/lpr mice, 15 of which were TLR9+/+ and 13 of which were 
TLR9 A. The genetic composition of both generations of mice was approximately 50% 
MRL/Mp. One mouse in each group died before sacrifice at 19-21 weeks of age. In a 
separate cohort, homozygous TLR3'/_ mice, generously provided by Richard Flavell (55), 
from a mixed genetic background (B6 and 129Sv) were bred to MRL/Mp//,r///,r mice as 
above. Intercrossing of FI offspring in 9 mating pairs produced 33 Faslpr/lpr mice, 9 of 
which were TLR3+/+ and 11 of which were TLR3'/_. Intercrossing of heterozygous 
TLR3+/ F2 mice in 3 additional mating pairs produced 26 Faslpr/lpr mice, 8 of which were 
TLR3+/+ and 6 of which were TLR3'/_. Two TLR3+/+ mice died before sacrifice at 19-21 
weeks of age.
To generate TLR3 A mice of homogenous genetic composition, TLR3+/ from the 
FI generation above were backcrossed an additional eight generations to purebred 
MRL/Mp//W77/"‘ mice (Jackson Laboratory), selecting those mice which were homozygous 
for the Faslpr/lpr mutation. At this point (>99.8% of genome derived from MRL/Mp 
strain), TLR3+/' mice were verified to be MHC1^  and Ig373 haplotypes by FACS analysis of 
peripheral blood cells. These mice were then intercrossed to produce 11 TLR3+/+ and 9 
TLR3 /_ mice from three different mating pairs. One mouse of each type died before 
analysis at 18 weeks of age. C57BL/6 mice (Charles River Laboratories) were 
maintained in our mouse colony to an age of 26 weeks.
ANA and anti-dsDNA immunofluorescence.
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Serum was obtained via retro-orbital puncture just prior to sacrifice. For ANA, 
serum was diluted 1:200 and used for indirect immunofluorescence on fixed Hep-2 ANA 
slides (Antibodies Incorporated), with fluorescein-conjugated goat anti-mouse IgG 
(Southern Biotech) as the detection reagent. Slides were read on a fluorescent 
microscope at 400x magnification and scored as either nuclear homogenous, nuclear 
speckled, or cytoplasmic staining patterns by a reader blinded to the genotype of the 
mice. In addition, each serum sample was scored for staining of mitotic chromosomes. 
Images were captured with a constant exposure time of 4.0 seconds for TLR9 sera and 
2.5 seconds for TLR3 sera. For TLR9 F2 mice, endpoint titration of serum was 
performed at reciprocal dilutions of 50, 200, 800, 2000, 104,4 x l0 4, and 105, and samples 
were scored for the presence of nuclear staining, regardless of pattern or cytoplasmic 
staining. Serum samples from 26 week old C57BL/6 mice were negative for ANA at 
1:50 dilution (data not shown).
For anti-dsDNA, 1:10 diluted serum was applied to fixed Crithidia luciliae slides 
(Antibodies Incorporated), with biotin-conjugated goat anti-mouse IgG (Southern 
Biotech) and Alexa Fluor 555-conjugated streptavidin (Molecular Probes) as detection 
reagents. Crithidia DNA was co-localized with 4 ’,6-diamidino-2-phenylindole (DAPI, 
Molecular Probes). Slides were read at lOOOx magnification and scored 0-4 for intensity 
of kinetoplast staining by a reader blinded to the genotype of the mice. Images were 
captured with a constant exposure time of 0.5 seconds in red (IgG) and blue (DAPI) 
channels, then transferred into green (IgG) and red (DAPI) channels.
Anti-Sm Western blot and ELISA.
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For Western blot, purified bovine Sm antigen (Immunovision) was separated by 
SDS-PAGE, transferred to nitrocellulose membrane, and probed with 1:200 diluted 
serum, using alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotech) 
and BCIP/NBT substrate (KPL, Inc.) as detection reagents. The monoclonal mouse anti- 
Sm antibody Y12 (145) was used as a standard. Blots were scored for the presence of 
visible anti-Sm bands at either 10-15 kD for Sm D protein or 25-35 kD for Sm B/B’ 
proteins. For ELISA, polystyrene plates were coated with Sm antigen, blocked with 1 % 
BSA in PBS, and serial dilutions of serum from 1:50 to 1:36,450 were added. Anti-Sm 
antibodies were detected with alkaline phosphatase-conjugated goat anti-mouse IgG 
(Southern Biotech), and absorbance at 405/630nm was compared to the Y 12 standard to 
quantitate.
Anti-cardiolipin ELISA.
Polystyrene plates were coated with cardiolipin by incubation with 100 pg/ml 
bovine cardiolipin (Avanti Polar Lipids) in 100% ethanol at 4 °C until completely 
evaporated (12-18 hours). Plates were blocked with 1% BSA in PBS, and serial dilutions 
of serum from 1:100 to 1:2700 were added. Anti-cardiolipin antibodies were detected 
with alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotech), and 
absorbance at 405/630nm was compared to the FD1 standard to quantitate. Anti- 
cardiolipin standards were generously provided by Marc Monestier.
Analysis of lymphocyte subsets and serum IgG.
Spleen and lymph node cells were isolated, counted, and stained with the 
following antibodies for fluorescence-activated cell sorting analysis: anti-Thyl.2 
(30H12), anti-CD4 (GK1.5), anti-CD8 (TIB105), anti-CD44 (IM7), anti-CD62L (Mel-
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14), and anti-CD22.2 (Cy34.1). All antibodies except anti-CD22.2 (BD Pharmingen) 
were made in our laboratory. Total serum IgG and IgG2a were determined by ELISA. 
Polystyrene plates were coated with goat anti-mouse IgG (Southern Biotech), blocked 
with 1% BSA in PBS, and serial dilutions of serum from 1:104 to l:7 .3xl06 were added. 
IgG or IgG2a was detected with alkaline phosphatase-conjugated goat anti-mouse IgG or 
goat anti-mouse IgG2a (Southern Biotech), and absorbance at 405/630nm was compared 
to known mouse IgG or IgG2a standards to quantitate.
Serum IFN-a ELISA.
Serum was collected at the age of 17-18 weeks for TLR9, or at the time of 
sacrifice for TLR3 mice, and IFN-a was measured by ELISA. Polystyrene plates were 
coated with monoclonal rat anti-mouse IFN-a (PBL Biomedical Laboratories), blocked 
with 1% BSA in PBS, and 1:10 diluted serum was added. IFN-a was detected with 
rabbit anti-mouse interferon-a (PBL Biomedical Laboratories) and alkaline phosphatase- 
conjugated goat anti-rabbit IgG (Southern Biotech). Absorbance at 405/630nm was 
compared to recombinant mouse IFN-aA standard (PBL Biomedical Laboratories) to 
quantitate. Limit of detection of the assay was 1.0 ng/ml in undiluted serum.
Analysis of kidney disease.
Kidneys were bisected, and one half was fixed in formalin and the other in 
paraformaldehyde (0.7% in PBS with 1.37% L-lysine and 0.2% sodium periodate). 
Paraformaldehyde-fixed kidneys were then dehydrated in 30% sucrose and flash-frozen 
in OCT. Formalin-fixed kidneys were paraffin-embedded, sectioned, and H&E or PAS 
stained (Histo-Scientific Research Laboratories). Stained sections were scored for 
glomerular and interstitial disease by a renal pathologist (Michael Kashgarian) who was
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blinded to the genotype of the mice. For IgG deposition, frozen kidneys from 8 TLR9+/+ 
and 8 TLR9/_ mice were sectioned and stained with biotin-conjugated goat anti-mouse 
IgG (y chain-specific, Southern Biotech, Birmingham, Alabama) and Alexa Fluor 647- 
conjugated streptavidin (Molecular Probes, Eugene, Oregon). For C3 deposition, frozen 
kidney sections were stained with monoclonal rat anti-mouse C3 (Connex) and Alexa 
Fluor 647-conjugated goat anti-rat IgG (cross-adsorbed against mouse IgG, Molecular 
Probes, Eugene, Oregon). Stained sections were read on a fluorescent microscope at 
400x magnification and images were captured with a constant exposure time of 0.5 
seconds. To quantitate IgG and C3 deposition, mean fluorescence was calculated from 
captured images; 2 representative glomeruli per mouse were outlined and mean pixel 
intensity was calculated with Adobe Photoshop.
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Figure 1. TLR9-deficient sera lack anti-DNA and anti-chromatin staining 
patterns. (A) ANAs were determined in sera (1:200 dilution) from 20-week old 
F2 mice. TLR9+/+ sera are shown in upper panels (from left: homogenous pattern, 
speckled pattern, and speckled pattern); TLR9 / sera are shown in lower panels 
(from left: speckled pattern, speckled pattern, and cytoplasmic pattern). Some 
TLR9+/+ sera had predominantly speckled patterns superimposed upon faint 
homogenous staining (middle panel). White arrows indicate cells in metaphase 
which demonstrate positive (upper panels, TLR9+/+) or negative (lower panels, 
TLR97 ) chromatin staining. Original magnification 400x. (B) Digitally enlarged 
images of metaphase cells with positive (TLR9+/+, upper) or negative (TLR9'/ , 
lower) chromatin staining. (C) Serum ANAs were classified as either nuclear 
homogenous, nuclear speckled, or cytoplasmic staining patterns. Black bars 
indicate TLR9+/+ sera (n = 19); white bars indicate TLR9 A sera (n = 16). (D) As in 
(C), but serum ANAs were classified as either positive or negative for mitotic 
chromatin staining. *P < 0.02, **P < 0.01, ***P < 0 .0001, Fisher’s exact test.
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Figure 2. Unaltered ANA patterns in TLR3-deficient sera. (A) Serum ANAs 
were determined as in Figure 1. TLR3+/+ sera are shown in upper panels (from left: 
homogenous pattern, speckled pattern, and speckled pattern); TLR3'/_ sera are 
shown in lower panels (from left: homogenous pattern, speckled pattern, and 
speckled pattern). White arrows indicate cells in metaphase which demonstrate 
positive chromatin staining. Original magnification 400x. (B) Digitally enlarged 
images of metaphase cells with positive chromatin staining. (C) Serum ANAs 
were classified as either nuclear homogenous, nuclear speckled, or cytoplasmic 
staining patterns. Black bars indicate TLR3+/+ sera (n = 15); white bars indicate 
TLR3 7' sera (n = 17). (D) As in (C), but serum ANAs were classified as either 
positive or negative for mitotic chromatin staining.
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Figure 3. Reduced anti-dsDNA autoantibodies in TLR9" ' but not TLR3'A mice.
(A) Anti-dsDNA antibodies were detected by Crithidia luciliae immunofluorescence. 
IgG antibodies to C. luciliae DNA are shown in green (left panels), and DAPI 
staining of DNA is shown in red (center panels). White arrows indicate the 
kinetoplast. Specific anti-dsDNA antibodies are identified by co-localization of IgG 
and DAPI staining in the kinetoplast (yellow, right panels). Representative TLR9+/+ 
sera are shown in upper two rows (intensity scores of 3+ and 1+), and TLR9'A sera are 
shown in lower two rows (intensity scores of 1+ and 0). Original magnification 
lOOOx. (B-C) Specific anti-dsDNA staining of C. luciliae kinetoplast was scored 
from 0 to 4 as in (A) for either TLR9+/+ (n = 19) and TLR9_/ (n = 16) sera (B), or 
TLR3+/+ (n = 15) and TLR3 A (n = 17) sera (C). *P < 0.02, Mann-Whitney U test.
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Figure 4. Presence of anti-Sm and anti-cardiolipin autoantibodies in 
TLR-deficient mice. (A) Anti-Sm antibodies were detected by Western blot in 
TLR9+/+ (WT, n = 19) and TLR9 ; (KO, n = 16) sera. The monoclonal anti-Sm 
antibody Y12 was used as a positive control. Pictured portion of the gel is from 
29-34kD, corresponding to the B and B ’ cluster of Sm proteins. (B) Anti-Sm 
antibodies were detected in TLR3+/+ (WT, n = 15) and TLR3 A (KO, n = 17) sera as in 
(A). Non-autoimmune control sera are also pictured (neg, n = 4). (C) Sera from 
TLR9 and TLR3 cohorts was scored as either positive or negative for anti-Sm 
antibodies by Western blot as in (A) and (B). (D-E) Anti-Sm antibodies were 
confirmed by ELISA in either TLR9+/+ (n = 19) and TLR9 ' (n = 16) sera (D), or 
TLR3+/+ (n = 15) and TLR3_/' (n = 17) sera (E). (F) Anti-cardiolipin antibodies were 
detected in serum from 17-18 week old TLR9+/+ (n = 19) and TLR9 ; (n = 16) mice by 
ELISA. Bars represent median values. **P < 0.005, Fisher’s exact test (C) or 
Mann-Whitney U test (D).
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Figure 5. Lymphadenopathy, hypergammaglobulinemia, activated lymphocytes, 
and circulating interferon in TLR-deficient mice. (A-D) TLR9+/+ (filled diamonds, 
n = 19), TLR9 /' (open diamonds, n = 16), TLR3+/+ (filled circles, n = 15), and TLR3'/_ 
(open circles, n = 17) mice were sacrificed at 20 weeks of age and assessed for 
evidence of aberrant immune activation; non-autoimmune C57BL/6 control mice 
(open squares, n = 4) were sacrificed at 26 weeks of age. (A) Spleens and the two 
largest axillary lymph nodes were weighed. (B) Total serum IgG and IgG2a were 
determined. (C) Splenocyte subsets were enumerated by FACS analysis for T cells 
(Thyl.2+), DNTC (CD4-/CD8- double-negative T cells), and B cells (CD22+). (D) 
Splenic CD4+ T cells were classified as either naive (CD44- CD62L+), activated 
(CD44+ CD62L+), or memory (CD44+ CD62L-) phenotype. The analysis in (D) was 
performed on 12 TLR3+/+ and 12 TLR3 y mice. (E) IFN-a levels in serum from 17-18 
week-old TLR9+/+ (n = 19) and TLR9_/ (n = 16) mice were determined by ELISA.
(F) As in (E) for TLR3+/+ (n = 15) and TLR3_/ (n = 17) mice at the time of sacrifice. 
Limit of detection of the assay was 1.0 ng/ml.
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Figure 6. Glomerulonephritis in the absence of anti-DNA autoantibodies.
Histological renal disease was assessed in TLR9+/+ (n = 19), TLR9 ' (n = 16),
TLR3+/+ (n = 15) and TLR3 7 (n = 17) mice at 20 weeks of age. (A-F) Paraffin 
kidney sections from TLR9+/+ (A-B) and TLR9 / (C-D) mice were stained with H&E 
(A, C) or PAS (B, D). Interstitial infiltrates (E) and glomerular disease (F) were 
scored from 0-4 for all mice. (G-L) Paraffin kidney sections from TLR3+/+ (G-H) and 
TLR3'/_ (I-J) mice were stained with H&E (G, I) or PAS (H, J). Interstitial infiltrates 
(K) and glomerular disease (L) were scored from 0-4 for all mice. Representative 
images are shown. Original magnification was lOOx for H&E sections (A, C, G, I) 
and 400x for PAS sections (B, D, H, J).
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Figure 7. Glomerular immune deposits do not require anti-DNA antibodies.
(A) Glomerular immune deposits were detected by direct immunofluorescence for 
IgG (upper panels) and complement C3 (lower panels) in frozen kidney sections 
from TLR9+/+ (left panels), TLR9'A (center panels), and non-autoimmune C57BL/6 
control mice (right panels). Representative images are shown. Original 
magnification 400x. (B) Mean glomerular fluorescence intensity (arbitrary units) 
was determined for IgG and C3 in TLR9+/+ (filled diamonds, n = 8) and TLR97' 
(open diamonds, n = 8) mice.
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Figure 8. Serum autoantibodies in backcrossed TLR3-deficient MRL/lpr mice.
(A) Serum ANAs from 18 week old mice at 1:200 dilution were classified as nuclear 
homogenous, nuclear speckled, or cytoplasmic staining patterns. Black bars indicate 
TLR3+/+ sera (n = 10), and white bars indicate TLR3 y sera (n = 8). (B) As in (A), but 
serum ANAs were classified as either positive or negative for mitotic chromatin 
staining. (C) Total serum IgG and IgG2a were determined. (D) Serum anti-Sm 
antibodies were quantitated by ELISA. (E) Antibodies to Sm D protein (14 kD) and 
Sm B protein cluster (25-30 kD) were verified in representative TLR3+/+ (WT) and 
TLR3 ; (KO) serum by Western blot. The monoclonal anti-Sm antibody Y12 was 
used as a positive control.
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Chapter 3: Contributions of TLR9 and TLR7 to Autoantibody 
Production and Disease Pathogenesis
Autoantibodies in SLE can be broadly classified as reacting to macromolecular 
complexes containing either DNA or RNA (7, 20, 22, 24). We observed that in the 
context of an F2 hybrid genetic background, lupus-prone mice deficient in TLR9 failed to 
generate autoantibodies to dsDNA and DNA-containing antigens such as chromatin. 
Despite this lack of a canonical autoantibody specificity, TLR9_/ mice nevertheless 
developed signs of severe autoimmune disease, including lupus nephritis. Moreover, 
several markers of immune activation were increased in TLR9; mice compared to wild- 
type controls, and the generation of autoantibodies to RNA-containing antigens such as 
Sm was similarly enhanced. We questioned whether the absence of TLR9 signaling, or 
the altered autoantibody repertoire generated in the absence of TLR9 was responsible for 
the potentially exacerbated disease in autoimmune TLR9y mice. In order to address this 
possibility, TLR9-deficient mice were extensively backcrossed to a homogenous genetic 
background known to induce spontaneous lupus-like disease. We then confirmed our 
initial findings on the effect of TLR9 on the autoantibody repertoire, and investigated the 
role of TLR9 and autoantibodies in autoimmune pathogenesis.
Because TLR9 was found to be critical for the generation of antibodies to DNA- 
containing antigens, we speculated that another TLR would be required for production of 
antibodies to RNA-containing antigens. Although TLR3 is a receptor for dsRNA, 
absence of this receptor in lupus-prone mice did not affect autoantibody production or 
clinical disease, presumably due to the lack of TLR3 expression on B cells or the paucity
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of double-stranded regions in endogenous RNA antigens. A more promising candidate is 
TLR7, a receptor for ssRNA (56-58). TLR7 is highly homologous to TLR9 (154), and, 
like TLR9, is expressed in endosomal compartments of B cells and pDCs, and transmits 
signals exclusively through the adaptor protein MyD88 (51, 72, 107). We therefore 
generated autoimmune-prone TLR7-deficient mice on a partially defined genetic 
background, and investigated the requirement for this receptor in the generation of 
autoantibodies to RNA-containing antigens. In addition, because the absence of TLR9 
appeared to modify clinical disease in our initial analysis, we examined the effect that 
TLR7 deficiency had on the pathogenesis of SLE.
Generation of Lupus-Prone Mice Deficient in TLR9 or TLR7
In order to analyze the effects of TLR9 on SLE in a more controlled genetic 
experiment, we generated TLR9-deficient autoimmune mice of a homogenous and 
defined genetic background. TLR9+/ hybrid mice were backcrossed eight generations to 
Fas-deficient, lupus-prone MRL/Mp//,r//pr mice (139), at which point over 99.8% of the 
genome was statistically derived from the MRL/Mp strain. We also verified that all 
TLR9' mice expressed the MHCk/k and Ig^3 haplotypes derived from MRL/Mp (data not 
shown). To further exclude bias in these studies, we analyzed mice from heterozygous 
mating pairs, wherein TLR9+/+ mice were used as littermate controls for TLR9 ; animals.
Because TLR7 is located on the X chromosome (154), we were able to analyze 
TLR7-deficient lupus-prone mice on a partially defined genetic background without 
extensive backcrossing. Hybrid TLR7+/' females were generated, then backcrossed three 
generations to male MRL/Mp//,r///,r mice, selecting only those mice which were
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homozygous for the Faslpr,lpr mutation as well as the MHCk/k and Iga/a haplotypes. After 
the third backcross generation, TLR7+/y and TLR7/y male littermates were used for 
analysis. Importantly, no loci from an undefined genetic background could be 
homozygous in these mice, as every locus harbored at least one copy of the MRL/Mp 
allele derived from the male parent.
ANA Profiles in Autoimmune TLR-Deficient Mice
The fluorescent ANA assay is historically the most sensitive detection method for 
antibodies to both RNA-containing and DNA-containing antigens as they exist in situ in 
their native forms (7, 141). As described in Chapter 2, classification of the nuclear 
staining pattern as either homogenous (corresponding to anti-DNA antibodies), or 
speckled (indicative of antibodies to RNA splicing complexes such as Sm and RNP) can 
also reveal the dominant autoantibody specificity in autoimmune sera (21-23). We 
therefore began our analysis of the autoantibody repertoire in TLR9; MRL/MpZpr///,r 
(hereafter, TLR9 7 ) mice with the ANA assay. As is typical in the MRL/Mp/pr///,r strain, 
the majority of wild-type sera produced a homogenous nuclear staining pattern, and 25 of 
26 TLR9+/+ mice produced anti-chromatin antibodies, as determined by equatorial 
staining of chromosomes in metaphase cells (Fig. 9A-C). In contrast, none of the sera 
from 21 TLR9 ; mice produced homogenous staining, and only 2 mice generated 
antibodies capable of binding to mitotic chromatin (Fig. 9A-C, P < 0.0001). These 
results confirm our earlier findings in F2 hybrid mice, and indicate a severe impairment 
in the generation of antibodies to native DNA and chromatin in lupus-prone TLR9'A mice.
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Analysis of the staining patterns generated by TLR9-deficient sera revealed a 
potential shift in repertoire specificity, favoring antibodies to RNA-containing antigens. 
An equivalent fraction of sera from both groups produced speckled nuclear staining 
patterns, but an additional pattern emerged in TLR9-deficient sera that was not observed 
in wild-type controls. Sera from 15 of 21 TLR9_/ mice stained the HEp-2 cell substrate 
in a primarily cytoplasmic pattern, accounting for a significant shift in the ANA pattern 
distribution (Fig. 9A-B, P < 0.0001 for comparison of pattern distribution between 
TLR9+/+ and TLR9'/_).
Among the multiple specificities that produce cytoplasmic staining, antibodies to 
RNA and RNA complexes are most common. Fine granular or web-like staining of 
perinuclear cytoplasm, along with faint speckled nuclear staining (Fig. 9A, lower right 
panel) is characteristic of antibodies to aminoacyl-tRNA synthetases (anti-Jo-1 
antibodies) (23). TLR9 A sera also produced a more homogenous cytoplasmic staining 
pattern (data not shown), typical of anti-ribosomal antibodies (23, 26). In addition, the 
cytoplasmic staining patterns generated by T L R 9 se ra  may be due to anti-Ro/SSA or 
anti-La/SSB antibodies, or even antibodies to naked RNA (26, 82). Although 
cytoplasmic ANAs can also be produced by antibodies to organelles such as endosomes, 
the Golgi apparatus, or mitochondria, these antibodies stain discrete regions of the 
cytoplasm in a characteristic pattern (23) which was not observed in sera from TLR9; 
mice (Fig. 9A and data not shown). Thus, although TLR9-deficient and wild-type sera 
both produced nuclear speckled patterns characteristic of anti-Sm/RNP antibodies, only 
TLR9 7 mice generated antibodies reacting with presumed RNA antigens in the cytosol.
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Analysis of ANA staining by TLR7-deficient or wild-type sera revealed patterns 
typical of SLE. The majority of mice in both groups produced anti-DNA antibodies, as 
determined by homogenous nuclear staining, and all serum samples contained anti­
chromatin antibodies (Fig. 10A-C). Although sera from both groups of mice produced 
nuclear speckled patterns, this characteristic staining of Sm/RNP antigens was observed 
in only 3 of 20 TLR7'/y mice, compared to 6 of 20 TLR7+/y mice (Fig. 10A-B, P > 0.05). 
Moreover, sera from wild-type mice tended to produce a pure speckled staining in the 
absence of any other patterns, while speckled patterns in TLR7-deficient sera were 
obscured by a superimposed homogenous staining (Fig. 10A). Although this was not a 
statistically significant difference, it suggested an impairment in the generation of 
antibodies to RNA complexes in TLR7"/y mice, and prompted the analysis of specific 
autoantibodies to RNA-containing antigens.
Impaired Generation of Specific Autoantibodies in TLR-Deficient Mice
The lack of homogenous nuclear and mitotic chromatin staining patterns in TLR9 
; sera indicated a block on the generation of antibodies to DNA-containing antigens. We 
sought to confirm this with several assays for anti-DNA antibodies. Because of the high 
specificity of Crithidia luciliae immunofluorescence in the detection of antibodies to 
dsDNA (143, 144), we began with this assay. TLR9 7 serum showed a substantial 
decrease in antibodies binding the dsDNA of the C. luciliae kinetoplast (Fig. 11A, P < 
0.0001). Although this decrease was highly significant, there was not a complete block 
in anti-dsDNA antibody production, as sera from some mice did specifically stain the 
kinetoplast. This low level of anti-dsDNA antibody production in TLR9; mice is in
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contrast to the complete absence of antibodies to native DNA/chromatin as determined by 
the ANA assay. It is probable that this difference reflects the nature of the endogenous 
antigens in lupus: mammalian DNA exists in a complex with histones and the other 
protein components of chromatin, and is rarely encountered as naked dsDNA. Thus, the 
physiologic autoantigen is chromatin, and the presence of antibodies to an artificial 
antigen such as naked dsDNA may be less relevant to autoimmune pathogenesis (155).
Although immunofluorescent-based assays are useful for the detection of specific 
autoantibodies, it is difficult to use these assays to determine serum antibody 
concentrations. We therefore turned to ELISA-based assays to quantitate the decrease in 
antibodies to DNA-containing antigens in TLR9 7 sera. Using an anti-nucleosome 
ELISA in which the detection antigen was the combination of histones and dsDNA, we 
observed an order of magnitude decrease in specific anti-DNA antibodies in TLR97 sera 
(Fig. 1 IB, P < 0.0001). When we employed a standard ELISA for dsDNA in which the 
detection antigen was the combination of poly-L-lysine and dsDNA, however, there was 
not a significant decrease in TLR97 sera (Fig. 11C). TLR7/y sera, in contrast, exhibited 
no defect in the generation of anti-DNA antibodies by either assay (Fig. 11D-E). The 
apparently conflicting findings in TLR97 sera illustrate two points. First, this highlights 
the low specificity of ELISA-based assays, which are known to be susceptible to high 
false positive rates (141, 143, 156). Second, this again implicates the chromatin complex 
of DNA and histones as the endogenous antigen recognized by TLR9 in SLE, while 
antibodies binding to purified dsDNA may represent cross-reactivity with other nucleic 
acid autoantigens, or charge-based non-specific association. It is therefore imperative to
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use ELISA-based assays in concert with the traditional immunofluorescent ANA to 
account for both of these potential problems.
We also employed ELISA based assays for anti-RNA complex antibodies to 
further investigate the suggestive findings from the altered ANA patterns in TLR9- and 
TLR7-deficient sera. We found no difference between TLR9+/+ and TLR9' sera for 
antibodies to either the Sm antigen or the Sm/RNP complex, which agreed with the 
equivalent incidence of speckled nuclear ANA patterns in the two groups (Fig. 12A-B). 
Also in agreement with ANA staining patterns was the complete lack of anti-Sm 
antibodies in TLR7'/y mice (Fig. 12C). However, because anti-Sm antibodies occur with 
a relatively low prevalence in murine lupus (145) and only 4 of 20 TLR7+/y sera harbored 
detectable anti-Sm antibodies, the lack of anti-Sm in TLR7/y sera did not represent a 
significant difference (P = 0.106 by Fisher’s exact test). We therefore used a less 
selective antigen, the complex of Sm and RNP, to detect antibodies to RNA-containing 
antigens in these mice. Although there was still only a small subset of wild-type mice 
that produced high titers of anti-Sm/RNP, we nevertheless observed a significant 
decrease in anti-Sm/RNP autoantibodies in TLR7-deficient sera (Fig. 12D, P = 0.0454). 
We found that all wild-type sera contained anti-Sm/RNP antibodies above the limit of 
detection, while these antibodies were undetectable in 5 of 20 TLR7 /y sera (P = 0.0471 
by Fisher’s exact test). We therefore conclude that TLR7 can facilitate the production of 
antibodies to RNA-containing antigens in SLE, as at least one subset of these antibodies 
was decreased in autoimmune TLR7'/y mice.
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Opposing Effects of TLR7 and TLR9 on Clinical Disease and Immune Activation
Having observed the effects of deficiency of TLR7 or TLR9 on autoantibody 
production, we then determined what impact the absence of these receptors would have 
on the manifestation of clinical autoimmune disease. Lupus-prone TLR9+/+ and TLR9; 
littermates were analyzed for the typical signs of SLE in the MRL/Mp'7" '^  model at 13-14 
weeks of age, when evidence of disease was clearly apparent in most mice. We found 
that TLR9' mice had a significant increase in the incidence and severity of autoimmune 
skin disease compared to wild-type controls (Fig. 13A, P = 0.0136). Concordant with 
this was increased lymphadenopathy and splenomegaly in TLR9_/ mice (Fig. 13B, P = 
0.0043 and 0.0023, respectively), as had been observed in the initial F2 hybrid analysis.
We also analyzed these parameters in TLR7+/y and TLR7/y mice, which were 
sacrificed at 16 weeks of age. This cohort of mice exhibited less accelerated disease than 
the TLR9 mice, presumably due to the less extensive backcrossing and the fact that all 
the mice were males. Analysis of skin disease revealed an opposite effect in TLR7- 
deficient mice that than seen in TLR9 A animals, as TLR7 /y mice had no apparent skin 
disease at this time point (Fig. 13A). Although skin disease was evident in TLR7+/y mice, 
it occurred with a relatively low frequency such that the difference between the two 
groups did not reach statistical significance (P = 0.0878). Analysis of lymphadenopathy, 
however, did reveal a significant decrease in both lymph node and spleen weight in 
TLR7'/y mice compared to wild-type littermates (Fig. 13B, P = 0.0005 and 0.0295, 
respectively).
Increased spleen and lymph node weight in MRL/Mp//’r/,pr mice is generally a 
result of uncontrolled lymphocyte activation and failed cell death, as autoreactive
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lymphocytes expressing an activated phenotype accumulate in these organs. We 
therefore enumerated T and B cell subsets in these organs as a measure of global immune 
activation. As expected from their increased spleen and lymph node weight, TLR9 A 
mice had an increased number of CD4+ helper T cells as well as a three-fold increase in 
the number of CD4' CD8 double-negative T cells in the spleen (P = 0.0096 and 0.002, 
respectively), while CD8+ T cells and total B cell numbers were unaffected (Fig. 13C). 
TLR7-deficient mice, in contrast, exhibited a decrease in this aberrant population of 
double-negative T cells (Fig. 13C, P = 0.0155), thought to arise from the inability to 
delete activated cells in Fas-deficient animals (139). Analysis of T cell activation status 
in the lymph node revealed similar phenotypes. TLR9'/_ mice had a decrease in naive 
phenotype CD4+ cells, with a concomitant increase in activated and memory phenotype 
cells, while TLR7 /y mice had an increase in naive cells, which a parallel decrease in cells 
of a memory phenotype (Fig. 13D, P = 0.0033 for TLR9 and 0.0019 for TLR7). Similar 
results were observed in the spleen (data not shown). Finally, deficiency of these 
receptors also affected B cell activation. Splenic B cells from TLR9 7 mice expressed 
higher levels of the activation markers CD44 and CD69 (P = 0.0002 and 0.0333, 
respectively), while B cells in TLR77y mice expressed lower levels of CD44 (Fig. 13E, P 
= 0.0026). Taken together, these data indicate that while the lack of TLR9 led to 
accelerated disease and increased global immune activation, lack of TLR7 had the 
opposite effect, decreasing disease and immune activation in autoimmune mice.
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Divergent Effects of TLR7 and TLR9 on Plasmacytoid Dendritic Cells
We found that TLR7 and TLR9 appeared to have opposing effects on lymphocyte 
activation in SLE. Since these receptors are expressed not only by B cells but by 
interferon-producing pDCs as well (52,72), we hypothesized that the lack of these 
receptors could similarly influence the activation state of pDCs. Identifying pDCs as 
C D llc int pDCA-l+ cells (157), we found that splenic pDCs from TLR9_/ mice appeared 
to be more activated than wild-type pDCs based on the increased expression of MHC 
class II (Fig. 14A). Conversely, pDCs from TLR7/y mice had a lower level of class II 
expression, implying a more immature, un-activated state. This effect was specific to 
pDCs, as conventional, C D llc hl myeloid dendritic cells (mDCs) did not reveal any 
change in activation marker expression in the absence of either receptor (Fig. 14A-B). 
Comparing class II expression across all wild-type and TLR-deficient mice in each cohort 
revealed a significant increase in TLR9 A mice and a corresponding decrease in TLR7'/y 
mice (Fig. 14C, P < 0.0001 for TLR9 and P = 0.0144 for TLR7). Plasmacytoid DCs 
from TLR9 a mice also expressed an increased level of the activation markers B7-1 and 
B7-2 (P = 0.0007 and 0.0002, respectively), an effect which was not observed in TLR7- 
deficient mice (Fig. 14C).
The altered expression of activation markers by pDCs in TLR-deficient mice 
suggested a specific effect of these receptors on pDC function in SLE. The major 
functional consequence of pDC activation by TLRs, however, is the secretion of type I 
interferons (IFN-I). Because IFN-I has also been implicated in the pathogenesis of 
autoimmune disease, we determined circulating levels of IFN-a in TLR-deficient lupus- 
prone mice. In agreement with the increased pDC activation state, we observed an
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increase in serum IFN-a in TLR9 ' mice (Fig. 15). Although quantification of systemic 
IFN may not detect small amounts of IFN produced locally, we nevertheless found that 
more than half of TLR9; sera contained detectable levels of IFN-a, compared with only 
2 of 26 wild-type sera (P = 0.0009 by Fisher’s exact test). This again indicates an 
increased level of global activation of pDCs, accompanied by an increase in systemic 
IFN-a production in autoimmune TLR9; mice. Because very few sera from either 
TLR7+/y or TLR7/y mice contained detectable levels of IFN-a, we could not determine 
what effect TLR7 deficiency had on systemic IFN-I production. The decreased pDC 
activation state observed in TLR7'/y mice, however, did not completely preclude the 
production of IFN-I, as low levels of IFN-a were detected in some TLR7'/y sera (Fig. 15).
TLR7 and TLR9 Differentially Affect IgG Isotype Production
Activation of TLRs within B cells can lead to the production of class-switched 
antibodies (74, 75), and factors elaborated by activated mDCs and pDCs can also 
stimulate B cell antibody production and isotype switch (97, 98, 120). We therefore 
determined total serum IgG levels as a measure of global B cell activation in TLR- 
deficient mice. TLR9'/_ sera contained elevated levels of every IgG isotype, but the most 
prominent increases were in IgG2a and IgG3, which were two-fold greater than in wild- 
type sera (Fig. 16, P = 0.0038 for IgG l, 0.0043 for IgG2a, 0.0006 for IgG2b, and P < 
0.0001 for IgG3). Conversely, sera from TLR7/y mice had decreased levels of total IgG, 
but this decrease was specific for the inflammatory isotypes IgG2a and IgG3 (Fig. 16, P < 
0.0001 for both). Interestingly, the isotypes profoundly and divergently affected by the 
absence of TLR7 or TLR9 are the immunoglobulin isotypes most potently induced by
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IFN-I (97). These findings further support the reciprocal effects of TLR7 and TLR9 on 
pDC activation, and raise the question of whether the altered IgG isotype profiles in 
TLR-deficient mice are due to a primary B cell defect or a secondary effect of pDC 
activation and IFN-I production.
Impact o f TLR Deficiency on Lupus Nephritis and Mortality
The definitive measure of end-organ pathology in SLE is the presence of lupus 
nephritis. In agreement with increased evidence of disease by every other measure, 
TLR9-deficient mice developed exacerbated kidney disease. We observed increased 
glomerular size, cellularity, and protein deposition in TLR9' kidney sections, leading to 
a composite glomerulonephritis score that was significantly greater than wild-type 
littermates (Fig. 17, A and C, P = 0.0024). Kidneys from MRL/Mp//,r///,r mice also show a 
characteristic interstitial infiltration of lymphocytes and monocytes, primarily centered 
around major vessels (perivascular infiltrate), but occasionally invading the cortical 
parenchyma as well. Although we observed a trend toward increased severity of 
interstitial infiltrates in TLR9; mice, this did not reach statistical significance (Fig. 17C). 
TLR7-deficient mice, in contrast, appeared to have ameliorated renal disease, with 
decreased glomerular protein deposition and preserved glomerular structure (Fig. 17B). 
In a reflection of the findings in TLR9 A mice, TLR7/y mice exhibited a non-significant 
trend toward decreased interstitial disease, but showed a significant decrease in 
glomerular disease (Fig. 17D, P = 0.019). The primary effect on glomerular disease and 
protein deposition may implicate the reciprocally increased or decreased IgG2a/IgG3 
titers in TLR9 or TLR7 sera as a critical mediator of nephritis in these mice.
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We observed an increase in nearly every marker of disease severity in lupus-prone 
TLR97 mice, along with a reciprocal decrease of several of these markers in TLR7'/y 
mice. It remained unclear, however, whether these disease markers truly affected 
mortality in these mice. We therefore allowed a second cohort of TLR9+/+, TLR9+/', or 
TLR9; MRL/Mp,/,r//pr littermates to develop spontaneous disease, and monitored them 
without intervention until the time of death or irreversible morbidity. We found that 
TLR9-deficient mice had accelerated mortality relative to wild-type controls, as median 
survival was reduced from 31 weeks in TLR9+/+ mice to 16 weeks in TLR9_/ mice (Fig.
18, P = 0.0261). TLR9+/' heterozygote mice appeared to have an intermediate phenotype, 
although we have not yet collected enough data on these mice to make that conclusion. 
Preliminary analysis of a few TLR9+/' sera revealed ANA patterns similar to wild-type 
sera (data not shown), but the level of immune activation and clinical disease in these 
mice has not been determined. It thus remains possible that TLR9 could operate in a 
dose-dependent manner in SLE, which could have important implications for allelic 
variation and genetic predisposition to SLE in humans. Finally, our preliminary analysis 
of TLR7-deficient mice was not designed to assess mortality. As none of the mice in 
either the TLR7+/y or TLR7/y groups died before analysis at 16 weeks of age, it is 
unknown whether the absence of TLR7 will prolong lifespan in lupus-prone mice as a 
consequence of decreased disease severity.
Association of Disease Severity with Antibodies to RNA Complexes
We observed a decrease in antibodies to the RNA-containing Sm/RNP antigen in 
TLR7-deficient mice, while ANA patterns in TLR9-deficient mice indicated an increased
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incidence of antibodies to other RNA species. At the same time, we found ameliorated 
disease in TLR7 /y mice and exacerbated disease in TLR9'/_ mice. We therefore 
determined whether the presence of anti-RNA complex antibodies was associated with 
disease severity in these mice. TLR9+/+ and TLR9 A mice were each subdivided into two 
groups based on the presence of anti-Sm or anti-Sm/RNP antibodies as determined in 
Figure 12. Although TLR9 /_ mice appear to generate antibodies to other RNA-containing 
antigens besides Sm/RNP, we reasoned that the presence of these characteristic 
autoantibodies was at least a first approximation of elevated levels of antibodies to RNA 
complexes. We then found that the exacerbation of skin disease in TLR9-deficient mice 
was correlated with the presence of these specific antibodies, as TLR9 ; mice with anti- 
Sm/RNP antibodies had a significant increase in skin disease compared to TLR9_/ mice 
without anti-Sm/RNP (Fig. 19A, P = 0.0069).
The presence of antibodies to RNA complexes also appeared to enhance global 
immune activation in these mice. Although the potential increase in lymph node weight 
in TLR9‘; mice with anti-Sm/RNP did not reach statistical significance (Fig. 19B, P = 
0.07), these mice did show enhanced T cell activation, with a decreased proportion of 
splenic CD4+ T cells of a naive phenotype (Fig. 19C, P = 0.0209). The presence of 
antibodies to RNA-containing antigens also correlated with the activation of pDCs, which 
exhibited an increased activation state in TLR9_/ mice with these antibodies (Fig. 19D, P 
= 0.0302). Finally, TLR9; mice with anti-Sm/RNP antibodies also had elevated levels of 
total IgG2a and IgG3 (Fig. 19E-F, P = 0.0142 and 0.0302, respectively). These increased 
markers of systemic inflammation may be secondary to increased production of IFN-I. 
Although circulating levels of IFN-a were not associated with anti-Sm/RNP antibodies in
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TLR9; mice (data not shown), this association has been documented in human lupus 
patients (117).
The presence of anti-Sm/RNP antibodies in wild-type mice did not appear to 
affect global immune activation by most of these parameters (Fig. 19, A-C, E-F). It is 
possible that either the ability to signal through TLR9, or the presence of circulating anti­
chromatin antibodies exerted a regulatory effect in these mice and prevented global 
immune activation by antibodies to RNA-containing antigens. Even in TLR9+/+ mice, 
however, the presence of anti-Sm/RNP antibodies was associated with increased 
activation of pDCs (Fig. 19D, P = 0.0379). This highlights the potential importance of 
RNA-containing immune complexes in pDC activation, which have previously been 
demonstrated to be more potent inducers of IFN-I production than DNA-containing 
immune complexes (87, 114).
Discussion
We found that the requirement for TLR9 in the production of autoantibodies to 
DNA-containing antigens, first observed in lupus-prone F2 hybrid mice, also applied to 
TLR9; mice fully backcrossed to the MRLIMplprllpr strain. There appeared to be a more 
stringent requirement for TLR9 in the generation of anti-chromatin and anti-nucleosome 
antibodies than for the generation of antibodies to naked dsDNA. This suggests that the 
endogenous antigens recognized by TLR9 are complexes of DNA and histones, or at least 
that these antigens exist as complexes before delivery to TLR9-containing endosomes. 
ANA patterns from TLR9-deficient mice also suggested a shift in the autoantibody 
repertoire toward RNA-containing antigens, particularly those that exist in the cytosol.
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We also found that TLR7, a receptor for ssRNA, appeared to facilitate the production of 
antibodies to RNA-containing antigens such as Sm/RNP complexes involved in the 
processing of nuclear RNA. Although the prevalence of anti-Sm antibodies was not high 
enough in TLR7 wild-type mice to conclude that TLR7 is required for the generation of 
these antibodies, we plan to analyze a second cohort of TLR7+/y and TLR7'/y mice. 
Doubling the sample size of each group will provide the statistical power to definitively 
answer this question.
Analysis of clinical disease and markers of immune activation in TLR-deficient 
mice revealed opposing effects of TLR7 and TLR9. In the context of autoimmunity, 
TLR7 appeared to have a primary inflammatory role, as global immune activation and 
disease activity were decreased in its absence. TLR9, in contrast, appeared to have a 
regulatory role inhibiting the pathogenesis of SLE, as disease was exacerbated in TLR9- 
deficient mice. Because these two receptors are expressed in similar cell types and share 
downstream signaling pathways (72, 107, 158, 159), it was surprising that they should 
have such dramatically divergent effects on autoimmune disease. It is possible that the 
recruitment of additional adaptors or regulators of intracellular signaling by one of these 
TLRs could explain their disparate phenotypes, although there is currently no evidence 
for this. Competition between these receptors for shared adaptor molecules could also 
allow cross-inhibition when both receptors are ligated (160, 161), but this mechanism 
alone is unlikely to account for the completely opposite phenotypes observed in TLR7'/y 
and TLR9; mice. Instead, the autoantibodies induced by these receptors may be 
responsible for the phenotypes of their respective genetic knockouts. In this model, 
antibodies to RNA-containing autoantigens act as potent inducers of inflammation and
65
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
IFN-I production, a concept that has been documented in previous studies (117). 
Decreased anti-Sm/RNP antibodies in TLR7/y mice and the appearance of additional anti- 
RNA complex antibodies in TLR9'/_ mice could then account for ameliorated or 
exacerbated disease, respectively. Indeed, the association of anti-Sm/RNP antibodies 
with disease severity in TLR9 A mice suggests that the autoantibody repertoire can 
directly affect SLE pathogenesis.
These findings highlight two critical and potentially pathologic functions of TLRs 
in SLE. First, activation of the innate immune system by TLRs directs the autoantibody 
response to the characteristic lupus autoantigens; without appropriate TLR signaling, 
these antibodies are not generated. Second, TLRs can have a dramatic impact on disease 
pathogenesis, either by promoting disease in the case of TLR7, or regulating disease in 
the case of TLR9. The results presented here also illustrate the difficulty of establishing 
cause-effect relationships in in vivo models of autoimmune disease. For example, 
stimulation of TLRs in B cells could lead to the production of characteristic autoantibody 
profiles with either inflammatory (in the case of TLR7) or regulatory (in the case of 
TLR9) effects. These antibodies could then mediate tissue damage and control IFN-I 
production by pDCs. Alternatively, stimulation of TLRs in pDCs could directly affect 
IFN-I production, which would then secondarily control T cell activation, tissue damage, 
and autoantibody production by autoreactive B cells. To distinguish between these two 
possibilities, we will create an in vivo experimental model in which TLR9 deficiency is 
restricted to B cells. In addition, we will also perform in vitro stimulation experiments to 
dissect the mechanism of increased IFN-a production in TLR9-deficient mice.
Integration of data from all these experiments may allow us to discover the causal
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To generate TLR9 A mice of homogenous genetic composition, TLR9+/ from the 
FI cross to MRL/Mp/pr/,pr (Chapter 1) were backcrossed an additional eight generations to 
purebred M R L /M p^^ mice (Jackson Laboratory), selecting those mice which were 
homozygous for the ¥a.s,prllpr mutation. At this point (>99.8% of genome derived from 
MRL/Mp strain), TLR9+/ mice were verified to be MHC1^  and Ig^3 haplotypes by FACS 
analysis of peripheral blood cells. These backcross generation 8 mice were then 
intercrossed to produce 26 TLR9+/+ mice (14 male and 12 female) and 21 TLR9 A mice (7 
male and 14 female), which were analyzed between 13 and 14 weeks of age. For 
mortality assessment, additional TLR9+/~ mice were intercrossed to produce a second 
cohort of TLR9+/+, TLR9+/ , and TLR9'/_ mice, which were observed for a period of at 
least 12 weeks for all mice and up to 33 weeks for some mice. The survival analysis is 
ongoing.
To generate TLR7-deficient mice of a partially defined genetic background, 
female TLR7+/ mice of a mixed genetic background (C57BL/6 and 129Sv) were 
generously provided by Richard Flavell. These were bred to male MRL/Mp/pr///,r mice 
(Jackson Laboratory) to produce FI hybrids. Female TLR7+/' hybrids were then 
backcrossed an additional three generations to male M R L /M p^ '' mice. After the first 
backcross generation, TLR7+/ mice homozygous for the Fas//)r///"' mutation were selected
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for breeding. After the second backcross generation, mice were assayed for MHC and Ig 
haplotypes by FACS analysis of peripheral blood cells. Only those TLR7+/ mice that 
were MHC1^  and Ig3'3 were selected for breeding. Male TLR7+/y and TLR7/y offspring (n 
= 20 each genotype) from the third backcross generation were analyzed at 16 weeks of 
age. Statistically, 87.5% of genetic loci in these mice are homozygous for MRL alleles, 
while the remaining 12.5% are heterozygous.
ANA and anti-dsDNA immunofluorescence.
Serum was obtained at the time of sacrifice. ANA immunofluorescence on HEp- 
2 cells was performed at 1:200 dilution of serum as previously described (Chapter 2). 
Images were captured at 400X magnification with a constant 2.5 second exposure time. 
Crithidia luciliae immunofluorescence was performed at 1:50 dilution of serum as 
previously described (Chapter 2). Images were captured at 1000X magnification with a 
constant 0.7 second exposure time.
Anti-DNA and anti-Sm/RNP ELISA.
For anti-nucleosome ELISA, polystyrene plates were coated with bovine histones 
(Sigma), then secondarily coated with dsDNA from calf thymus (Sigma) that was phenol- 
extracted and SI nuclease treated to remove single-stranded regions. For anti-dsDNA 
ELISA, polystyrene plates were coated with poly-L-lysine (Sigma), then secondarily 
coated with dsDNA as above. Plates were then blocked with 1% BSA in PBS, and serial 
dilutions of serum from 1:200 to 1:5400 were added. Anti-DNA antibodies were 
detected with alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotech), 
and absorbance at 405/630nm was compared with either PL2-3 anti-nucleosome 
monoclonal antibody or PL9-6 anti-dsDNA monoclonal antibody to quantitate. PL2-3
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had 37-fold lower affinity for poly-L-lysine-dsDNA than for nucleosomes, and PL9-6 
had 15-fold lower affinity for nucleosomes than for poly-L-lysine-dsDNA. Anti-Sm 
ELISA was performed with serial dilutions of serum from 1:200 to 1:5400 as previously 
described (Chapter 2). Anti-Sm/RNP was performed similarly, but plates were coated 
with Sm/RNP complex antigen (Immunovision).
Determination of clinical disease.
Skin disease was scored at the time of sacrifice. Mice were scored for the 
presence and surface area of typical lesions on the dorsum of the head, neck, and back. 
Lesions generally consisted of alopecia, fibrosis, ulceration, and occasionally active 
bleeding. Scores ranged from 0-4 for affected area up to 4 cm2, with up to 1 additional 
point for the presence of ear dermatitis. Spleen and lymph node weights were determined 
as previously described (Chapter 2). Analysis of kidney disease was performed as 
previously described (Chapter 2), except that sections were scored by S. Christensen, 
who was blinded to the genotype of the mice.
Analysis of lymphocyte and dendritic cell activation.
Spleen and lymph node cells were isolated and T and B cell subsets and activation 
markers were determined as previously described (Chapter 2). Anti-CD69 antibody 
(H1.2F3, BD Biosciences) was used as an additional marker for B cell activation.
Myeloid and plasmacytoid DCs were identified with anti-CD 1 lc (HL3, BD Biosciences) 
and anti-mpDCA-1 (Miltenyi Biotec). Anti-MHC class II (M5/114.152, Biolegend), anti- 
B7-1/CD80 (16-10A1, BD Biosciences), and anti-B7-2/CD86 (GL1, BD Biosciences) 
were used to assess DC activation.
Serum IFN-a ELISA.
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IFN -a ELISA was performed as previously described (Chapter 2), except that 
serum was added at 1:5 dilution.
Analysis of IgG isotvpes.
Levels of IgG isotypes in serum were determined by Beadlyte Mouse 
Immunoglobulin Isotyping Kit (Upstate) according to the manufacturer’s instructions. 
Serum was tested at 1:250,000 dilution for TLR9 samples and 1:200,000 dilution for 
TLR7 samples.
Statistics.
Unless otherwise indicated, statistical comparisons between groups of mice were 
performed with the Mann-Whitney U test. For the comparison of dichotomous variables, 
Fisher’s exact test was used. For the comparison of the ANA pattern distribution 
between TLR9+/+ and TLR9 ; mice (3 potential patterns), a 3x2 Chi square analysis was 
used. For the analysis of survival curves, the logrank test was used. Statistical analysis 
was performed with GraphPad Prism version 4.0a or GraphPad InStat version 3.0b for 
Macintosh, GraphPad Software, San Diego, California.
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Figure 9. TLR9-deficient sera lack anti-DNA and anti-chromatin staining 
patterns. (A) ANAs from TLR9+/+ (WT) sera are shown in upper panels (left, 
homogenous nuclear pattern; right, speckled nuclear pattern), and TLR97 (KO) sera 
in lower panels (left, speckled nuclear pattern; right, cytoplasmic pattern). White 
arrows indicate cells in metaphase that demonstrate positive (upper panels, TLR9 
WT) or negative (lower panels, TLR9 KO) staining of mitotic chromatin. (B) Serum 
ANAs were classified as either nuclear homogenous, nuclear speckled, or 
cytoplasmic staining patterns. Black bars indicate TLR9 WT sera (n = 26), and 
white bars indicate TLR9 KO sera (n = 21). (C) As in B, but serum ANAs were 
classified as either positive or negative for mitotic chromatin staining.
***, P < 0.0001 by either Chi square analysis (B), or Fisher’s exact test (C).
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Figure 10. TLR7-deficient sera may have decreased staining of RNA-containing 
nuclear antigens. (A) ANAs from TLR7+/y (WT) sera are shown in upper panels 
(left, homogenous nuclear pattern; right, speckled nuclear pattern), and TLR7/y (KO) 
sera in lower panels (left, homogenous nuclear pattern; right, speckled nuclear 
pattern). Speckled patterns in TLR7 KO sera were a mix of speckled staining with 
superimposed homogenous staining. White arrows indicate cells in metaphase that 
demonstrate positive staining of mitotic chromatin. (B) Serum ANAs were classified 
as either nuclear homogenous, nuclear speckled, or cytoplasmic staining patterns. 
Black bars indicate TLR7 WT sera (n = 20), and white bars indicate TLR7 KO sera 
(n = 20). (C) As in B, but serum ANAs were classified as either positive or negative 
for mitotic chromatin staining.
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Figure 11. Antibodies to DNA-containing autoantigens are reduced in 
TLR9-deficient mice. (A) Anti-dsDNA antibodies in TLR9 WT (n = 26) and TLR9 
KO (n = 21) sera were detected by Crithidia luciliae immunofluorescence. Intensity 
of staining C. luciliae kinetoplast DNA was scored from 0-4. (B-C) Anti-nucleosome 
(B) or anti-dsDNA (C) antibodies were determined by ELISA in TLR9 WT or TLR9 
KO sera. Bars represent median values. (D-E) Anti-nucleosome (D) or anti-dsDNA 
(E) antibodies were determined by ELISA in TLR7 WT (n = 20) or TLR7 KO (n = 
20) sera. Bars represent median values. ***, P <  0.0001 by Mann-Whitney U test.
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Figure 12. Anti-Sm and anti-RNP autoantibodies in TLR-deficient mice.
(A-B) Anti-Sm (A) or anti-Sm/RNP antibodies were determined by ELISA in TLR9 
WT (n = 26) and TLR9 KO (n = 21) sera. Bars represent median values. (C-D). 
Anti-Sm (C) or anti-Sm/RNP (D) antibodies were determined by ELISA in TLR7 
WT (n = 20) or TLR7 KO (n = 20) sera. Bars represent median values.
*, P < 0.05 by Mann-Whitney U test.
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CD44+ CD69+
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Figure 13. TLR7 and TLR9 have opposing effects on clinical disease and 
lymphocyte activation. TLR9 WT (black bars, n = 26), TLR9 KO (white bars, n =
21), TLR7 WT (gray bars, n = 20), and TLR7 KO (striped bars, n = 20) mice were 
assayed for various parameters of clinical disease and immune activation at the time of 
sacrifice. (A) Severity of skin disease was determined. (B) Spleens and the two largest 
axillary lymph nodes were removed and weighed. (C) Splenocyte subsets were 
enumerated by FACS analysis for CD4+ T cells, CD8+ T cells, CD4 /CD8' double 
negative T cells (DNTC), and B cells. (D) Lymph node CD4+ T cells were classified as 
either naive (CD44' CD62L+), activated (CD44+ CD62L+), or memory (CD44+ CD62L ) 
phenotype. (E) Splenic B cells were assayed for expression of the activation markers 
CD44 and CD69. Data are presented as mean +/- SEM. *, P < 0.05; **, P < 0.01 by 
Mann-Whitney U test.
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Figure 14. TLR7 and TLR9 have opposing effects on piasmacytoid DC 
activation. (A) Left panel: splenic conventional DCs (C D lie11 pDCA-1) and 
piasmacytoid DCs (C D llc int pDCA-l+) were identified by FACS. Right panels: 
MHC class II expression was determined in conventional DCs (upper panels) and 
piasmacytoid DCs (lower panels) from TLR9 WT (blue) and TLR9 KO (red) mice 
(left histograms) or TLR7 WT (dark blue) and TLR7 KO (dark red) mice (right 
histograms). Representative samples from the same experiment are shown. (B) 
Expression of MHC class II, B7-1, and B7-2 was determined in conventional DCs 
from TLR9 WT (black bars, n = 26), TLR9 KO (white bars, n = 21), TLR7 WT (gray 
bars, n = 20), and TLR7 KO (striped bars, n = 20) mice. Data are presented as mean 
+/- SEM. (C) As in B, but activation marker expression was determined in 
piasmacytoid DCs. *, P < 0.05; **, P < 0.01; ***, P < 0.0001 by Mann-Whitney U 
test.
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Figure 15. Elevated serum IFN-a in TLR9-defIcient mice. Serum IFN-a was 
determined at the time of sacrifice for TLR9 WT (n = 26), TLR9 KO (n = 21), TLR7 
WT (n = 20) and TLR7 KO (n = 20) mice. Limit of detection was 0.1 ng/ml in 
serum. *, P < 0.05 by Mann-Whitney U test.
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Figure 16. TLR7 and TLR9 differentially affect IgG isotype production.
Serum IgG isotypes were determined at the time of sacrifice for TLR9 WT (black 
bars, n = 26), TLR9 KO (white bars, n = 21), TLR7 WT (gray bars, n = 20), and 
TLR7 KO (striped bars, n = 20) mice. Data are presented as mean +/- SEM.
**, P < 0.01; ***, P < 0.0001 by Mann-Whitney U test.
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Figure 17. TLR7 and TLR9 have opposing effects on lupus nephritis. (A)
Representative TLR9 WT (left panel, glomerular score = 2), and TLR9 KO (right 
panel, glomerular score = 4) glomeruli are shown. (B) Representative TLR7 WT (left 
panel, glomerular score = 3), and TLR7 KO (right panel, glomerular score = 2) 
glomeruli are shown). (C) Interstitial infiltrates and glomerular disease were scored 
from 0-4 for TLR9 WT (n = 26) and TLR9 KO (n = 21) mice. (D) As in C, but for 
TLR7 WT (n = 20) and TLR7 KO (n = 20) mice. *, P < 0.05; **, P < 0.01 by 
Mann-Whitney U test.
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Figure 18. Accelerated mortality in autoimmune TLR9-deficient mice.
TLR9 WT (blue line, n = 22), TLR9 heterozygote (black dashed line, n = 18), 
and TLR9 KO (red line, n = 24) littermates were observed until the time of 
death. Median survival for WT mice was 31.1 weeks, with 4 deaths during 
observation period. Median survival for heterozygote mice was 19.7 weeks, 
with 5 deaths during the observation period. Median survival for KO mice 
was 16 weeks, with 12 deaths during the observation period. *, P < 0.05 for 
comparison of WT versus KO mice by the logrank test.
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Figure 19. Presence of antibodies to RNA complexes is associated with clinical 
disease and immune activation. TLR9 WT mice (black symbols) were divided into 
two subgroups: those with anti-Sm or anti-Sm/RNP antibodies > 1 |lg/ml (RNA+, 
n = 11), and those without (RNA-, n = 15). TLR9 KO mice (white symbols) were 
similarly classified as anti-Sm or anti-Sm/RNP > 1 (ig/ml (RNA+, n = 9) or < 1 flg/ml 
(RNA-, n = 12). Skin disease (A), and lymph node weight (B) were determined as 
previously described. (C) Nai've phenotype (CD62L+ CD44 ) CD4+ T cells were 
determined as percentage of splenic CD4+ cells. (D) MHC class II+ pDCs were 
determined as percentage of total pDCs. IgG2a (E) and IgG3 (F) were determined as 
previously described. *, P < 0.05; **, P < 0.01 by Mann-Whitney U test.
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Chapter 4: Mechanism of Autoantibody and Interferon Alpha 
Production in TLR9-Deficient Autoimmune Mice
Signaling via TLRs is required for the generation of specific autoantibodies in 
SLE. We have thus far shown, in two different genetic cohorts, that the generation of 
antibodies to the prototypical DNA-containing autoantigens of lupus cannot occur in the 
absence of TLR9. The mechanism of TLR9-mediated autoantibody production, however, 
remains unclear. TLR9 is expressed on multiple cell types including B cells and 
piasmacytoid and myeloid DCs (72, 162), and all of these cell types can be stimulated by 
endogenous TLR9 ligands in the context of autoimmunity (80, 116, 118). Thus, although 
B cell-intrinsic TLR stimulation is a critical aspect of normal immune responses (75), it is 
possible that anti-DNA B cells are secondarily activated by the ligation of TLR9 on other 
cells such as pDCs. In this scenario, cognate interactions with or soluble mediators 
secreted by these proposed accessory cells could provide the necessary costimulation, and 
TLR expression by autoreactive B cells would then be dispensable. In order to determine 
the cellular requirements for TLR9 expression in autoantibody production, we generated 
lupus-prone chimeric mice in which TLR9-deficiency could be restricted to cells of the B 
lineage.
In addition to the dramatic reduction in autoantibodies to DNA-containing 
antigens, genetic absence of TLR9 promoted IFN-a production, exacerbated clinical 
signs of autoimmune disease, and accelerated mortality in lupus-prone mice. As in the 
case of antibody production, however, the cellular mechanism for this phenotype was 
unknown. We suspect that the altered autoantibody repertoire contributes to pathogenesis
82
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
in TLR97 mice, but it is also possible that deficiency of TLR9 in pDCs or other cells of 
the innate immune system can directly enhance systemic inflammation and disease 
activity. A synergistic effect of autoantibody specificity and TLR expression within 
responding cells could also occur, such that TLR9-deficient serum and a lack of TLR9 on 
DC subsets would both be required for the phenotype of exacerbated SLE in TLR97 
mice. Analysis of selective TLR9-deficiency in chimeric mice allowed preliminary 
insight into the mechanism of pathogenesis, but was not conclusive. We therefore 
devised an experimental system to determine the relative contributions of circulating 
autoantibodies and DC-intrinsic TLR expression to innate immune activation and 
inflammatory cytokine production in autoimmunity. We performed controlled 
stimulation experiments of dendritic cell subsets from wild-type or TLR97 mice in the 
presence of various combinations of TLR ligands and either wild-type or TLR97 serum. 
Our results reveal a primary role for B cells and their autoantibody products in the 
pathogenesis of SLE in TLR97 mice.
Generation of Chimeric Mice
In order to determine whether the TLR9-mediated generation of specific 
autoantibodies occurs by a B cell-autonomous mechanism, we restricted the genetic 
knockout of TLR9 to cells of the B lineage in autoimmune mice. This was accomplished 
with bone marrow chimerism in irradiated recipients. The combination of bone marrow 
from B cell-deficient JH7' donors and TLR97 donors created a chimeric mouse in which 
all B cells were TLR9-deficient, which we designated B.97 (Fig. 20A). The use of a 4:1 
ratio of the two donors, favoring the JH7 marrow, ensured that the majority of non-B cells
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expressed a functional TLR9. Controls for this experiment included B.9+/+ chimeras, 
which had the same proportion of B cells as B .9 ; mice but were TLR9 wild-type, and 
All.9^ mice, in which all hematopoietic cells were TLR9-deficient with a normal ratio of 
B cell precursors (Fig. 20A). All donors and recipients were of the lupus-prone 
MRL/Mp//)r///,r strain, and all recipients were B cell deficient to prevent potential 
confounding by surviving B cells in the irradiated hosts, or from pre-existing 
autoimmune disease.
To verify the expected TLR9-chimerism of experimental mice, we used 
quantitative polymerase chain reaction (PCR) amplification of TLR9 alleles from 
genomic DNA of sorted splenocytes. Quantitation of relative levels of the wild-type or 
knockout allele allowed us to determine the degree of chimerism in various cell types as 
well as the total spleen. As expected, B.9+/+ mice were entirely TLR9 wild-type, with no 
amplification of the disrupted allele (Fig. 20B). In B.9_/ mice, B cells were completely 
TLR9-deficient, while other cell types showed varying levels of chimerism. Total 
splenocytes (of which ~10% were B cells, Fig. 24B below) were less than one-fourth 
TLR9'/_, while only about 10% of macrophages were derived from the TLR9-deficient 
marrow (Fig. 20B). Piasmacytoid DCs revealed a higher level of TLR9_/ chimerism.
This could be due to the technical limitations inherent in isolating and amplifying DNA 
from this rare subset of cells (<0.5% of total splenocytes in chimeric mice, data not 
shown), or it could represent a modest but selective expansion of TLR9 A pDCs. In either 
case, the majority of pDCs and other non-B cells in B.9 A mice were TLR9 wild-type. In 
A1L97 mice, the vast majority of all cell types were TLR9-deficient, but there was a small 
fraction of total splenocytes (~8%), as well as macrophages and pDCs (2.3% and 4.5%,
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respectively), that retained the wild-type TLR9 (Fig. 20B). These cells may be non­
dividing host cells that persisted in the spleen until the mice were analyzed at 16 weeks 
post-reconstitution, or they may represent the progeny of rare stem cells which survived 
radiation. As in B.97' animals, however, all B cells in A11.97' mice were TLR9-deficient 
(Fig. 20B).
B Cell-Intrinsic Requirement for TLR9 in Autoantibody Production
Having created chimeric mice in which deficiency of TLR9 was restricted to the 
B cell lineage, we then examined the generation of circulating autoantibodies in these 
mice. We first verified that chimeras had sufficient reconstitution of B cells and serum 
immunoglobulin after a period of 16 weeks (see analysis below). Analysis of serum 
ANAs then revealed that B.9 7 sera, like A11.9_/' sera, generated ANAs with predominantly 
cytoplasmic staining patterns (Fig. 21A-B). This indicated a defect in the generation of 
anti-DNA antibodies, analogous to the autoantibody repertoire in non-chimeric TLR97 
mice (Chapter 3). This was in stark contrast to sera from B.9+/+ controls, the majority of 
which produced homogenous nuclear staining patterns in the absence of any cytoplasmic 
staining (Fig. 21A-B). The distribution of ANA patterns in B.97 and A11.9'/_ serum was 
significantly different from B.9+/+ serum (P < 0.0001 and P = 0.0015 for comparison of 
B.9+/+ versus B.97' and A11.97', respectively). A striking dichotomy was also observed in 
the staining of chromatin in metaphase cells, with all B.9+/+ sera containing antibodies 
that bound mitotic chromatin, compared to none of the sera from B.97 or A11.9 ' mice 
(Fig. 21, A and C, P < 0.0001 for comparison of B.9+/+ versus either B.97 or A11.97').
Thus, sera from mice with TLR9-deficient B cells specifically lacked antibodies capable
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of binding the characteristic DNA-containing autoantigens of SLE. Importantly, the 
failure of B.9 7 sera to produce homogenous nuclear and anti-chromatin staining patterns 
indicates that the presence of functional TLR9 on the majority of non-B cells in these 
mice was not sufficient to allow the production of antibodies to DNA-containing 
antigens.
Analogous to non-chimeric TLR97 sera, autoantibodies in B.9'7' and A11.9'7' sera 
stained cytoplasmic antigens in a fine granular to homogenous pattern, highlighting the 
perinuclear region without staining of specific cytoplasmic organelles (Fig. 21 A). Such 
patterns are characteristic of antibodies to aminoacyl-tRNA synthetases (anti-Jo-1 
antibodies) or anti-ribosomal antibodies (23, 26). We also observed a novel nucleolar 
staining pattern in two of the B.9'7' sera (Fig. 21A and data not shown). Staining of 
nucleoli, along with coincident cytoplasmic staining and the absence of chromatin 
staining, can indicate the presence of antibodies to either ribosomal P protein or a protein 
of unknown function designated polymyositis-scleroderma overlap syndrome (PM/Scl)- 
related nucleolar protein (23, 163). Because RNA is an inherent component of ribosomes 
and nucleoli, the autoantibody repertoire of chimeric mice with TLR9-deficient B cells, 
like that of non-chimeric TLR97 mice, appears shifted towards the recognition of 
endogenous RNA-containing antigens. Moreover, this shift occurs in a B cell 
autonomous fashion.
The absence of antibodies to DNA and chromatin in chimeric mice with TLR9- 
deficient B cells was confirmed by specific assays for these autoantibodies. Both B.9'7' 
and A11.9'7 sera contained significantly reduced levels of anti-dsDNA antibodies 
compared to sera from B.9+/+ mice, as determined by immunofluorescent staining of
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Crithidia luciliae kinetoplast dsDNA (Fig. 22A, P = 0.0036 and 0.0115 for B.97 and 
A11.97 , respectively). B.97' and A11.97 mice also failed to generate high levels of anti- 
nucleosome antibodies, which were common in mice with B cells expressing wild-type 
TLR9 (Fig. 22B, P = 0.0135 and 0.0311 for comparison of B.9+/+ with B.97 or A11.97 , 
respectively). There was no difference in the three groups, however, when anti-dsDNA 
antibodies were measured with a poly-L-lysine-based ELISA (Fig. 22C). This 
discrepancy between different ELISAs is similar to what was observed in non-chimeric 
TLR97 mice (Chapter 3), and again highlights the lack of specificity of these assays as 
well as the greater relevance of DNA-histone complexes in the generation of 
autoantibodies. Taken together, the ANA and specific anti-DNA assays on sera from 
chimeric mice reveal a requirement for TLR9 expression within B cells for effective 
production of antibodies to characteristic DNA-containing antigens in SLE. Moreover, 
the presence or absence of TLR9 on non-B cells did not appear to have any effect on 
autoantibody production, as B.97’ and A11.97 mice generated autoantibody profiles which 
were indistinguishable.
Creation of Additional Chimeras and B Cell Reconstitution
To help determine if there was a dose-response relationship involving the extent 
of TLR9 chimerism on non-B cells, we also generated B.97 chimeric mice with a higher 
ratio of TLR97 marrow to JH7 marrow. Thus, in addition to the B.97 (20%) mice 
previously discussed, we also analyzed a small group of B.97' (50%) mice. Quantitative 
PCR of sorted cells from these mice confirmed that approximately half of non-B cells 
were TLR9-deficient (data not shown), compared with 10-40% of non-B cells in B.97
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(20%) mice (Fig. 20B). We then had three increasing levels of TLR9-deficiency on non- 
El hematopoietic cells: a minority of TLR9' cells in B .9 ; (20%) mice, approximately half 
TLR9 a cells in B .9A (50%) mice, and a vast majority of TLR9'; cells in A11.9_/ mice. As 
an additional control, we also created A11.9+/+ mice in which all stem cells were TLR9 
wild-type and B cell sufficient. ANA staining patterns and anti-DNA antibodies in these 
two additional groups were the same as their TLR9-deficient or wild-type counterparts 
(data not shown).
In order to create the desired degree of TLR9 chimerism, varying proportions of B 
cell-sufficient bone marrow were used in the different groups (20%, 50%, or 100% as 
described). It was therefore important to determine the extent of B cell reconstitution in 
the chimeric mice. At 16 weeks post-reconstitution, B cells were present in the spleen in 
all chimeric mice. Although there were no significant differences between the groups, 
there was a trend toward a higher percentage of total splenic B cells in mice that received 
a higher ratio of B cell-sufficient marrow (Fig. 23A). When we examined the 
percentages of follicular splenic B cells, however, the greater extent of reconstitution in 
these mice became significant. Chimeric A11.97 mice had more splenic follicular B cells 
than either B.9+/+ (20%) or B .9 ; (20%) mice (P = 0.0229 and 0.0034, respectively), while 
the percentage of follicular B cells in A11.9+/+ mice was comparable to that in A11.9 /_ mice 
(Fig. 23B). B .9 /_ (50%) mice had a similar percentage of follicular B cells as B .9; (20%) 
mice (Fig. 23B). The ratio of B cell precursors in the donor marrow therefore appeared 
to determine the extent of B cell reconstitution in the periphery. Importantly, there were 
similar proportions of peripheral B cell subsets in B.9+/+ (20%) and B .9; (20%) mice, and
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thus the extent of reconstitution was not a confounding variable in comparisons between 
these two groups.
Clinical Disease and Immune Activation in TLR9 Chimeric Mice
Chimeric TLR9-deficient mice afforded the opportunity to determine the effect of 
a B cell-specific lack of TLR9 on disease pathogenesis as well as autoantibody 
production. Two important findings in non-chimeric TLR97 mice were the elevated 
activation state of pDCs and increased circulating levels of IFN-a (Chapter 3). Because 
circulating immune complexes can activate DCs in a TLR-dependent manner (116, 118), 
it was unclear whether the altered autoantibody profiles or the lack of TLR9 on DCs was 
the primary cause of the observed pDC phenotype in TLR97 mice. We therefore 
analyzed the activation state of DCs in chimeric mice, wherein the autoantibody 
repertoire is dissociated from TLR9 expression on non-B cells. We found a significant 
increase in MHC class II expression by pDCs in B.97' (20%) mice compared to B.9+/+ 
(20%) mice (Fig. 24A-B, P = 0.0076). A similar increase in class II expression was also 
observed among myeloid dendritic cells (mDCs) in B.97 (20%) mice (Fig. 24C, P = 
0.0385). Increased DC activation was therefore not due to an intrinsic lack of TLR9 on 
these cells, since the majority of pDCs and mDCs in B.97' (20%) mice were TLR9 wild- 
type. Furthermore, the absence of TLR9 on pDCs or mDCs did not further increase their 
activation state in the presence of TLR9-deficient B cells, as B.97' (20%), B.97 (50%), 
and AII.97' mice exhibited similar levels of class II expression among DC subsets (Fig.
24, A and C).
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To determine the functional consequences of pDC activation in chimeric mice, we 
also measured circulating IFN-a levels, but found that none of the chimeric mice in any 
group had high systemic IFN-a at 8, 12, or 16 weeks post-reconstitution (data not 
shown). It is unclear if this represents a failure of interferon production by donor-derived 
pDCs in chimeric mice, or perhaps some effect of radiation non-hematopoietic cells in 
the recipient animal involved in IFN-I production. Low IFN-a levels were not simply 
due to a lack of autoimmune disease, however, as skin disease was manifest in most 
chimeric mice between 12 and 16 weeks post-reconstitution. There was no difference in 
the incidence or severity of skin disease between experimental groups (data not shown). 
Similarly, measurement of spot proteinuria at the time of sacrifice (16 weeks) revealed 
some evidence of kidney disease in most mice without a significant difference between 
groups (data not shown). The contribution of a B cell-specific deficiency of TLR9 to the 
pathogenesis of end organ disease cannot be determined from this limited data set, but 
additional experiments may reveal a specific effect of TLR9 expression within B cells.
Although regulation of specific autoantibody production by TLR9 was a purely B 
cell-intrinsic phenomenon and the activation of DCs was at least partly attributable to 
TLR9 expression within B cells, other markers of immune activation were less dependent 
upon TLR9 expression in B cells. B cell-specific lack of TLR9, for example, was not 
sufficient to promote exaggerated lymphadenopathy. While B.9+/+ (20%) and B.97 (20%) 
mice had comparable lymph node weights, both were significantly less than lymph nodes 
from A11.97' mice (Fig. 25A P = 0.0115 and 0.0089, respectively). The apparently 
intermediate lymph node weight of B.97 (50%) mice supports the notion that TLR9- 
deficiency in non-B cells is required for the induction of severe lymphadenopathy. These
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findings on lymph node weight cannot be explained by the extent of B cell reconstitution 
alone, as chimeric A11.9+/+ mice, which had the highest level of reconstitution, had low 
lymph node weights similar to B.97' (20%) mice (Fig. 25A). Activation of CD4+ T cells 
followed a similar pattern, although both B cell-intrinsic and -extrinsic mechanisms of 
TLR9-deficiency appeared to play a role. While B.97 (20%) mice had a smaller fraction 
of naive T cells than B.9+/+ (20%) mice (P = 0.0232), a more profound reduction was 
observed in B.97' (50%) and A11.97 mice (Fig. 25B, P = 0.0052 for comparison of B.9+/+ 
versus A11.97'). The extent of B cell reconstitution may also be a factor in T cell 
activation, however, as chimeric A11.9+/+ mice also exhibited a low level of naive CD4+ T 
cells (Fig. 25B).
Serum levels of total IgG2a and IgG3 were also determined in TLR9 chimeras, 
since these were the isotypes with the greatest increase in non-chimeric TLR97 mice.
We found that B cell-specific deficiency of TLR9 was not sufficient to induce 
hypergammaglobulinemia (Fig. 26A-B). Particularly for IgG3, A11.97 mice had 
increased serum immunoglobulin compared to B.97 (20%) mice (Fig. 26B, P = 0.0324). 
Varying degrees of B cell reconstitution in the different groups were unlikely to account 
for this difference, as the percentage of splenic B cells did not correlate with serum levels 
of IgG3 in individual mice (Fig. 26C, P = 0.5218 by Pearson correlation, r = 0.1087). 
Thus, analysis of markers of disease severity and immune activation in TLR9 chimeric 
mice suggested that neither B cells nor other hematopoietic cells were exclusively 
responsible for the effect of TLR9-deficiency on the exacerbation of SLE. While a B 
cell-specific absence of TLR9 could lead to increased activation of DCs in B.97
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chimeras, it was not sufficient induce other markers of disease activity such as 
lymphadenopathy and hypergammaglobulinemia.
Stimulation of IFN-a Production by Autoimmune TLR9" ' Serum
We hypothesized that the autoantibodies produced by TLR9-deficient B cells 
could be responsible for increased IFN-a production in autoimmune TLR9_/ mice. 
Although the increased pDC activation state in chimeric B.9_/ mice supported this, the 
presence of a small percentage of TLR9-deficient DCs in the chimeras as well as the lack 
of detectable serum IFN-a clouded the interpretation of these experiments. We therefore 
set up an in vitro stimulation of purified pDCs and mDCs from TLR9-deficient or wild- 
type mice, wherein the autoantibody repertoire could be completely dissociated from 
TLR9 expression by the responding cells. These cells were then cultured in the presence 
of autoimmune serum from either wild-type or TLR9-deficient mice, or stimulated with 
synthetic TLR ligands as positive controls. To create nascent immune complexes of 
autoantibodies and endogenous DNA or RNA ligands, syngeneic apoptotic thymocytes 
were also added, either alone or in addition to autoimmune serum. We found that serum 
from TLR9-deficient mice, but not wild-type serum, induced a high level of IFN-a 
production in both pDCs and mDCs from wild-type and TLR9-deficient mice (Fig. 27A- 
B). The addition of apoptotic thymocytes, either alone or in the presence of serum, did 
not appear to affect IFN-a secretion. Importantly, the IFN-a detected in these cultures 
was not simply due to circulating interferon from TLR9' serum, as both the wild-type 
and TLR9-deficient serum used contained less than 250 pg/ml IFN-a (data not shown), 
and serum was diluted ten-fold for these experiments.
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The interferon stimulatory capacity of serum from TLR9-deficient mice reveals 
several important facets of interferon biology in SLE. First, IFN-a production in these 
experiments was induced by TLR9v serum, regardless of the genotype of the responding 
cells. Thus, the primary defect responsible for elevated IFN-a production by DC subsets 
in TLR9'/_ mice lies in the generation of circulating serum factors, and not in dysregulated 
IFN-I pathways in pDCs. Second, although TLR9+/+ serum did not induce IFN-a in wild- 
type cells, it did allow a low level of IFN-a secretion in TLR9-deficient pDCs and 
mDCs. This suggests that an intrinsic increase in IFN-I production by dendritic cells is 
also present in TLR9 A mice, although this effect was not observed in the presence of 
TLR9_/ serum, presumably because the serum alone provided a maximal interferon- 
inducing stimulus. Third, the ability of TLR9-deficient pDCs to respond to factors in 
TLR9/_ serum indicates that the stimulatory ligand in these experiments is not likely to be 
DNA. The failure of TLR9_/' pDCs to produce IFN-a in response to a synthetic C-type 
CpG oligonucleotide (Fig. 27A) confirms the absence of DNA-sensing TLR pathways in 
these cells. Fourth, serum from TLR9-deficient mice induced IFN-a not only in pDCs, 
but also in mDCs. The interferon stimulatory factor in TLR9; serum can therefore 
bypass normal regulatory mechanisms preventing IFN-I secretion in most cell types, 
perhaps due to altered endosomal trafficking of nucleic acid ligands (109). Finally, we 
also observed that the addition of apoptotic thymocytes was not required for the 
stimulatory capacity of TLR9_/ serum. This may be explained by the provision of 
apoptotic material from the high degree of cell death in these cultures (Fig. 29, below), or 
it may reflect the presence of pre-formed stimulatory complexes in TLR9; serum.
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Distinct DC Activation Programs Induced by TLR9 WT or KO Serum
The effect of TLR9-deficient serum on the production of other inflammatory 
cytokines was also investigated. Serum from both wild-type and TLR9-deficient mice 
induced modest secretion of IL-12 p40, which was greater than unstimulated cells but an 
order of magnitude less than the level induced by a C-type CpG oligonucleotide in mDCs 
(Fig. 28A-B). In both wild-type and TLR9-deficient mDCs, however, TLR9_/ serum was 
slightly less effective in stimulating IL-12 p40 than wild-type serum (Fig. 28B). Low to 
undetectable levels of the IL-12 p70 dimer were induced by either wild-type or TLR9 /_ 
serum in these experiments (< 1 pg/ml, data not shown). The lack of IL-12 p70 may 
indicate pairing of IL12 p40 with IL-23 p l9  to create the IL-23 dimer, which appears to 
have a potent inflammatory role in autoimmunity (164). A somewhat variable level of 
IL-10 secretion was observed in two different experiments, but unlike the induction of 
IL-12 p40, TLR9 ' serum tended to produce a slightly higher level of IL-10 than wild- 
type serum (Fig. C-D). We also measured levels of IL-6, IL-1(3 and TNF-a in these 
cultures, and found similar results to IL-12 p40, with low to modest levels of these 
cytokines induced by both wild-type and TLR9-deficient serum (data not shown).
Finally, we found that DCs from both TLR9+/+ and TLR9' mice produced comparably 
high levels of inflammatory cytokines (particularly IL-12) in response to the synthetic 
TLR7 ligand imiquimod (R837), indicating that there was not an inherent increase in 
TLR7 stimulation pathways in TLR9; DCs (data not shown).
We also determined survival and activation marker expression by DCs following 
these stimulations, and found contrasting effects on these two parameters. While 
viability was low after 24 hours in unstimulated cells, the presence of TLR97 serum
94
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
improved survival in wild-type and TLR9-deficient pDCs and mDCs (Figure 29A-B). 
This improvement in survival was even greater than that induced by stimulatory CpG in 
wild-type cells. Improved viability was not matched by increased costimulatory 
molecule expression, however, as TLR97 serum-stimulated cells expressed an even lower 
level of B7-2 than unstimulated cells (Fig. 29C-E). Wild-type serum had the opposite 
effect on dendritic cells. While serum from TLR9+/+ mice induced a partial upregulation 
of B7-2, it reduced viability in responding cells, particularly in pDCs (Fig. 29A-E). The 
effect of wild-type or TLR9-deficient serum on expression of MHC class II or CD40 was 
similar to the effect on B7-2, although CD40 was not as effectively induced on pDCs as 
on mDCs (data not shown). Circulating factors in autoimmune TLR9-deficient serum 
thus appeared to enhance DC survival and IFN-a secretion while maintaining the 
immature phenotype of these cells, suggesting that serum from wild-type or TLR9 7 mice 
can induce two different activation pathways in dendritic cells.
Discussion
We have thus demonstrated that B cell-intrinsic expression of TLR9 is required 
for the generation of antibodies to DNA-containing autoantigens in SLE. This B cell- 
specific requirement for TLR9 was expected from initial studies documenting the TLR- 
dependent activation of isolated, autoreactive B cells in culture (29, 80, 82). The 
paradigm that TLR ligation within antigen-specific B cells is required for antibody 
production in normal immune responses (75) can thus be extended to include 
autoimmunity and the activation of anti-nuclear B cells. Thus, while multiple cell types 
express TLRs capable of recognizing endogenous nucleic acids, autoreactive B cells are
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unique in the expression of a somatically rearranged surface receptor for these same 
ligands. On a molecular level, therefore, B cells reside at the interface of innate and 
adaptive immunity in SLE, and are likely to be responsible for the primary break in 
tolerance to self nuclear antigens.
The increased activation state of dendritic cells in B.97 chimeric mice and the 
interferon-stimulatory capacity of TLR97 serum indicated that circulating factors 
produced by TLR9-deficient B cells could influence the activation of wild-type DCs.
Prior studies have indicated that immune complexes of endogenous nucleic acid bound to 
autoantibodies can induce cytokine secretion and costimulatory molecule expression by 
DCs (114-116). In addition to transmitting an activation signal via Fc-gamma receptors, 
the immunoglobulin portion of the complex appears critical in the delivery of nucleic 
acids to appropriate endosomal compartments for recognition by intracellular nucleic 
acid-sensing TLRs (118). Without specific anti-nuclear antibodies acting as vehicles for 
the transport of endogenous DNA or RNA, innate tolerance of self nucleic acids is 
maintained in dendritic cells. On a cellular level, therefore, B cells coordinate the 
interaction of antigen-specific recognition by the adaptive immune system with the potent 
effector mechanisms of the innate immune system in SLE pathogenesis.
The exact nature of the interferon-stimulatory factor in TLR97 serum remains 
unknown. Because it requires the presence of TLR9-deficient B cells, however, we 
suspect that the autoantibody repertoire is either directly or indirectly responsible for 
elevated IFN-a production. Interestingly, an apparent increase in antibodies to RNA- 
containing antigens was accompanied by increased circulating IFN-a in non-chimeric 
TLR97' mice, while a decrease in anti-Sm/RNP antibodies in TLR7/y mice was coincident
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with a decreased activation state of pDCs (Chapter 3). This suggested that RNA- 
containing immune complexes could be more potent stimulators of pDCs than DNA 
complexes, a concept supported by in vitro stimulation of pDCs with human lupus serum 
(87, 114). A related possibility is that DNA-containing immune complexes, by virtue of 
sub-optimal TLR9 stimulation by mammalian DNA (66), may inhibit IFN-a production 
by pDCs. The absence of anti-DNA antibodies in TLR9 7 serum could then release 
responding pDCs from this tonic inhibition, allowing efficient IFN-I secretion. 
Alternatively, TLR9-deficient mice may generate some other circulating inducer of IFN- 
a , which requires B cells but is independent of autoantibodies. Further studies on pDC 
activation by TLR-deficient serum, such as stimulation with serum from TLR7-deficient 
mice and stimulation with purified IgG from these serum samples, will be critical to 
further define the interferon-stimulatory factor. Mixing of wild-type serum with TLR97 
serum in these experiments may also help elucidate an inhibitory effect of antibodies to 
DNA-containing antigens.
An interesting finding from our in vitro experiments was that TLR97 serum 
induced high levels of IFN-a in both myeloid and plasmacytoid dendritic cell subsets. 
Although mDCs are not traditionally responsible for IFN-I production, these cells can be 
transformed into efficient interferon-secreting cells under certain conditions (109, 165). 
Importantly, when intracellular trafficking is altered such that nucleic acids are retained 
in endosomal, rather than lysosomal compartments in mDCs, signaling via the MyD88- 
IRF7 axis is facilitated and these cells can produce high levels of IFN-I (109). It is 
therefore possible that FcR-mediated internalization of RNA-containing immune 
complexes in TLR9 7 serum can retain these complexes in specialized endosomal vesicles
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for efficient IFN-a production. It is also possible, however, that IFN-a induction by 
serum from TLR9-deficient mice occurs by a TLR-independent mechanism. Several 
recent findings have identified innate sensors for cytoplasmic RNA and DNA that can 
induce IFN-I production independently of TLR signaling in multiple cell types (60-63). 
These sensors are thought to be instrumental in defense against viral infection, but may 
also be involved in the recognition of endogenous nucleic acids when mechanisms for the 
clearance of apoptotic cells are overwhelmed (166). Stimulation of MyD88-deficient 
DCs will allow us to determine the relative contributions of TLR-dependent and 
-independent mechanisms of IFN-a production in response to autoimmune TLR9 A 
serum.
In addition to the induction of IFN-a, serum from TLR9 7 mice appeared to 
promote a distinct activation program in dendritic cells. This program was characterized 
by increased survival, decreased expression of costimulatory molecules, minimal 
secretion of inflammatory cytokines such as IL-6 and IL-12, and a potential increase in 
IL-10 production. Contrasting effects were observed when DCs were stimulated with 
wild-type serum. The ability of these cells to persist in an immature state may allow 
prolonged secretion of IFN-I, facilitating SLE pathogenesis through the prolific effects of 
this cytokine. Although IL-10 usually functions as a regulatory cytokine to suppress 
inflammation, the presence of IFN-a can transform IL-10 into a potent inflammatory 
mediator through the action of STATI (167). Thus, increased IL-10 secretion by TLR9/_ 
serum may also promote immune activation in SLE. The cytokine or cellular milieu may 
also influence the expression of costimulatory molecules, as serum from TLR9 A mice 
inhibited expression of MHC class II and B7-2 in our in vitro experiments, but B cell-
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derived factors increased class II expression by DCs in B.97' chimeric mice. In the 
context of additional signals in vivo, pDCs exposed to the appropriate autoantibody 
repertoire may mature into efficient antigen-presenting cells and thereby promote 
autoreactive T cell activation. The lack of TLR9 on B cells can thus have profound 
effects on autoimmune disease, as autoantibodies produced by these cells induce a 
specific activation program in dendritic cells, which in turn can facilitate SLE 
pathogenesis.
Materials and Methods
Generation and verification of chimeric mice.
Bone marrow cells were isolated from MRL/Mp,/"y//’r (TLR9+/+), JH/_ MRL/Mp//,r///)r, 
and TLR97 M R L /M p ^ '’ mice between 6-10 weeks of age. All donor and recipient mice 
were backcrossed at least 9 generations to MRL/Mp/pr/'^. For each experiment in a total 
of 5 separate experiments, bone marrow was pooled from 1-2 donor mice of each type. A 
total of 4x l0 6 cells were injected intravenously into recipient JH_/ MRL/Mp^7^  mice 
irradiated with 700-800 cGy from an X-Rad 320 X-ray irradiator. Recipient mice were 
6-10 weeks of age at the time of reconstitution, and were analyzed at 16 weeks post 
reconstitution. B.9+/+ mice received 20% TLR9+/+ and 80% JH A marrow, B .97 (20%) 
mice received 20-25% TLR9 7 and 75-80% JH/_ marrow, B.9 ; (50%) received 50%
TLR9 a and 50% JH_/ marrow, A11.97' received exclusively TLR97 marrow, and A11.9+/+ 
received exclusively TLR9+/+ marrow.
For verification of TLR9 chimerism, B cells (B220+, CD22+, CD1 lb', CD1 lc",
Thy 1.2") and macrophages (B220\ C D 22, CD1 lb+, CD1 l c , Thy 1.2) were sorted from
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total splenocytes in 2 of 5 experiments, or B cells (B220+, CD22+, CD1 lc \  mpDCA-1, 
Thy 1.2") and pDCs (B220+, C D 22, C D llc int, mpDCA-l+, T hy l.2 ) were sorted from total 
splenocytes in 2 of 5 experiments. Antibodies used were as previously described 
(Chapters 2-3) in addition to anti-B220 (RA3-6B2, BD Biosciences) and anti-CD 1 lb 
(M l/70, BD Biosciences) antibodies. Sorted cells or total splenocytes were digested at 
106 cells/ml at 55 degrees in a digest buffer containing 1.5 mg/ml Proteinase K 
(Novagen).
Amplification of genomic DNA was performed with Brilliant SYBR Green 
QPCR Master Mix (Stratagene) on the Mx3000P Real-Time PCR System (Stratagene). 
Amplification of TLR9 wild-type allele was performed with the external primer (5’ GCA 
ATG GAA AGG ACT GTC CAC TTT GTG 3’) and the wild-type specific primer (5’ 
GAA GGT TCT GGG CTC AAT GGT CAT GTG 3’). Amplification of TLR9 knockout 
allele was performed with the external primer above and the knockout specific primer (5’ 
ATC GCC TTC TAT CGC CTT CTT GAC GAG 3’). Amplification of wild-type allele 
(relative to TLR9+/+ control) was compared with amplification of knockout allele (relative 
to TLR97 control) to determine percentage of TLR9 knockout allele in each sample. 
Determination of ANA and anti-dsDNA antibodies.
Serum was obtained at the time of sacrifice. ANA immunofluorescence on HEp- 
2 cells was performed at 1:200 dilution of serum as previously described (Chapter 2). 
Images were captured at 400X magnification with a constant exposure time of 4.0 
seconds. Crithidia luciliae immunofluorescence was performed at 1:50 dilution of serum 
as previously described (Chapter 2). Images were captured at 1000X magnification with
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a constant exposure time of 0.8 seconds. Anti-nucleosome and anti-dsDNA ELISAs 
were performed as previously described (Chapter 3).
Analysis of clinical disease and immune activation.
Skin disease was scored at the time of sacrifice as previously described (Chapter 
3). Proteinuria was determined with Albustix reagent strips (Bayer). Spleen and lymph 
node cells were isolated and T and B cell subsets and activation markers were determined 
as previously described (Chapter 2). Plasmacytoid and myeloid DC activation status was 
determined as previously described (Chapter 3). Serum IFN-a ELISA was performed as 
previously described (Chapter 2), except that serum was added at 1:5 dilution. Levels of 
IgG isotypes in serum were determined as previously described (Chapter 3).
In vitro stimulation of dendritic cell subsets.
Plasmacytoid DCs (T h y l.2 , CD22 , B220+, Ly6C+, CD1 lc int) and myeloid DCs 
(Thy 1.2', C D 22, B 220, Ly6C', CD1 lchl) were sorted from total splenocytes using 
antibodies described previously in addition to anti-Ly6C antibody (AL-21, BD 
Biosciences). Sorted cells were stimulated for 24 hours in media supplemented with 10% 
Ultra-Low IgG Fetal Calf Serum (Gibco) in polystyrene plates at 35,000 cells per 100 pi. 
Stimuli included C-type CpG oligonucleotide ODN-2395 (Coley Pharmaceuticals) at 0.5 
pM, imiquimod (R837, Invivogen) at 1 pg/ml, serum from TLR9+/+ or TLR9_/' mice at 
10% final concentration, or apoptotic thymocytes at a 1:2 ratio of apoptotic cells to 
stimulated cells. Serum was pooled from 4 MRL/MpMp'' mice of each genotype, 
between 12-18 weeks of age. Apoptotic thymocytes were generated by irradiation of 
MRL/Mp//,r///"’ thymocytes with 1000 cGy followed by incubation in serum-free media 
with 1 pM dexamethasone (Sigma) for 6 hours at 37 degrees.
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IFN-a ELISA was performed as previously described (Chapter 2), except that 
culture supernatant was added at 1:1.5 or 1:2 dilution. Determination of inflammatory 
cytokine secretion was performed with a Bio-Plex mouse cytokine 6-plex kit for IL-1|3, 
IL-6, IL-12 p40, IL-12 p70, and TNF-a (Bio-Rad) according to the manufacturer’s 
instructions. Activation marker expression was determined as previously described 
(Chapter 3), in addition to the use of anti-CD40 (3/23, BD Pharmingen) antibody.
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Figure 20. Generation and verification of TLR9-chimeric mice. (A) Generation 
of radiation chimeras with bone marrow from combination of 1 or 2 donors. (B) 
Quantitative PCR for TLR9 KO allele on sorted splenocytes from chimeric mice. 
Black bars indicate total splenocytes, white bars indicate sorted B cells, gray bars 
indicate macrophages, and striped bars indicate pDCs. Data are presented as mean 
+/- SEM.
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Figure 21. ANA patterns from chimeric mice reveal a B cell-intrinsic 
requirement for TLR9. (A) ANAs are shown for B.9+/+ sera in left-most panels 
(upper and lower, homogenous nuclear pattern), for B.9 7 sera in middle panels (upper, 
nucleolar pattern; lower, cytoplasmic pattern), and for A11.9'7' sera in right-most panels 
(upper, speckled nuclear pattern; lower, cytoplasmic pattern). White arrows indicate 
cells in metaphase that demonstrate positive (left-most panels, B.9+/+) or negative 
(middle and right-most panels, B .97 and A11.97) staining of mitotic chromatin.
(B) Serum ANAs were classified as either nuclear homogenous, nuclear speckled and 
nucleolar, or cytoplasmic staining patterns. Black bars indicate B.9+/+ sera (n = 9), 
white bars indicate B.9 7 sera (n = 13), and striped bars indicate A11.9'7 sera (n = 7).
(C) As in B, but serum ANAs were classified as either positive or negative for mitotic 
chromatin staining. **, P < 0.01 by Chi square analysis and ***, P < 0.0001 by 
Fisher’s exact test for comparison of B.9+/+ versus B.9 7 or A11.9'7'.
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Figure 22. The requirement for TLR9 in the generation of autoantibodies to 
DNA-containing antigens is B cell-intrinsic. (A) Anti-dsDNA antibodies in 
B.9+/+ (n = 9), B.9 7 (n = 13), and A11.9 7- (n = 7) sera were detected by Crithidia 
luciliae immunofluorescence. Intensity of staining C. luciliae kinetoplast DNA 
was scored from 0-4. (B-C) Anti-nucleosome (B) or anti-dsDNA (C) antibodies 
were determined by ELISA in sera from chimeric mice. Bars represent mean (A) 
or median (B-C) values. *, P < 0.05; **, P < 0.01 by Mann-Whitney U test.
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Figure 23. B cell reconstitution in chimeric mice. Total B cells (CD22+, panel 
A) and follicular B cells (CD22+ CD23+ CD2110, panel B) were determined in 
spleens of B.9+/+ (n = 9), B.9 7' 20% (n = 13), B.9 7' 50% (n = 5), A11.9-7 (n = 7), and 
A11.9+7+ (n = 3) chimeric mice at 16 weeks post-reconstitution.
*, P < 0.05; **, P < 0.01 by Mann-Whitney U test.
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Figure 24. Dendritic cell activation may occur secondary to autoantibody 
production. (A) Expression of MHC class II was determined in plasmacytoid DCs 
from B.9+/+ (n = 9), B.9 7- 20% (n = 13), B .9 ' 50% (n = 5), A11.9’'- (n = 7), and 
A11.9+/+ (n = 3) chimeric mice. (B) Representative MHC class II expression on 
plasmacytoid DCs from B9+/+ (blue line) and B.9_/‘ (red line) mice. (C) As in A, 
except that activation marker expression was determined in myeloid DCs.
*, P < 0.05; **, P < 0.01 by Mann-Whitney U test.
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Figure 25. Lymphadenopathy and T cell activation in chimeric mice. B.9W+ 
(n = 9), B.9 '- 20% (n = 13), B.9 7 50% (n = 5), A11.9'7 (n = 7), and A11.9+/+ (n = 3) 
chimeric mice were analyzed at 16 weeks post-reconstitution. (A) Two largest 
axillary lymph nodes were removed and weighed. (B) Naive phenotype (CD62L+ 
CD44 ) CD4+ T cells were determined as percentage of splenic CD4+ cells.
*, P < 0.05; **, P < 0.01 by Mann-Whitney U test.
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Figure 26. Absence of TLR9 on B cells is not sufficient to induce 
hypergammaglobulinemia in chimeric mice. Total serum IgG2a (A) and IgG3 
(B) were determined at the time of sacrifice for B.9+/+ (n = 9), B.9'/_ 20% (n = 13), 
B.9_/ 50% (n = 5), AII.9- (n = 7), and A11.9+/+ (n = 3) chimeric mice. (C) Serum 
IgG3 was not correlated with total splenic B cells for all chimeric mice (n = 37). 
*, P < 0.05; **, P < 0.01 by Mann-Whitney U test.
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Figure 27. Serum from TLR9-deficient mice induces IFN-a production in 
dendritic cell subsets. Splenic plasmacytoid DC (pDC, panel A) or myeloid DC 
(mDC, panel B) were sorted from TLR9 WT or TLR9 KO mice and either 
unstimulated (white bars) or stimulated with C-type CpG (black bars), apoptotic 
thymocytes (gray bars), TLR9 WT sera alone (striped white bars), TLR9 KO sera 
alone (spotted white bars), TLR9 WT sera plus apoptotic thymocytes (striped gray 
bars), or TLR9 KO sera plus apoptotic thymocytes (spotted gray bars). Secreted 
IFN-a was measured after 24 hours. Data are representative of two separate 
experiments.
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Figure 28. Effect of serum from wild-type or TLR9-deficient mice on cytokine 
production by dendritic cells. Splenic plasmacytoid DC (pDC, panel A) or myeloid 
DC (mDC, panels B-D) were sorted from TLR9 WT or TLR9 KO mice and either 
unstimulated (white bars) or stimulated with C-type CpG (black bars), apoptotic 
thymocytes (gray bars), TLR9 WT sera alone (striped white bars), TLR9 KO sera 
alone (spotted white bars), TLR9 WT sera plus apoptotic thymocytes (striped gray 
bars), or TLR9 KO sera plus apoptotic thymocytes (spotted gray bars). (A-B) 
Secreted IL-12 p40 was measured after 24 hours. Data are representative of two 
separate experiments. (C-D) Secreted IL-10 was measured after 24 hours. Each 
panel represents one experiment.
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Figure 29. TLR9-deficient serum allows dendritic cells to persist in an immature 
state. Splenic plasmacytoid DC (pDC, panels A and C) or myeloid DC (mDC, panels 
B and D) were sorted from TLR9 WT or TLR9 KO mice and either unstimulated 
(white bars) or stimulated with C-type CpG (black bars), apoptotic thymocytes (gray 
bars), TLR9 WT sera alone (striped white bars), TLR9 KO sera alone (spotted white 
bars), TLR9 WT sera plus apoptotic thymocytes (striped gray bars), or TLR9 KO sera 
plus apoptotic thymocytes (spotted gray bars). Viability (A-B) and B7-2 expression 
(C-D) were measured after 24 hours. (E) Representative expression levels of B7-2 on 
WT mDC (left) or KO mDC (right) that were either unstimulated (filled histogram) or 
stimulated with TLR9 WT sera plus apoptotic thymocytes (blue line), or TLR9 KO 
sera plus apoptotic thymocytes (red line). Data are representative of two separate 
experiments.
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Chapter 5: Role of TLR9 in Antigen-Specific B Cell Development, 
Activation and Differentiation
TLR9 is required for the generation of antibodies to DNA-containing antigens in a 
mouse model of SLE. Moreover, we have demonstrated that signaling through TLR9 
must occur within B cells for effective anti-DNA antibody secretion. Yet the precise 
effect of TLR9 on the development, activation and differentiation of anti-DNA B cells 
remains unclear. For example, because stimulation with TLR9 ligands is a potent 
stimulator of antibody secretion and plasma cell differentiation in vitro (74, 99), we 
suspected that activation of TLR9 in anti-DNA B cells would primarily facilitate their 
differentiation into antibody-secreting cells. Equally plausible is that TLR9 stimulation 
could be responsible for the initial activation of otherwise anergic B cells, thus permitting 
the subsequent differentiation of these cells by other mechanisms. Finally, it is also 
possible that TLR9 directly affects the development of anti-DNA B cells. There is a clear 
threshold effect in the development of autoreactive B cells, such that high-affinity clones 
are edited or deleted, while low affinity clones are allowed to exist in the periphery in a 
partially inactivated or anergic state (78, 168-170). If TLR9 signaling can alter this 
threshold, or perhaps can rescue autoreactive cells from deletion, it is possible that low- 
affinity anti-DNA B cells may never escape to the periphery in TLR9/ mice, and thus 
prevent anti-DNA antibody formation. Conversely, activation through TLR9 may 
facilitate the deletion of anti-DNA B cells during development, such that an excess of 
anergic autoreactive cells could exist in the periphery in TLR97 mice.
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In order to establish the site of TLR9-mediated production of anti-DNA 
antibodies, we used established autoreactive BCR transgenic systems. To track the fate 
of anti-DNA B cells in the presence or absence of TLR9, we used the 3H9 BCR heavy 
chain transgene, which was initially cloned from an autoimmune MRL/Mp//,r///,r mouse 
(171). This heavy chain can create a variety of anti-ssDNA and anti-dsDNA affinities 
when paired with endogenous kappa and lambda light chains (172, 173). To determine 
whether the effects of TLR9 on autoreactive B cell activation are specific for the anti- 
DNA specificity, we also studied B cells from anti-IgG rheumatoid factor transgenic 
mice. The AM 14 heavy chain, also cloned from an autoimmune MRL/Mp//,r///,r mouse 
(41), can create the rheumatoid factor anti-IgG2aa specificity when paired with 
appropriate endogenous V k8 light chains (174). Although TLR9 is required in vitro for 
full activation of AM 14 B cells by DNA-containing immune complexes (80, 81), these 
cells can also be stimulated by RNA-containing immune complexes in a TLR7-dependent 
fashion (82). The AM14 system thus allowed us to study the role of TLR9 in vivo in the 
activation of autoreactive B cells with a BCR specificity not restricted to DNA antigens.
Development and Central Tolerance of Anti-DNA B Cells are Unaffected by TLR9
Developing B cells expressing a BCR with high affinity for endogenous DNA are 
deleted at the pre-B to immature B cell transition in the bone marrow (170). A lower 
affinity reactivity to DNA allows developing B cells to exit the bone marrow and exist in 
the periphery in an inactive state in normal mice (168). Because endogenous light chains 
can create a wide range of affinity for DNA when paired with the 3H9 heavy chain (172, 
173), many light chains are purged from the developing B cell repertoire of 3H9
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transgenic mice by deletion and receptor editing. This results in a reduced peripheral B 
cell frequency and altered light chain repertoire, favoring light chains such as VX1 that 
support low DNA reactivity (175). Importantly, these central tolerance mechanisms 
appear to be intact in autoimmune-prone mouse strains such as MRL/Mp'/,'///)r (176, 177). 
To determine whether central tolerance of anti-DNA B cells is altered in the absence of 
TLR9, we analyzed peripheral B cell populations in TLR9 wild-type and TLR9-deficient 
3H9 transgenic mice, as well in non-transgenic wild-type mice of the MRL/Mp//’r//pr strain. 
We found that both 3H9 wild-type and TLR9'/_ mice exhibited a significant reduction in 
splenic B cells compared to non-transgenic controls (Fig. 30A, P = 0.0159 for 
comparison of 3H9 wild-type or TLR9 A versus non-transgenic). In addition, the 
frequency of Xl+ cells among splenic B cells was increased in both wild-type and TLR9- 
deficient 3H9 mice compared to non-transgenic controls (data not shown). Thus, these 
aspects of the central deletion of high-affinity anti-DNA clones (reduced peripheral B 
cells and shifted light chain repertoire) are not compromised by the absence of TLR9.
While low-affinity Xl+ anti-DNA B cells appear developmentally arrested in non- 
autoimmune mice, these cells assume a mature follicular phenotype and secrete anti- 
dsDNA antibody in lupus-prone M R L /M p^^ mice (177). We determined whether 
TLR9 signaling played any role in the peripheral development of mature anti-DNA B 
cells in autoimmune 3H9 transgenic mice. We first observed that XI+ B cells from both 
wild-type and TLR9/_ mice exhibited a 10-fold decrease in surface levels of XI compared 
to B cells from non-transgenic mice (Fig. 30B). This decreased expression of the BCR 
has been noted in multiple 3H9 strains, and has been associated with anergy due to 
prolonged exposure of the cells to specific antigen (177). Although Xl+ cells from 3H9
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TLR97 mice had a slightly lower expression of surface XI than 3H9 wild-type (average 
XI MFI = 229.6 for wild-type and 170.8 for TLR97', P = 0.0079), it is unclear if this is 
functionally significant. We did observe a significant difference in peripheral B cell 
subsets in 3H9 wild-type and TLR97' mice, however. TLR9-deficient animals had more 
Xl+ cells of a mature, follicular phenotype (CD2110 CD23+) than wild-type controls (P = 
0.0079), accompanied by a corresponding decrease in CD21'° CD23 cells in TLR97 mice 
(Fig. 30C-D). This double-negative population comprises both immature T1 B cells that 
have not yet acquired these developmental antigens (178), and activated B cells in 
MRL/Mp//,r//pr mice that have lost expression of typical B cell markers (179). Examining 
other markers of immature B cells, we found that less than 5% of Xl+ cells in both 3H9 
wild-type and TLR97' mice expressed the AA4.1 antigen, and that B220 expression was 
similar between wild-type and TLR97' mice (data not shown). Furthermore, many of the 
CD2110 CD23 cells expressed the activation marker CD44 (data not shown and Fig. 31, 
below), suggesting that these cells were a product of B cell activation rather than arrested 
development. Taken together, these data indicate that the absence of TLR9 does not 
prevent the peripheral maturation of anti-DNA B cells, and may even allow these cells to 
persist with a mature, follicular phenotype.
Peripheral Tolerance of Anti-DNA B Cells is Maintained in the Absence of TLR9
The lack of effect of TLR9 on central or peripheral development of anti-DNA B 
cells indicated that TLR9 primarily influenced the activation of mature peripheral B cells. 
We therefore used surface markers to examine the activation state of Xl+ anti-DNA B 
cells in 3H9 wild-type and TLR9 7 mice. We found that more than half of Xl+ cells in
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3H9 wild-type mice expressed high levels of the activation marker CD44, and that nearly 
one fifth had maintained high CD44 expression while losing expression of CD22, an 
indication of differentiation into antibody-secreting plasmablasts (180). In contrast, the 
majority of XT cells in TLR9; mice were of a naive phenotype (CD22+ CD4410), with 
fewer cells expressing CD44 and essentially no detectable plasmablasts (Fig. 31, A and 
D, P = 0.0079). The presence of some CD44hl Xl+ B cells in 3H9 TLR9; mice, along 
with the lack of XI plasmablasts, suggests that the primary effect of TLR9 on anti-DNA 
B cell activation is in the transition from activated B cell to differentiated antibody- 
secreting cell. However, the decrease in CD44hl B cells, as well as the significant 
decrease in CD69 expression among TLR9; Xl+ cells (Fig. 3 IE, P = 0.0317) indicates 
that TLR9 may also play a role in the initial activation of anti-DNA B cells.
To verify the absence of anti-DNA antibody-secreting cells in 3H9 TLR9' mice, 
we assayed for additional markers of plasma cell differentiation. First, analysis of 
CD138 (Syndecan-1) in wild-type 3H9 mice confirmed that a subset of CD22 Xl+ cells 
in these mice expressed this highly specific marker of differentiated antibody-secreting 
cells (181). CD138 expression on Xl+ cells from 3H9 TLR9; mice, by comparison, was 
significantly decreased (Fig. 31, B and E, P = 0.0079). Similarly, staining for 
intracellular XI revealed the presence of anti-DNA antibody-secreting cells in wild-type 
mice, while Xl+ cells with a high concentration of intracellular antibody were absent in 
TLR9 ; mice (Fig. 31, C and E, P = 0.0079). Finally, quantification of the number of 
anti-DNA antibody forming cells in the spleen demonstrated that while 3H9 wild-type 
mice generated a moderate to high frequency of XI-secreting cells, TLR9_/ mice 
exhibited a background level of XI secretion that was similar to that in non-transgenic
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mice (Fig. 32, P < 0.0079 for comparison of 3H9 wild-type versus TLR97'). TLR9 thus 
had a profound effect on the differentiation of effective anti-DNA antibody secreting 
cells in 3H9 transgenic mice.
Splenic Localization of Anti-DNA B Cells in TLR9-Deficient Mice
Previous reports have indicated that one mechanism for maintaining tolerance of 
anti-DNA B cells is their exclusion from the B cell follicle: while anti-DNA B cells are 
clustered at the edges of the T cell zones in normal mice, they can be found within the B 
cell follicle in lupus-prone MRL/Mp//vy//,r mice (177). In addition, the break in tolerance 
of anti-DNA B cells in otherwise normal mice of advanced age is coincident with the 
entry of these cells into the follicle (182). It is thus possible that the block in anti-DNA 
antibody secretion in TLR97~ mice could be due to the exclusion of precursor B cells 
from follicular locations. However, splenic histology revealed that X+ cells were found 
throughout the B cell follicle in both 3H9 wild-type and TLR9 7 mice (Fig. 33A). Anti- 
DNA Xl+ cells were generally not observed in the marginal zone of the spleen (Fig. 33A), 
a finding consistent with the low frequency of CD21hl CD23 cells in both wild-type and 
TLR97 mice (Fig. 30C-D). Although autoreactive B cells can preferentially home to 
marginal zone compartments (183-185), low affinity anti-DNA B cells appear to be 
regulated by a different mechanism, at least in M R L /M p ^ '- mice.
Following tolerance breakdown in autoimmunity, anti-DNA B cells appear to 
migrate into T cell zones of the spleen, where autoreactive antibody-secreting cells have 
been found to cluster (177, 186). Similarly, we observed the congregation of anti-DNA 
Xl+ cells in the center of T cell-rich peri-arteriolar lymphoid sheaths (PALS) in the spleen
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of 3H9 wild-type mice. These cells were also found in extrafollicular sites at T cell zone- 
red pulp border, and their intense intracellular XI staining was indicative of antibody- 
secreting cells (Figure 33B, left panel). Histologic identification of Xl+ cells in TLR9_/ 
spleens revealed two important differences (Figure 33B, right panel). First, Xl+ cells with 
intense cytoplasmic staining were exceptionally rare, indicating the absence of anti-DNA 
antibody-secreting cells in these mice. Second, the few Xl + cells found were individual 
cells residing at the edge of the PALS, as opposed to clusters of cells within the center of 
the T cell zone. The mechanism of TLR9-mediated anti-DNA antibody production thus 
appears to be distal to the entry of autoreactive B cells into splenic follicles, but proximal 
to the differentiation and accumulation of antibody-secreting cells in T cell zones of the 
spleen.
Rheumatoid Factor B Cell Activation Does Not Require TLR9 In Vivo
Our earlier studies of non-transgenic TLR97 mice revealed that despite the block 
in anti-DNA autoantibody production in these mice, antibodies to RNA-containing 
antigens were produced at comparable or higher levels than in wild-type controls 
(Chapter 3). The presence of elevated levels of IgG2a and IgG3 further indicated that 
there was not a global B cell defect imposed by the absence of TLR9. Nevertheless, it 
was important to determine whether TLR9 could have subtle effects on the activation or 
differentiation of autoreactive B cells with a BCR specificity not directly related to DNA 
or chromatin. For this we turned to the AM 14 rheumatoid factor system, in which 
transgenic AM 14 B cells break peripheral tolerance only in lupus-prone mice and only in 
the presence of their specific antigen IgG2aa (174). AM 14 is particularly informative for
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studying the role of TLR9 in B cell activation and antibody secretion, as it is a 
physiologic autoantibody associated with a clinical disease (rheumatoid arthritis), and 
AM 14 B cells have been shown to be activated by TLR signaling. While TLR9 
stimulation by chromatin-IgG immune complexes is one mechanism of AM 14 activation 
in vitro and has been linked to spontaneous rheumatoid factor secretion in vivo (80, 81, 
187), these cells can also be stimulated by complexes of IgG and RNA via TLR7 (82). 
The AM 14 system thus allows us to study a population of autoreactive B cells wherein 
TLRs may be instrumental for effective activation, but TLR9 is not required per se.
Analogous to our study of 3H9 anti-DNA B cell activation, we determined 
activation marker expression by AM14 transgenic B cells from mice either sufficient or 
deficient for TLR9. In the majority of these experiments, TLR9+/ heterozygous mice 
were used as controls with intact TLR9 expression. A smaller group of TLR9+/+ and 
TLR9 a mice were also compared in separate experiments with identical results. Using 
CD22 and CD44 to define naive, activated, and plasmablast B cell populations in AM14+ 
cells, we found a high level of plasmablast differentiation in both TLR9 heterozygous and 
-deficient mice (Fig. 34, A and C). Not only did the absence of TLR9 not prevent the 
activation and differentiation of rheumatoid factor B cells, we also observed a significant 
increase in AM14+ cells with an activated phenotype in TLR9; mice, along with a 
corresponding decrease in naive cells (Fig. 34, A and C, P = 0.0026). Analysis of 
intracellular AM14 confirmed that the majority of CD22 AM14+ cells in both groups of 
mice were antibody-secreting cells with high concentrations of intracellular rheumatoid 
factor (Fig. 34, B and D). Expression of similar levels of CD69, B7-1, and B7-2 
activation markers in wild-type and TLR97 AM14+ cells further indicated that there was
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no defect in autoreactive rheumatoid factor B cell activation in the absence of TLR9 (data 
not shown).
Functional antibody secretion in AM 14 transgenic mice was also determined, and 
again revealed no defect in the absence of TLR9. The numbers of splenic AM14 
antibody-secreting cells were comparable in TLR9 heterozygous and -deficient mice, 
with both groups of mice exhibiting a wide range of AM14 activation indicative of the 
stochastic spontaneous rheumatoid factor response (Fig. 35A). We were also able to 
monitor the kinetics of AM 14 activation in live mice using a serum ELISA to identify 
spontaneous AM 14 “seroconversion” (presented in Chapter 6 ). TLR9-deficient mice did 
not exhibit any defect in either the magnitude of rheumatoid factor secretion or the 
kinetics of onset of autoimmunity in the AM 14 system (Fig. 35B). In fact, there was a 
trend toward increased serum levels of AM14 in younger TLR9; mice, although this was 
not statistically significant. Thus neither the initial activation nor the terminal 
differentiation of AM14 rheumatoid factor B cells was inhibited in the absence of TLR9 
in vivo.
Discussion
These experiments demonstrate that the ability to generate efficient anti-DNA 
antibody-secreting cells is blocked in the absence of TLR9, even with forced expression 
of an anti-DNA BCR transgene. Thus, the lack of antibodies to DNA-containing 
antigens in non-transgenic TLR9'/_ mice is not simply due to a low precursor frequency, 
or the inability of these cells to compete for sparse survival or activation factors. We also 
discovered that TLR9 played no clear role in either the central or peripheral development
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of anti-DNA B cells. Low-affinity anti-DNA B cells were able to progress to a mature, 
follicular phenotype in both wild-type and TLR97 mice, and the contracted peripheral B 
cell pool in 3H9 mice of both genotypes indicated that effective central deletion of high- 
affinity precursors had occurred. It is unclear whether TLR9 is expressed during B cell 
development, but our findings indicate that TLRs do not play a significant role in shaping 
the mature B cell repertoire. This could have important implications for the development 
of autoreactive B cells, suggesting that selection is primarily determined by the affinity of 
self ligands for the BCR, regardless of their costimulatory capacity.
In contrast to B cell development, the absence of TLR9 had a dramatic impact on 
the activation and differentiation of peripheral anti-DNA B cells, preventing the 
formation of antibody-secreting plasmablasts. It has been demonstrated that T cell help is 
a critical factor in breaking functional tolerance of 3H9 anti-DNA B cells, as provision of 
cognate CD4+ helper cells permits anti-DNA antibody secretion even in non-autoimmune 
mice (125). It is now clear that a fundamental requirement for TLR9 signaling also exists 
in these cells. The relationship between TLR-mediated and T cell-mediated 
costimulation of autoreactive B cells is not yet defined, but our data indicate that in the 
case of anti-DNA B cells, B cell-intrinsic TLR activation is a final checkpoint for 
plasmablast differentiation that cannot be overcome by other modes of stimulation. This 
concept is supported by the fact that while T-independent antibody responses can be 
mounted against appropriate antigens in vivo (188), inability to activate TLRs in B cells 
prevents effective antibody production (75). In addition to facilitating the differentiation 
of anti-DNA B cells into efficient producers of antibody, TLR9 also appeared to promote 
the early activation of these cells. TLR9 may therefore play a role in the initial activation
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of otherwise anergic autoreactive B cells. This is an intriguing possibility in light of the 
demonstration that self-reactive anti-HEL B cells are resistant to TLR9-mediated 
activation due to tolerogenic signaling through the BCR (79). It is unclear whether anti- 
DNA B cells are regulated in the same manner, whether co-ligation of the BCR and 
TLR9 by the same antigen complex can overcome this regulation, or whether other 
factors such as T cell help are required for effective activation of autoreactive B cells.
Although TLR stimulation can promote the activation of autoreactive AM 14 B 
cells in vitro (80, 82), we found that TLR9 was not required for the activation and 
differentiation of these cells in lupus-prone mice in vivo. The requirement for TLR9 in 
autoantibody production is therefore limited to cells expressing a BCR with appropriate 
specificity for DNA-containing antigens. In fact, we were surprised to discover that 
AM 14 B cells from TLR9-deficient mice exhibited a level of activation even greater than 
TLR9-sufficient controls. There are at least three potential explanations for this finding. 
First, because AM 14 B cells can be stimulated by RNA-containing immune complexes 
via TLR7 (82), and because such complexes appear to be more stimulatory for dendritic 
cell activation than DNA-containing complexes (Chapter 4), it is possible that TLR7 
activation can explain the higher CD44 expression of AM 14 B cells from TLR9'/' mice. 
Second, the increased DC activation and circulating IFN-a that exist in non-transgenic 
TLR9' mice (Chapter 3) could allow for a non-specific increase in the activation state of 
all B cells. This would then be a tertiary effect of TLR9 on global B cell activation, as 
production of IFN-a by pDCs appears to be a result of the altered autoantibody repertoire 
in TLR9/_ mice (Chapter 4). Finally, it is possible that TLR9 could exert a static 
inhibition of all B cells regardless of BCR specificity, although this possibility has not
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3H9 heavy chain transgenic mice (168) were crossed to TLR9-deficient mice to generate 
3H9+ TLR9 ; and 3H9+ TLR9+/+ strains maintained in separate breeding pairs. AM 14 
heavy chain transgenic mice (174) were crossed to TLR9-deficient mice to generate 
AM14+ TLR9+/' mice, which were further crossed to TLR97 mice to produce AM14+ 
TLR9+/' and TLR9 y littermates for analysis. Additional experiments were also performed 
with AM14+ TLR9+/+ and AM14+ TLR9/_ mice from separate breeding pairs. All mice 
were backcrossed at least 8 generations to MRL/Mp/pr///,r. 3H9 transgenic mice and non- 
transgenic controls were analyzed at 12 weeks of age. AM14 transgenic mice were 
analyzed for serum antibody beginning at 8-9 weeks of age, and sacrificed at 16-18 
weeks of age.
Analysis of transgenic B cells and activation markers.
Spleen cells were isolated as previously described (Chapter 2). Anti-DNA >d+ cells from 
3H9 transgenic mice were identified with anti-Xl antibody (R11-153, BD Biosciences). 
Rheumatoid factor AM14+ cells were identified with 4-44 anti-idiotype antibody 
produced in our laboratory. Antibodies for B cell activation and differentiation status 
were used as previously described, in addition to anti-CD21 (7G6), anti-CD23 (B3B4), 
anti-CD138 (281-2, anti-syndecan-1), and the AA4.1 monoclonal antibody, all obtained
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from BD Biosciences. Intracellular XI was detected with anti-Xl antibody (LS 136.2) 
produced in our laboratory.
Quantification of antibody-secreting cells by ELISpot.
Polystyrene plates were coated with polyclonal goat anti-mouse IgM (Chemicon) and 
blocked with 1% BSA in PBS. Serial dilutions of splenocytes from 100,000 cells per 
well to 3,700 cells per well were added in media supplemented with 2.5% fetal calf 
serum (Gemini Bio-Products) and incubated for 5 hours at 37 degrees. Antibodies were 
detected with either biotin-conjugated R11-153 anti-XI antibody (for 3H9 anti-DNA) or 
biotin-conjugated 4-44 anti-idiotype antibody (for AM 14 rheumatoid factor), followed by 
streptavidin-conjugated alkaline phosphatase (Molecular Probes). Development was 
performed with bromochloroindoyl phosphate (Amresco) in 0.5% agarose, and spots 
were counted using a dissecting microscope.
Spleen histology.
Frozen spleens mounted in Tissue-Tek O.C.T. (Sakura) were cut into 7p.m sections and 
thaw-mounted onto positively-charged Superfrost/Plus slides (Fisher). Tissue was 
blocked with 1% BSA plus 10% rat serum in PBS/0.1% Tween-20, and stained with anti- 
XI (R11-153) or polyclonal goat anti-mouse total X (Southern Biotech), and CD22.2 or 
Thy 1.2 antibodies. Alkaline phosphatase was developed with naphthol AS-MX (Sigma) 
and Fast Blue BB Base (Sigma), and horseradish peroxidase was developed with 3- 
amino-9-ethylcarbazole (Sigma).
Serum AM 14 ELISA.
Polystyrene plates were coated with polyclonal goat anti-mouse IgM (Chemicon), 
blocked with 1% BSA in PBS, and serial dilutions of serum from 1:100 to 1:2700 were
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added. AM14 rheumatoid factor antibodies were detected with biotin-conjugated 4-44 
anti-idiotype antibody and streptavidin-conjugated alkaline phosphatase (Molecular 
Probes), and absorbance at 405/630nm was determined. AM 14 concentrations in serum 
were determined by comparison with a known concentration of antibody in supernatant 
from an AM14-transfected cell line.
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Figure 30. TLR9 does not affect the development of anti-DNA B cells.
(A) Splenic B cells (CD22+) were determined in 3H9 transgenic TLR9 WT (n = 5) 
or TLR9 KO (n = 5) mice, and in non-transgenic Tg(-) mice (n = 4). (B) Surface 
expression of lambda-1 was determined in 3H9 TLR9 WT (blue line), 3H9 TLR9 
KO (red line) and Tg(-) (filled histogram) mice. Cells shown are A,l+ B cells.
(C) Expression of CD21 and CD23 was determined on splenic A,l+ cells from 3H9 
TLR9 WT or TLR9 KO mice. (D) Xl+ cells were classified as follicular (CD2110 
CD23+), marginal zone (MZ, 0 0 2 1 “ CD23 ), or T1/plasmablast phenotype (CD2110 
CD23 ) for 3H9 TLR9 WT (black bars, n = 5) and 3H9 TLR9 KO (white bars, n = 
5) mice. Data are presented as mean +/- SEM. *, P < 0.05; **, P < 0.01 by 
Mann-Whitney U test. Because subsets of A,l+ cells are interdependent variables, 
statistical comparisons for one subset are indicative of whole distribution. Data are 
representative of 2 independent experiments.
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Figure 31. Activation and differentiation of anti-DNA B cells are abrogated in 
the absence of TLR9. (A-C) CD22 and CD44 (A), CD22 and CD 138 (B), or CD22 
and intracellular Xl (C) expression were determined on Xl+ cells from spleens of 
3H9 TLR9 WT (upper plots) and 3H9 TLR9 KO (lower plots) mice. (D) Xl+ cells 
from 3H9 TLR9 WT (black bars, n = 5) and 3H9 TLR9 KO (white bars, n = 5) mice 
were classified as naive (CD22+ CD4410), activated (CD22+ CD44hi), or plasmablast 
phenotype (CD22' CD44hl) based on surface markers as in A. (E) Expression of 
CD138, intracellular Xl, or CD69 was determined on Xl+ cells from 3H9 TLR9 WT 
(black bars, n = 5) and 3H9 TLR9 KO (white bars, n = 5) mice. Data are presented 
as mean +/- SEM. *, P < 0.05; **, P c  0.01 by Mann-Whitney U test. Because 
subsets of Xl+ cells in panel D are interdependent variables, statistical comparisons 
for one subset are indicative of whole distribution. Data are representative of 2 
independent experiments.
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Figure 32. Absence of anti-DNA antibody-secreting cells in 
TLR9-deficient mice. IgM/A,l antibody-secreting cells were determined in 
3H9 TLR9 WT (n = 5), 3H9 TLR9 KO (n = 5), and non-transgenic Tg(-) (n = 2) 
mice. Data are presented as ELISpots per million splenocytes. **, P < 0.01 by 
Mann-Whitney U test. Data are representative of 2 independent experiments.
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Figure 33. Localization of anti-DNA B cells in TLR9-deficient mice.
(A) Spleen sections from 3H9 TLR9 WT and 3H9 TLR9 KO mice were stained 
for total A, (blue) and B cell follicles (CD22, red). Anti-DNA A+ cells are 
observed within the B cell follicle in both TLR9 WT and TLR9 KO mice.
(B) As in A, except that sections were stained for Al (red) and T cell zones 
(Thyl, blue). Anti-DNA Al+ antibody-secreting cells accumulate and invade the 
T cell zone in TLR9 WT, but not TLR9 KO mice. Representative images are 
shown.
130






10u 101 1 0 ' 10° 1(T
TLR9 KO







10u 101 1 0 ' 10J  10* 
TLR9 KO







r -  O!l 













Figure 34. Activation and differentiation of rheumatoid factor B cells in the 
absence of TLR9. (A) CD22 and CD44 expression was determined on AM14+ cells 
from spleens of AM 14 TLR9+/ heterozygote (upper plot) and AM 14 TLR9 KO (lower 
plot) mice. (B) CD22 and intracellular AM14 expression were determined on AM14+ 
cells from spleens of AM14 TLR9 WT (upper plot) and AM14 TLR9 KO (lower plot) 
mice. (C) AM14+ cells from AM14 TLR9+/" heterozygote (black bars, n = 11) and 
AM14 TLR9 KO (white bars, n = 13) mice were classified as naive (CD22+ CD4410), 
activated (CD22+ CD44hi), or plasmablast phenotype (CD22 CD44hi) based on surface 
markers as in A. Data are presented as mean +/- SEM. (D) Expression of intracellular 
AM14 was determined in AM14+ cells from AM14 TLR9 WT (n = 4) and AM14 
TLR9 KO (n = 5) mice. Data in B and D are representative of 3 independent 
experiments. **, P < 0.01 by Mann-Whitney U test. Because subsets of AM14+ cells 
in panel C are interdependent variables, statistical comparisons for one subset are 
indicative of whole distribution.
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Figure 35. Secretion of rheumatoid factor antibody in the absence of TLR9.
(A) AM 14 IgM antibody secreting cells were determined in AM 14 TLR9+/' 
heterozygote (n = 11) and AM14 TLR9 KO (n = 13) mice at 16 weeks of age. 
Data are presented as ELISpots per million splenocytes. (B) Serum AM14 IgM 
antibody was determined in AM 14 TLR9+/' heterozygote (black diamonds, n = 11) 
and AM14 TLR9 KO (white diamonds, n = 13) mice at varying time points.
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Chapter 6: Importance of T Cell Help in Autoreactive B Cell Activation
Our work has revealed that signaling through TLRs is a fundamental requirement 
for specific activation of autoreactive B cells in SLE. TLR activation alone, however, is 
unlikely to account for autoantibody production without additional costimulatory signals. 
Cognate interactions with CD4+ helper T cells are required for effective autoantibody 
production in autoimmune disease (123, 124), and also appear to be critical for the 
initiation of autoimmunity in the 3H9 anti-DNA transgenic model (125). Whether 
continued T cell help is also required for the maintenance or propagation of autoantibody 
production, however, is unknown. We therefore used the AM 14 rheumatoid factor 
transgenic system (174) to determine the requirements for CD4+ T cells at specific stages 
of autoreactive B cell activation, after the autoimmune response had already been 
established.
After the initial activation and expansion of autoreactive B cells, downstream 
events include heavy chain class-switch to IgG isotypes, somatic hypermutation and 
affinity maturation of autoreactive clones (41, 189, 190), and the generation of long-lived 
plasma cells (191), or possibly autoreactive memory cells. Cognate T cell help may be a 
limiting factor for these potentially pathologic B cell activation pathways. The ability to 
analyze these later outcomes in antigen-specific autoreactive B cells is limited by the use 
of conventional transgenic systems. Expression of ectopically-integrated heavy chain 
transgenes in these B cells does not allow for class switch or somatic hypermutation, and 
may interfere with terminal plasma cell differentiation. We therefore created a site- 
directed transgenic animal, inserting the AM 14 rheumatoid factor transgene into the
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germline IgH locus. Analysis of B cell activation and differentiation in these mice will 
facilitate the analysis of secondary events in autoreactive B cell biology.
Functional Removal of T Cell Help After Initiation of an Autoimmune Response
Activation and differentiation of AM 14 rheumatoid factor (anti-IgG2aa) 
transgenic B cells into antibody-secreting plasmablasts occurs spontaneously in lupus- 
prone mice (174), while these cells do not differentiate or produce antibody in normal 
mice (192). Generation of AM14 antibody-secreting cells occurs in a stochastic, time- 
dependent manner in MRL/Mp//,r//pr mice. Our lab has recently described the abrupt 
expansion of these cells in the spleen and peripheral blood between 10 and 20  weeks of 
age (187). We reasoned that activation of AM14 antibody-secreting cells could also be 
detected by an increase in circulating levels of AM 14 IgM antibody. As expected, 
individual mice exhibited an age-dependent increase in serum AM 14 antibody when 
followed over time (Chapter 5 and data not shown). We then compared serum levels of 
AM14 with expansion of splenic AM14 plasmablasts by ELISpot, and found that the 
level of AM 14 antibody in terminal serum was a highly specific indicator of splenic 
plasmablast generation (Figure 36, P < 0.0001 for agreement of positive ELISA with 
positive ELISpot by Fisher’s exact test). We were therefore able to track circulating 
AM 14 antibody in live mice over time to identify the point at which the phenomenon of 
seroconversion occurred.
Depletion of helper T cells with the anti-CD4 monoclonal antibody GK1.5 has 
been demonstrated to reduce autoantibody secretion in both young and aged lupus-prone 
mice with established disease (121, 122). The specific consequences of this removal of T
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cell help for antigen-specific B cells in an established autoimmune response remained 
unknown. We therefore used GK1.5 antibody to deplete CD4+ T cells from autoimmune 
AM 14 mice immediately following spontaneous seroconversion. As previously reported, 
however, CD4+ T cells were resistant to depletion in mice with established disease (122). 
Treatment of MRL/Mp,pr/'^ mice with varying doses of GK1.5 over a two-week period 
produced only a 40% depletion of splenic CD4+ T cells and 30% depletion of lymph node 
CD4+ T cells, although removal of circulating T cells was more effective, with 70% 
depletion (Fig. 37A-C). Moreover, increasing the dose of administered GK1.5 did not 
improve depletion efficiency (Fig. 37A-C). Resistance to antibody-mediated depletion 
was an effect specific to lupus-prone mice, as equivalent or lesser doses of GK1.5 were 
sufficient to produce 90% depletion of splenic CD4+ T cells and > 99% depletion of 
circulating CD4+ T cells in BALB/c mice in only one week (data not shown).
Although GK1.5-treated autoimmune mice were not completely depleted of CD4+ 
T cells, the residual T cells appeared functionally inhibited. There is precedent for a 
depletion-independent inhibitory effect of GK1.5, as treatment of lupus-prone mice with 
a non-depleting F(ab’)2 fragment of GK1.5 reduced disease to a comparable level as 
treatment with intact antibody (193). We observed a consistent, order of magnitude 
decrease in CD4 expression levels among residual T cells in GK1.5-treated mice (Fig. 
37D). This effect represented an actual decrease in surface protein levels and was not a 
result of masking by bound GK1.5, as the RM4-4 antibody used for detection binds to a 
different epitope on CD4. Moreover, staining of CD4+ cells with GK1.5 ex vivo revealed 
that all GK1.5 epitopes were blocked in treated mice, indicating that residual T cells were 
completely opsonized with GK1.5 (Fig. 37E). In addition, residual CD4+ T cells were
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enriched for naive, unactivated cells: they expressed lower levels of CD69 (Fig. 37F), had 
a higher percentage of CD62L+ CD44' cells (Fig. 37G, P < 0.0001), and had a lower level 
of BrdU incorporation over a 12-hour period (data not shown). These findings all 
indicated that remaining CD4+ T cells in GK1.5-treated mice were ineffective at 
providing cognate help to B cells. To directly test this, we treated MRL/Mp//’r///,r mice 
with GK1.5 for one week, then immunized with the hapten nitrophenyl (NP) conjugated 
to chicken gamma-globulin (CGG) and assayed for specific antibody production after an 
additional 10 days of GK1.5 treatment. Despite the incomplete depletion in these mice 
(42% reduction in splenic CD4+ T cells, data not shown), treatment with GK1.5 
completely inhibited the T-dependent IgG anti-NP response (Fig. 37H). Thus, even in 
the absence of complete depletion, treatment of lupus-prone mice with GK1.5 effectively 
eliminates T cell help for antibody-producing B cells.
Reduction in Autoantibody Production in the Absence of T Cell Help
We next determined whether the removal of T cell help with GK1.5 treatment had 
any effect on the expansion of AM 14 antibody-secreting cells. Recently seroconverted 
AM 14 mice were identified by circulating levels of AM 14 antibody, and were treated for 
2 weeks with either GK1.5 or control antibody. Determination of splenic AM 14 
plasmablasts by ELISpot then revealed a significant reduction in antibody-secreting cells 
in GK1.5-treated mice (Fig. 38A, P = 0.04). A similar reduction in serum AM14 
antibody was also observed, despite the fact that both groups of mice had comparable 
levels of circulating antibody prior to treatment (Fig. 38B, P = 0.0056 for comparison of 
control versus GK1.5 after 2 weeks of treatment). Although several of the GK1.5-treated
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mice had nearly complete reductions in AM 14 antibody production, many of these 
animals maintained a moderate level of autoantibody secretion. To determine whether a 
more prolonged removal of T cell help would further reduce AM14 antibody production, 
we also treated a cohort of mice with GK1.5 or control antibody for 4  weeks, and again 
observed a reduction in splenic AM14 anti body-secreting cells (Fig. 38A, P = 0.0052). 
However, even after 4 weeks without functional CD4+ T cell help, the GK1.5-treated 
mice had more antibody-producing cells than in age-matched mice that had not yet 
seroconverted (Fig. 38A, P = 0.0006). Examination of circulating AM 14 antibody 
revealed that antibody production increased over time in control mice, but serum levels of 
AM14 stayed relatively constant in GK1.5-treated mice (Fig. 38C, P = 0.0002 for 
comparison of control versus GK1.5 after 4 weeks of treatment). Taken together, these 
data indicate that CD4+ T cell help is required for efficient propagation of an established 
response, but a lower level of autoreactive B cell activation can be maintained in a T- 
independent manner.
Effects of T Cell Help on AM 14 B Cells and Plasmablasts
To determine what effect the removal of T cell help had on autoreactive B cells at 
various stages of activation, we analyzed the expression of developmental and activation 
markers on AM14+ B cells. Our lab has previously shown that the spontaneous AM 14 
response in lupus-prone mice is dominated by a population of rapidly-dividing 
plasmablasts that have lost expression of the B lineage marker CD22 and express 
increased levels of multiple activation markers (180). As expected from the decrease in 
antibody-secreting cells by ELISpot, we observed a marked reduction in CD22 AM 14
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plasmablasts in mice treated with GK1.5 (Fig. 39A). Although there was no decrease in 
the frequency of CD22+ AM14 B cells, there was a decrease in activation marker 
expression by these cells, which was most prominent for the early activation marker 
CD69 (Fig. 39B-E, P < 0.0001 for CD69 expression). Expression of some activation 
markers by CD22 plasmablasts was not affected by the removal of T cell help, as AM14 
plasmablasts from both GK1.5- and control antibody-treated mice expressed high levels 
of CD44 and CD69 (Fig. 39, B and D). We did observe a significant reduction in B7-1 
expression in AM14 plasmablasts from GK1.5-treated mice (P = 0.0142), an effect that 
was not observed in CD22+ AM 14 B cells (Fig. 39, C and E). Thus, costimulation from 
CD4+ T cells appeared to have different functional outcomes in CD22+ B cells and CD22 
plasmablasts.
The high level of activation marker expression by CD22' AM 14 plasmablasts, 
even in the absence of T cell help, suggested that maintenance of these cells could occur 
in a T cell-independent manner. It was unclear whether the disappearance of these 
plasmablasts after GK1.5 treatment was due to direct inhibition of these cells or whether 
the formation of antibody-secreting cells from naive CD22+ precursors was blocked. To 
determine how these two autoreactive B cell subsets were affected by the removal of T 
cell help, we assessed 5-bromo-2'-deoxyuridine (BrdU) incorporation after a 12 hour 
labeling period. After two-week treatment with GK1.5, proliferation of both CD22+ 
AM14 B cells and CD22 AM14 plasmablasts was reduced by approximately two-fold 
(Fig. 40, P = 0.0142 for CD22+ and 0.0008 for CD22 ). Thus, the provision of CD4+ T 
cell help is required for the continued proliferation of both CD22+ autoreactive B cells 
and differentiated CD22' plasmablasts in an established autoimmune response. We also
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examined the rate of cell death in these two populations of AM 14 cells. An intrinsically 
high level of apoptosis was found in CD22' plasmablasts as previously demonstrated 
(180), but we observed no difference in the death rate between cells from GK1.5-treated 
or control mice (data not shown). Interestingly, the residual level of AM 14 proliferation, 
both for CD22+ and CD22 cells, was not further reduced after 4 weeks of GK1.5 
treatment (Fig. 40). This again suggests the presence of T-independent mechanisms for 
maintenance of autoantibody production in SLE.
Splenic Localization of Residual Plasmablasts in the Absence of T Cell Help
We have previously shown that AM 14 plasmablasts proliferate in extrafollicular 
locations in the spleen, clustering around bridging channels adjacent to T cell zones (180, 
187, 189). We found that the functional removal of T cell help did not significantly alter 
the splenic localization of these cells. Although there were reduced numbers of cells with 
intense cytoplasmic staining for AM 14 in mice treated with GK1.5, these smaller clusters 
of plasmablasts were still found primarily at the T zone-red pulp border. This was true in 
mice treated for a period of either 2 weeks (Fig. 41 A) or 4 weeks (Fig. 41B). In fact, a 
greater invasion into the red pulp was observed in controls than in GK1.5-treated mice, in 
which AM14 cells were closely associated with T cell zones (Fig. 41A-B). It is likely 
that other factors besides interaction with T cells, such as chemokine gradients or 
cytokines produced by dendritic cells, are responsible for the selective retention of 
antibody-secreting cells at the edge of T cell zones in the spleen.
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Inhibition of CD40L Does Not Reduce AM 14 Plasmablasts
Stimulation by CD40L expressed on activated CD4+ T cells has been shown to be 
a critical component of T cell help for cognate B cells (126, 127), and has also been 
demonstrated to facilitate autoantibody production in the context of autoimmunity (128). 
To determine whether T cell help for AM 14 rheumatoid factor B cells was mediated by 
CD40L, we treated recently seroconverted mice with either MR-1 anti-CD40L antibody 
or control antibody for 2 weeks. Inhibition of CD40L with MR-1 in vivo has previously 
been shown to block the development of short-lived antibody-secreting cells in T- 
dependent immunization protocols (194). Unlike the analogous experiment with GK1.5, 
treatment of AM 14 mice with MR-1 did not reduce AM 14 antibody-secreting cells over a
2-week period (Fig. 42A). Analysis of AM 14 cell subsets in these mice revealed that 
while inhibition of CD40L did significantly reduce CD69 expression among CD22+ 
AM14 B cells (P = 0.0159), there was no effect on expression of CD44, CD69, or B7-1 
among CD22 plasmablasts (Fig 42B and data not shown). This suggests that CD40L is 
critical for the early activation of autoreactive B cells, while other T cell derived factors 
may be more important for the maintenance of differentiated plasmablasts in an 
established response. Important caveats of these experiments, however, are that we have 
not verified the complete inhibition of CD40L with this treatment regimen, and that our 
group sizes were not large enough to detect a subtle effect on autoantibody production. It 
is thus possible that CD40L may contribute to the generation or maintenance of 
autoreactive plasmablasts, but it does not appear to be absolutely required, as suggested 
by the partial effect of genetic ablation of CD40L in MRL/Mp//"v//,r mice (128).
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Generation of AM14 Site-Directed Transgenic Mice
Analysis of AM14 activation and antibody secretion in the absence of T cell help 
revealed that different aspects of the autoreactive B cell response could be differentially 
stimulated by T cell-derived factors. It is thus probable that downstream events in B cell 
activation such as somatic hypermutation, class-switching, and long-lived plasma cell or 
memory formation could also require costimulation from CD4+ T cells. In order to study 
these later stages of B cell activation in the AM 14 model, we created an AM 14 site- 
directed transgenic (AM14-sdTg), in which the rearranged VDJ gene segments of the 
AM 14 heavy chain were inserted into the JH region of the germline immunoglobulin 
heavy chain (IgH) locus. The presence of upstream VH and DH gene segments in site- 
directed BCR transgenes renders them particularly susceptible to RAG-mediated VH 
replacement during B cell development. This process of gene replacement occurs as 
upstream VH or DH gene segments undergo recombination signal sequence (RSS)- 
mediated recombination with an internal heptamer in the 3 ’ coding region of the inserted 
transgene (195). In the AM14-sdTg, recombination could potentially occur with this 
internal heptamer found in the VH J558 gene segment, or with the 5 ’ heptamer from the 
Jh4 gene segment, since AM 14 is rearranged to JH3 (Figure 43A). We therefore mutated 
the heptamers of these two RSS in order to improve stability of the transgene during B 
cell development. The Jh4  heptamer was mutated from 5 ’-CACAATA (on the antisense 
strand) to 5’-TGCAATA, and the internal heptamer was mutated from 5 ’-CACAATA (on 
the antisense strand) to 5’-CTCAATA. Mutation of the internal heptamer was a silent 
mutation that did not alter the protein sequence of the transgene.
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We then transfected the AM14-sdTg targeting construct into murine embryonic 
stem (ES) cells and screened for homologous recombination of the transgene into the 
germline IgH locus (Fig. 43A). Initial screening was done by PCR amplification of a 
region spanning the 1.2 kb of 5 ’ overlap between the targeting construct and the germline 
locus (black arrows in Fig. 43A). Of 223 independent ES clones screened, three were 
PCR-positive for correct upstream integration. Genomic DNA from these three clones 
was digested with EcoRI and hybridized to a JH4 probe by Southern blot. A 6.2 kb band 
corresponding to the native germline IgH locus was seen in all three clones, and a 9.4 kb 
band corresponding to the correct integration of the transgene was observed in only one 
clone (Fig. 43B). This ES cell clone was then injected into blastocysts, which were 
transferred into pseudopregnant female mice. Breeding of chimeric offspring resulted in 
transmission of the AM14-sdTg transgene to progeny mice in Mendelian ratios.
Expression of the AM 14 rheumatoid factor idiotype was confirmed in AM 14- 
sdTg mice after one backcross generation to Fas-intact MRL/Mp mice. Approximately
3-4% of splenocytes expressed the AM 14 idiotype created by pairing of the AM14-sdTg 
heavy chain with appropriate endogenous light chains, and expression was restricted to 
CD22+ B cells (Fig. 44A). Expression was also found in less than 1% of bone marrow 
cells, and was restricted to B220hl B cells (Fig. 44B). Significant expression of the AM 14 
idiotype was not observed in spleen or bone marrow of non-transgenic mice (Fig. 44A- 
B). The majority of splenic AM14+ cells in AM14-sdTg mice were IgM'° IgDhI, 
indicative of a mature, follicular phenotype (Fig. 44C). Expression of high levels of 
CD23 and lower levels of CD21 on most AM14+ cells also indicated a follicular 
phenotype (Fig. 44C). Approximately 10-15% of splenic AM14+ cells in AM14-sdTg
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mice exhibited a marginal zone B cell phenotype (IgMhl IgD10 CD21hl CD2310, Fig. 44C). 
These findings indicate that the AM14-sdTg is expressed appropriately during B cell 
development, allowing normal expression of IgM and IgD, and favoring development 
towards follicular phenotype peripheral B cells.
Production of IgG Rheumatoid Factor Antibodies in AM14-sdTg Mice
We next determined whether spontaneous activation and antibody production by 
AM14-sdTg B cells could occur in lupus-prone mice. AM14-sdTg mice were 
backcrossed seven generations to M RL/M p'^^ mice, and AM 14 antibody-secreting cells 
in the spleen were identified after 21 weeks, an age at which nearly all conventional 
AM14-transgenic MRL/Mp//,r//pr mice have undergone spontaneous seroconversion (187). 
We found that aged AM14-sdTg mice harbored AM 14 antibody-secreting cells of IgM, 
IgG2a, and IgG2b + IgG3 isotypes (Fig. 45A). All three isotypes were significantly 
increased relative to 7 week-old mice, indicating that spontaneous production of 
rheumatoid factor antibody is an age-dependent phenomenon (Fig. 45A, P = 0.0041 for 
IgM, 0.0095 for IgG2a, and 0.0035 for IgG2b + IgG3). The presence of antibody- 
secreting cells of multiple isotypes indicates that AM14-sdTg B cells can indeed class 
switch to IgG isotypes in the context of autoimmunity. Moreover, there appeared to be 
either a selective expansion or a more effective generation of IgG-producing cells, as 
aged mice produced more AM14 antibody-secreting cells of IgG2b + IgG3 isotype than 
IgM isotype (Fig. 45A, P = 0.0327). Analysis of circulating IgG AM 14 antibody 
confirmed the age-dependent expansion of class-switched AM 14 cells, with a significant 
increase in serum AM14 from an age of < 12 weeks to an age of 15 weeks (Figure 45B, P
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= 0.0004). An age-dependent increase in circulating IgM AM14 antibody was not 
observed, with both young and old mice producing generally low levels of IgM AM 14 (< 
10 ng/ml, data not shown).
Finally, we determined whether the spontaneous activation of AM14-sdTg cells 
produced a population of antibody-secreting plasmablasts analogous to those observed in 
AM14 conventional transgenic mice (180). Surprisingly, even in mice with high levels 
of AM 14 antibody-secreting cells by ELISpot, we found very few cells with the typical 
plasmablast phenotype: surface AM14+ CD22 (Figure 46A). This was in contrast to 
staining for intracellular antibody, which revealed an expansion of intracellular AM14+ 
CD22" cells in seroconverted mice (Figure 46B). Suspecting that the antibody-secreting 
cells in AM14-sdTg mice had lost surface expression of the BCR, we then compared 
expression of surface AM 14 with intracellular AM 14. This confirmed that the majority 
of intracellular AM14+ cells in these mice were indeed surface AM14 (Figure 46C). This 
was in contrast to antibody-secreting cells from AM 14 conventional transgenic mice, 
which were predominantly intracellular AM14+ and surface AM14+ (Figure 46D). Thus, 
antibody-secreting cells from AM14-sdTg mice exhibit a different phenotype than the 
previously described AM 14 plasmablasts in conventional transgenic mice (180, 187,
189), and may represent a more complete transition to terminally-differentiated plasma 
cells. It is unclear whether the ability to switch to IgG isotype production is directly 
responsible for this difference, although we were able to identify IgG2a-expressing 
surface AM14+ cells in these mice (data not shown).
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Discussion
We have shown that even after the initiation of a robust autoantibody response, 
CD4+ helper T cells are still required for the efficient propagation of that response. 
Within as little as two weeks, the number of rheumatoid factor-producing cells in the 
spleen decreased by nearly three-fold in GK1.5-treated mice compared to controls. T 
cells played important roles in multiple stages of autoreactive B cell activation, as they 
were required both for the early activation of B cells and to maintain a high level of 
proliferation among differentiated plasmablasts. Nevertheless, a low but significant level 
of autoantibody-secreting cells was maintained for as long as four weeks in the absence 
of T cell help. The fact that splenic plasmablasts, serum AM 14 antibody, and AM 14 
proliferation rates did not further decrease from 2 to 4 weeks indicates that this T cell- 
independent maintenance of antibody secretion is stable over time. We suspect that TLR 
stimulation is the driving force for T-independent autoantibody production, as AM 14 B 
cells can be activated by both TLR9 and TLR7 (82), and we have shown that TLR9 
activation is required for the efficient generation of anti-DNA antibody-secreting cells in 
vivo (Chapter 5). Dendritic cell-derived factors may also be important, such as IFN-I 
(97-99) or the B cell activating factor BAFF (119). The restricted location of AM 14 
plasmablasts at defined sites in the spleen—even in the absence of CD4+ T cell 
help—suggests that cell types such as DCs could be involved in the maintenance of 
autoantibody-producing cells in SLE.
In addition to facilitating the expansion of autoreactive plasmablasts, T cells are 
likely to be required for subsequent stages of B cell differentiation, including antibody 
class switch and the generation of long-lived plasma cells or memory cells. To allow
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study of these downstream events, we have created a rheumatoid factor site-directed 
transgenic model, AM14-sdTg. Like conventional AM14 transgenic mice, AM14-sdTg 
mice do not exhibit any defect in B cell development, and also experience an age- 
dependent expansion of rheumatoid factor-secreting cells in the spleen. Importantly, the 
ability of AM14-sdTg B cells to class switch was demonstrated by the fact that the 
majority of antibody-secreting cells in aged mice produced IgG isotypes. We observed a 
different phenotype of antibody-producing cells in AM14-sdTg mice than that described 
previously for conventional AM 14 transgenics (180), as very few of these cells in AM 14- 
sdTg mice expressed detectable surface AM 14. Because most antibody-secreting cells 
from AM14-sdTg mice were class-switched to IgG, it is possible that the inability to class 
switch to IgG in conventional transgenic mice prevents IgM-producing plasmablasts from 
fully differentiating to surface Ig-negative plasma cells. This could have important 
implications for the lifespan of these cells and the durability of autoantibody production. 
The AM14-sdTg will therefore be an important tool to study the generation of antigen- 
specific, long-lived plasma cells and memory B cells in autoimmunity.
Materials and Methods
Transgenic Mice.
AM14 heavy chain conventional transgenic mice (174) were backcrossed at least 
12 generations to M R L /M p^^ mice. All seroconverted mice used for depletion of CD4+ 
T cells were between 10-20 weeks of age.
AM14-sdTg mice were created as described above, in consultation with the 
Animal Genomics Gene Targeting Service at Yale University. The targeting construct
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was created from the original AM 14 conventional transgene, except that a 1.2 kb region 
of homology to the germline DH region was added at the 5 ’ terminus and a thymidine 
kinase cassette was added at the 3’ terminus. Mutagenesis of RSS heptamers was 
performed with the Quick-Change Site-Directed Mutagenesis Kit (Stratagene) according 
to the manufacturer’s instructions. PCR screening of transfected ES cell clones was 
performed with primers within the germline DH region (5’ ATC TAC ATA GCT AGA 
GAG CTA GAG G 3’) and the neomycin resistance cassette (5’ GCA TCG CAT TGT 
CTG AGT AGG TGT CA 3’). Southern blotting of EcoRI digests of genomic ES cell 
DNA was performed with radiolabeled probe. The 1.6 kb Hindlll-EcoRI fragment 
from the targeting construct was labeled with 32P-dCTP (Amersham), using the Random- 
Primed DNA Labeling Kit (Roche) according to the manufacturer’s instructions. 
Chimeric pups derived from blastocyst injection of ES cells were first bred to Fas-intact 
MRL/Mp mice to confirm germline transmission of the AM14-sdTg transgene. Mice 
were then backcrossed 7 generations to Fas-deficient M R L /M p^ '' mice for analysis of 
seroconversion.
Depletion of CD4+ T cells and inhibition of CD40L.
CD4+ T cells were depleted with GK1.5 anti-CD4 monoclonal antibody, either 
produced in our laboratory or in a bioreactor system at the Iowa State University 
Hybridoma Facility. Hybridoma culture supernatants were purified over Protein G 
columns (Amersham) dialyzed into PBS, and filter sterilized. Purified GK1.5 was tested 
for the ability to label CD4+ T cells and concentration was determined by optical density 
at 280nm and by ELISA for rat IgG. Mice were injected i.p. with GK1.5 or control rat 
gamma globulin (Rockland) at 1.5 or 2.0 mg/ml. For most experiments, mice were
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injected with 2.0 mg of antibody twice per week (4.0 mg/week). For dose titration, mice 
were injected with either 1.0 mg twice per week (2.0  mg/week), 2.0  mg twice per week 
(4.0 mg/week), or 2.5 mg twice per week plus 3.0 mg once per week (8.0 mg/week). For 
inhibition of the T-dependent response to NP-CGG, mice were treated with 4.0 mg/week 
for one week then immunized with 100 pg NP-CGG emulsified in alum, prepared in our 
laboratory as previously described (196). Mice were then treated with GK1.5 (4.0 
mg/week) for an additional 10 days, at which time T cell depletion and antibody 
production were determined. For depletion of CD4+ T cells in non-autoimmune mice, 
BALB/c mice were injected with a single injection of 1.0 mg or two injections of 1.0 mg 
over a one week period.
CD40L was inhibited with MR-1 anti-CD40L monoclonal antibody produced in 
our laboratory. Hybridoma culture supernatants were ammonium sulfate precipitated, 
purified with QAE anion-exchange beads (Amersham), dialyzed into PBS, and filter 
sterilized. Purified MR-1 was tested for the ability to label activated T cells and 
concentration was determined by optical density at 280nm and by ELISA for hamster 
IgG. Mice were injected i.v. with 0.4 mg of MR-1 or control hamster gamma globulin 
(Rockland) three times per week for a period of 2 weeks.
Quantification of antibody production by ELISpot and serum ELISA.
ELISpot for AM 14 IgM plasmablasts was performed as previously described 
(Chapter 5). For detection of IgG-producing plasmablasts, plates were coated with either 
anti-mouse IgG2aa (20.8.3 monoclonal antibody produced in our laboratory) or a cocktail 
of polyclonal goat anti-mouse IgG2b + anti-mouse IgG3 (Southern Biotech).
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Serum levels of AM 14 IgM antibody were determined by ELISA as described 
previously (Chapter 5). For initial correlation of serum antibody and splenic 
plasmablasts, mice were sacrificed and splenic AM 14 plasmablasts determined by 
ELISpot within 2 days of serum antibody determination. For identification of 
seroconverted mice, a cohort of AM 14 mice was screened every 2-3 weeks by serum 
ELISA for AM 14 antibody, and conversion was determined by serum AM 14 > 40 pg/ml. 
Treatment with GK1.5, MR-1, or control antibodies was then begun within 3 days of 
screening. Serum levels of AM 14 IgG antibody were determined by ELISA as described 
previously, except that plates were coated with a cocktail of polyclonal goat anti-mouse 
IgG2b + anti-mouse IgG3 (Southern Biotech). Relative levels of IgG were determined by 
comparison to optical density produced by supernatant from an AM 14 IgM-transfected 
cell line in a parallel IgM ELISA.
Anti-NP antibody was determined by ELISA. Polystyrene plates were coated 
with NP-conjugated BSA (produced in our laboratory), blocked with 1% BSA in PBS, 
and serial dilutions of serum from 1:50 to 1:156,000 were added. IgG antibodies were 
detected with alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotech), 
and absorbance at 405/630nm was compared with 23.3 anti-NP monoclonal antibody 
(produced in our laboratory) to quantitate.
Analysis of lymphocyte subsets, activation markers and proliferation rates.
Spleen cells were isolated as previously described (Chapter 2). CD4+ T cells were 
identified with RM4-4 monoclonal antibody (BD Biosciences) which does not cross-react 
with GK1.5. Identification of AM14+ cells and activation marker expression was 
determined as previously described (Chapter 5). IgM and IgD, and IgG2a-expressing
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AM14-sdTg B cells were detected with anti-IgMa (RS3.1, produced in our laboratory), 
anti-IgD (11-26, eBioscience), and anti-IgG2aa (20.8.3, produced in our laboratory) 
antibodies. For determination of proliferation rates, mice were given a single i.p. 
injection of 3 mg of BrdU (Sigma) 12 hours prior to sacrifice. BrdU incorporation was 
detected with anti-BrdU antibody (PRB-1, Phoenix Flow) as previously described (197). 
Apoptosis was determined with the CaspGLOW fluorescein active caspase staining kit 
(Biovision) according to the manufacturer’s instructions.
Spleen histology.
Spleen histology was performed as previously described (Chapter 5), except that 
AM 14 cells were detected with 4-44 monoclonal antibody produced in our laboratory.
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Figure 36. Serum levels of AM14 antibody correlate with expansion of 
AM14 plasmablasts in the spleen. A cohort of AM 14 transgenic mice (n = 
33) was serially bled every two weeks and assayed for serum AM 14 antibody 
by ELISA. Mice were sacrificed between 10 and 25 weeks of age, within 2 
days of the last serum assay, and AM14 expansion in the spleen was 
determined by ELISpot for AM14-secreting plasmablasts. Dashed lines 
indicate cutoff points for what was considered a positive assay. P < 0.0001 
by Fisher’s exact test.
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Figure 37. GK1.5 inhibits CD4+ T cell function without complete depletion. (A-C) 
MRL/Mp,pr//pr mice were injected with either control antibody (n = 4) or GK1.5 
anti-CD4 antibody at 2 mg/week (n = 2), 4 mg/week (n = 6), or 8 mg/week (n = 3) over 
a 2 week period. Percentages of CD4+ T cells were determined in spleen (A), lymph 
node (B), and peripheral blood (C). (D-F) Histograms show CD4+ T cells from control 
(black line) or GK1.5-treated mice (4 mg/week, filled histogram). (D) Decreased 
surface levels of CD4 in treated mice were determined with RM4-4 antibody. (E) 
Complete opsonization of CD4+ T cells with GK1.5 in vivo was determined by ex vivo 
staining with GK1.5. (F) Activation of CD4+ T cells was determined by levels of 
CD69. (G) Splenic CD4+ T cells from control (black bars, n = 9) or GK1.5-treated 
mice (4 mg/week, white bars, n = 9) were classified as naive (CD44' CD62L+), 
activated (CD44+ CD62L+), or memory (CD44+ CD62L ) phenotype. (H) Control or 
GK1.5-treated mice were immunized with NP-CGG, and serum anti-NP IgG titers 
were determined 10 days later (Un-lmz = unimmunized control). ***, P < 0.0001 by 
Mann-Whitney U test.
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Figure 38. Removal of CD4+ T cell help reduces AM14 rheumatoid factor 
antibody secretion. (A) AM 14 antibody-secreting cells were determined in 
seroconverted mice treated with GK1.5 (n = 9) or control antibody (n = 9) for 2 
weeks, or GK1.5 (n = 7) or control antibody (n = 9) for 4 weeks, or age-matched 
non-seroconverted mice (n = 7). Data are presented as ELISpots per million 
splenocytes. (B-C) Serum AM 14 antibody was determined in mice treated with 
GK1.5 or control antibody as in A for 0, 2, or 4 weeks. *, P < 0.05; **, P < 0.01 by 
Mann-Whitney U test.
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Figure 39. Differential effects of CD4+ T cell help on AM14 B cells and 
plasmablasts. (A) Splenic AM 14 CD22+ B cells and CD22' plasmablasts were 
identified in mice treated with control antibody (upper plot) or GK1.5 (lower plot). 
(B-C) CD69 (B) and B7-1 (C) expression were determined in AM14 CD22+ B cells 
(upper plots) and CD22 plasmablasts (lower plots) from mice treated with control 
antibody (blue lines) or GK1.5 (red lines). (D) CD44 and CD69 expression were 
determined in AM 14 CD22+ B cells and CD22 plasmablasts from mice treated with 
control antibody (black bars, n = 9) or GK1.5 (white bars, n = 9). (E) As in D, 
except for B7-1 and B7-2 expression. Data presented are mice treated for 2 weeks; 
similar results were observed with 4 week treatment.
*, P < 0.05; ***, P < 0.0001 by Mann-Whitney U test.
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Figure 40. Residual proliferation of AM14 B cells and plasmablasts after 
removal of CD4+ T cell help. 12-hour BrdU incorporation was determined in 
AM 14 CD22+ B cells and CD22' plasmablasts from mice treated for 2 or 4 weeks 
with control antibody (black bars, n = 9 for 2 weeks and 4 weeks) or GK1.5 
(white bars, n = 9 for 2 weeks, n = 7 for 4 weeks). *, P < 0.05; **, P < 0.01 by 
Mann-Whitney U test.
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Figure 41. Reduced numbers of AM14 plasmablasts remain adjacent to T 
cell zones after removal of CD4+ T cell help. (A) Spleen sections from mice 
treated for 2 weeks with either control antibody (left panel) or GK1.5 (right 
panel) were stained for T cell zones with Thyl (red) and AM 14 plasmablasts 
(blue). (B) As in A, except that mice were treated for 4 weeks with either control 
antibody (left panel) or GK1.5 (right panel).
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Figure 42. Inhibition of CD40L does not eliminate AM14 plasmablasts.
(A) AM14 antibody-secreting cells were determined in serconverted mice 
treated with anti-CD40L antibody MR-1 (n = 6) or control antibody (n = 6) for 
2 weeks. Data are presented as ELISpots per million splenocytes. (B) 
Expression of CD44 and CD69 were determined in splenic AM14 CD22+ B 
cells or CD22' plasmablasts from mice treated with control antibody (black 
bars, n = 5) or MR-1 (white bars, n = 4). *, P < 0.05 by Mann-Whitney U test.
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Figure 43. Construction of AM14 site-directed transgenic mice. (A) Targeting 
construct, germline IgH locus, and final integrated transgene are shown. Neo = 
neomycin resistance cassette; AM14 = rearranged AM14 VDJ3; DQ52 = 3’ germline 
Dh gene segment; J ]3 and J4 = germline JH gene segments; Efi = IgM enhancer; Cji = 
IgM C region exons; TK = thymidine kinase cassette. Vertical lines indicate 
restriction sites: EcoRI (E), H indlll (H), Sail (S), and Xhol (X). Dashed lines 
indicate regions of homologous recombination with germline IgH locus. White 
arrows indicate site-directed mutagenesis of RSS heptamers. Black arrows indicate 
PCR primers to screen for correct upstream integration. Striped bar indicates J4 
probe used in Southern blot. (B) Southern blot of EcoRI digest of genom ic D N A  
from 3 ES cell clones which were PCR-positive for correct upstream integration. 
Germline IgH band is 6.2 kb, correct integration of transgene produces 9.4 kb band, 
indicated by asterisk in ES #80.
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Figure 44. Expression of AM14-sdTg in spleen and bone marrow B cells.
(A) Expression of CD22 and AM14 idiotype was determined in spleen cells from 
AM14 site-directed transgenic (AM14-sdTg, left panel) or transgene-negative 
littermates (right panel). (B) Expression of B220 and AM 14 idiotype was 
determined in bone marrow cells from mice as in A. (C) Expression of IgM and 
IgD (left panel) or CD21 and CD23 (right panel) was determined on splenic AM14+ 
cells from AM14-sdTgic mice. Most AM14+ cells are IgD-expressing CD2110 
CD23hl follicular B cells.
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Figure 45. Spontaneous expansion of IgG AM14 antibody-secreting cells is 
age-dependent. (A) AM 14 antibody-secreting cells of IgM, IgG2a, or IgG2b + 
IgG3 isotypes were determined in old AM14-sdTg mice (black diamonds, n = 14 
for all except IgG2a n = 6); young AM14-sdTg mice (white circles, n = 4), or 
non-transgenic mice (gray triangles, n = 6 for all except IgG2a n = 4). Old mice 
were 21 weeks of age, young mice were 7 weeks of age. (B) Serum AM14 IgG2b + 
IgG3 was determined in AM14-sdTg mice at multiple different time points (n = 17 
for all time points except < 12 weeks n = 13). *, P < 0.05; **, P < 0.01 by 
Mann-Whitney U test.
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Figure 46. Antibody-secreting cells in AM14-sdTg mice do not express surface 
antibody. (A-C) AM14 antibody-secreting cells were identified in an aged 
AM14-sdTg mouse with many splenic AM14 ELISpots. (A) Surface staining of 
CD22 and AM14 revealed few typical CD22 plasmablasts. (B) Intracellular 
staining for AM14 revealed many CD22' antibody-secreting cells. (C) The 
majority of intracellular AM14+ cells in AM14-sdTg mice are negative for surface 
AM14. (D) The majority of intracellular AM14+ cells in a seroconverted AM14 
conventional transgenic (IgM-only) mouse are surface AM14+.
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Chapter 7: Conclusions and Future Studies
The findings presented here have begun to identify the factors required for the 
activation of autoreactive B cells. We have identified TLRs as critical factors in the 
production of autoantibody-secreting cells. Individual TLRs are required for the 
generation of specific antibodies to self nuclear components, with TLR9 controlling 
antibodies to DNA-containing antigens, and TLR7 promoting the formation of antibodies 
to RNA-containing antigens. The observations that TLR3 did not affect autoantibody 
production and that TLR9 was not required for production of rheumatoid factor 
autoantibodies highlight the specificity of the interactions between TLRs and 
autoantibody targets. We have further shown that TLR expression within B cells is 
required for autoantibody secretion, and that TLRs facilitate the differentiation of mature, 
peripheral B cells into efficient antibody-producing cells. TLRs are not the sole source of 
autoreactive B cell activation, however. We also discovered that CD4+ T cell help 
contributes to the continued activation of both early-activated B cells and differentiated 
plasmablasts, even after a robust response has been established.
Our work has also illustrated some of the consequences of autoreactive B cell 
activation for global immune activation and clinical disease in the context of SLE. We 
found that in the absence of TLR9 and anti-DNA autoantibody production, lupus-prone 
mice developed exacerbated disease with accelerated mortality. This was associated with 
an increased activation state of lymphocytes and dendritic cells, as well as elevated levels 
of circulating IFN-a. Our studies of TLR9-chimeric mice revealed that these effects on 
immune activation were at least partly due to factors elaborated in the absence of TLR9
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expression in B cells. Moreover, the ability of serum from TLR9-deficient, but not wild- 
type, mice to induce high levels of IFN-a production by pDCs further suggested that 
circulating autoantibodies played a causative role in promoting inflammation and 
exacerbated disease. The opposite was true for mice deficient in TLR7, as genetic 
ablation of this receptor ameliorated clinical disease and immune activation. Because the 
autoantibody repertoire of TLR7-deficient mice was shifted away from RNA antigens 
and the autoantibody repertoire of TLR9-deficient mice was shifted toward RNA 
antigens, it is possible that the relative level of antibodies to RNA complexes dictates—or 
potentially reflects—the severity of immune activation and clinical disease. The 
observation that antibodies to Sm/RNP were correlated with disease activity in TLR9- 
deficient mice supports this hypothesis.
Pathogenic Activation Cycles Centered Around B Cells and TLRs in SLE
Positive feedback activation cycles have evolved within the immune system to 
rapidly mount effective responses against invading pathogens. These amplification loops 
between B cells, T cells, and dendritic cells become dysregulated in autoimmune disease, 
in which the constant presence of self antigen allows continued expansion and 
propagation of the immune response. In SLE, positive feedback between autoreactive B 
and T cells may be particularly important for chronic progression of clinical disease, as 
well as the phenomenon of epitope spreading to target an increasing array of endogenous 
antigens (149). Our findings further support this model of self-reinforcing activation, and 
emphasize the importance of innate immune activation via TLRs in SLE pathogenesis. In 
addition, we have also identified dendritic cell subsets as important mediators of
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inflammation and immune activation. In all these various interactions and activation 
cycles, B cells and their autoantibody products play a critical role, as diagrammed in 
Figure 47.
An initiating event in systemic autoimmunity may be the release of endogenous 
nucleic acid antigens from apoptotic or necrotic cells, and the subsequent dual 
recognition of these antigens by B cells with anti-nuclear BCR specificity and appropriate 
TLRs. An increased predisposition to autoimmune disease has been documented in 
multiple experimental systems wherein clearance of apoptotic or necrotic debris is 
impaired (36-38), and also in humans lacking complement pathways for apoptotic 
clearance (39). The recognition of RNA or DNA ligands by TLRs can occur in a B cell- 
intrinsic manner, and can then facilitate differentiation of autoreactive B cells to 
antinuclear antibody-secreting cells. Autoantibodies produced by these cells can have 
direct pathogenic effects (4, 11), promoting tissue damage, cell death, and the release of 
additional endogenous TLR ligands. These TLR ligands could then promote additional B 
cell activation, creating a B cell autonomous activation cycle involving apoptotic cells, 
nucleic acid-sensing TLRs, and autoantibodies.
We have also found that circulating factors produced when TLR9 is absent on B 
cells (presumably autoantibodies) can mediate the activation of pDCs and promote 
efficient secretion of IFN-I. The ability of IFN-I to promote antibody production (97-99) 
then completes a second activation cycle, this one between B cells and pDCs. IFN-I can 
also induce the maturation of monocytes and immature DCs into efficient antigen- 
presenting cells (88 , 100), facilitating the activation of otherwise tolerant autoreactive T 
cells. These T cells could then provide the cognate help necessary for effective
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expansion and differentiation of autoreactive B cells. In addition, because BCR-mediated 
endocytosis can be coupled to antigen-processing pathways, B cells can also function as 
APCs for autoreactive T cells (149). This then creates two additional activation cycles, 
one involving B cells, DCs, and T cells, and the other a involving a reciprocal activation 
of autoreactive B and T cells.
Finally, an important interaction between B cells and myeloid DCs may also exist 
in autoimmune disease. Immune complexes of autoantibodies and endogenous DNA 
have been shown to induce maturation and cytokine secretion by mDCs (118), and our 
results indicate that B cell-derived serum factors from wild-type or TLR9-deficient mice 
can have distinct effects on DC activation. Autoreactive B cells may therefore directly 
promote the generation of mature DCs, without a requirement for IFN-I production (198). 
Reciprocally, cytokines produced by activated DCs, particularly the TNF family member 
BAFF (199, 200), can promote autoreactive B cell survival and antibody secretion to 
complete an activation cycle between mDCs and B cells. Thus, by virtue of the 
integration of signals from receptors of the innate and adaptive immune system, and by 
the ability to coordinate the actions of both innate and adaptive effector cells, B cells 
reside at the center of multiple activation loops in the etiology and pathogenesis of SLE.
TLRs and the Evolution of Innate Tolerance to Self Antigens
We found that in the absence of anti-DNA antibodies in TLR9-deficient mice, 
autoimmune disease was not prevented but was actually exacerbated. This raised the 
possibility that these antibodies do not directly contribute to pathology in SLE, and 
furthermore, that anti-DNA antibodies could be protective against autoimmune disease.
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Similar to studies of human lupus serum (87, 114), we also found that a higher 
prevalence of antibodies to RNA-containing antigens in TLR9_/ serum was associated 
with a more potent induction of IFN-I than that induced by anti-DNA antibodies present 
in wild-type serum. It thus appeared that the recognition of endogenous DNA by TLR9 
had different effects in B cells and pDCs. While TLR9 was clearly stimulatory for 
antibody production by anti-DNA B cells, it was less effective in activating IFN-I 
secretion by pDCs. This could provide insight into the evolution of nucleic acid-sensing 
TLRs and how defense against infection is tempered by the risk of autoimmunity.
Anti-DNA and anti-chromatin antibodies are the most prevalent specificities in 
multiple autoimmune syndromes, and there is an inherent predisposition toward anti- 
DNA reactivity in the germline V gene repertoire of the BCR (201). This suggests that 
the immune system is permissive for the development of these autoantibodies, at least 
relative to other anti-nuclear specificities. In addition, because of the inherently short 
half-life of RNA, DNA is more likely to persist in the extracellular milieu, and therefore 
more likely to encounter nucleic acid-sensing TLRs than RNA. Moreover, the same 
molecular modifications that increase the stability of mammalian RNA appear to inhibit 
its recognition by TLRs, thereby further decreasing the probability of TLR activation by 
endogenous RNA (67). Assuming that autoantibody complexes can facilitate dendritic 
cell activation by endogenous nucleic acids, the high frequency of anti-DNA antibodies 
coupled with the prevalence of DNA ligands in vivo thus pose a significant risk of 
aberrant DC activation in normal individuals. Yet this risk appears to be mitigated by a 
decreased stimulatory capacity of DNA-containing complexes in the activation of pDCs
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to produce IFN-I. In other words, a high sensitivity to TLR9 ligands in B cells may have 
co-evolved with a decreased sensitivity to these ligands in pDCs.
The TLR7-mediated IFN-I response of pDCs to RNA-containing antigens, in 
contrast, is particularly robust. As described above, RNA antigens released from 
apoptotic cells or contained in serum immune complexes are potent inducers of IFN-I. 
From an evolutionary perspective, the potentially dire consequences of pDC activation by 
endogenous RNA may be acceptable in light of the low prevalence of anti-RNA 
antibodies and the rapid degradation of endogenous RNA in vivo. Thus, tolerance to 
RNA is enforced not by pDCs, but mainly by the B cell antibody repertoire and the 
efficient clearance of extracellular RNA. In this respect, it is interesting that expression 
of TLR7 in B cells is strictly regulated, unlike the constitutive expression of TLR9 in 
these cells (202). In contrast to the common occurrence of anti-DNA antibodies, the 
suppression of antibodies to RNA-containing antigens appears particularly effective, even 
in individuals with autoimmune disease.
The relative levels of antibodies to DNA- or RNA-containing antigens, produced 
by B cells in response to ligation of TLR9 or TLR7, may therefore determine the 
functional consequences of autoreactive B cell activation. While the secretion of anti- 
DNA antibodies could be compatible with self tolerance and immune homeostasis, the 
generation of high titer antibodies to RNA-containing antigens is likely to induce 
autoimmune disease. Our findings further suggest that the regulated production of anti- 
DNA antibodies may even prevent low levels of anti-RNA antibodies from achieving a 
stimulatory capacity. Of course, SLE can and does develop in the absence of detectable 
antibodies to endogenous RNA antigens. It is possible that the lack of these antibodies in
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some individuals may be attributable to technical difficulties in their detection. It is clear, 
however, that anti-DNA antibodies can also exert pathogenic effects, such as direct 
deposition and tissue injury (11), and effective production of IFN-I by pDC under 
appropriate conditions (203).
Therapeutic Implications in SLE
The studies presented here also have important implications for the treatment of 
human autoimmune disease. First, our findings in TLR-deficient mice implicate TLRs as 
important mediators of immune activation and disease, and highlight these receptors as 
potential candidates for therapeutic inhibition in SLE. However, our demonstration of 
exacerbated disease in TLR9-deficient mice provides a note of caution for TLR inhibition 
in the context of autoimmunity. Although interventions to decrease TLR9 signaling in 
human lupus patients may be able to reduce anti-DNA B cell activation and autoantibody 
secretion, such interventions may also increase the prevalence of antibodies to RNA- 
containing antigens, promote elevated IFN-I production, and lead to heightened clinical 
disease in these patients. Selective inhibitors of TLR7 would be much more promising 
therapeutic candidates. Alternatively, dual inhibition of both receptors could have more 
profound effects on autoantibody production and clinical disease than inhibition of either 
receptor alone.
We have also identified IFN-I as a potential mediator of pathogenesis in SLE, 
adding to the long history of this family of cytokines in autoimmunity (88-92). Although 
the pathogenic nature of IFN-I in autoimmune disease is not a novel concept, we have 
discovered an important role for serum factors produced in the absence of TLR9
168
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(presumably a shifted autoantibody repertoire) in the production of these cytokines in 
vivo. It may therefore be possible to decrease IFN-I production by preventing the 
autoantibody-mediated delivery of endogenous TLR ligands to appropriate compartments 
in DC subsets. This could be accomplished either by altering the autoantibody repertoire 
at the level of B cells, or by inhibiting recognition of autoantibody complexes at the level 
of responding DCs. In the case of the latter, Fc receptor-mediated endocytosis and 
intracellular activation signals are candidates for therapeutic inhibition, as are TLR 
signaling pathways. In addition, pharmacologic agents such as chloroquine, which 
inhibits the endosomal acidification required for the activation of intracellular TLRs, 
could also reduce DC-mediated inflammation in SLE. Although chloroquine has been 
used clinically for decades to treat SLE and rheumatoid arthritis, continued investigation 
of this and related compounds may provide new insights and treatment options in 
systemic autoimmunity.
Finally, our studies on the role of CD4+ T cell help in autoreactive B cell 
activation point towards T cells as additional targets of therapeutic intervention.
Although a requirement for T cells in SLE was not unexpected, the dramatic decrease in 
antibody-secreting cells that we observed after a brief period of T cell inhibition 
illustrates the dynamic, short-lived nature of the autoantibody response. The fact that 
removal of CD4+ T cell help affected antibody secretion even after the initiation of a 
robust autoimmune response makes this approach particularly relevant to the treatment of 
human disease. Therapeutic inhibition of helper T cells may be most effective during 
disease flares, when a brief treatment window can reduce inflammation back to baseline 
levels without causing excessive immunosuppression. Although pharmacologic
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inhibition of T cell function has yet to prove beneficial in human lupus patients, this is an 
area of active research (204).
Future Studies
The more we have learned about B cells and TLRs in autoimmunity, the more 
questions we have generated. Although the findings presented here represent an 
important contribution to understanding the mechanisms and consequences of 
autoantibody production in SLE, several aspects of these mechanisms remain unresolved. 
For example, we have demonstrated a shift in ANA patterns of TLR9-deficient mice 
toward cytoplasmic, presumably RNA-containing, antigens, but we have not precisely 
identified these antigens. Treatment of the ANA substrate with RNase may abolish these 
staining patterns from TLR9-deficient serum, and thereby confirm the presence of 
autoantibodies to RNA-containing complexes. In addition, we have also begun studies to 
identify specific antibodies to characteristic autoantigen targets in TLR9-deficient mice. 
Preliminary work suggests that anti-ribosomal antibodies, identified by 
immunoprecipitation of RNA from whole-cell lysates, may become more prominent in 
the absence of TLR9. Similarly, we have presented evidence of a decrease in anti- 
Sm/RNP antibodies in TLR7-deficient mice, but were unable to determine whether TLR7 
was absolutely required for the generation of antibodies to RNA antigens. We are 
therefore preparing a second cohort of TLR7-deficient mice, which should provide the 
statistical power to detect a block in anti-Sm antibodies. In addition, we can extend our 
analysis to include other RNA-containing antigens such as those which appear to be 
targeted in TLR9-deficient mice.
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Another area of uncertainty is the mechanism of exacerbated or ameliorated 
disease in the absence of TLR9 or TLR7, respectively. Although we have provided 
evidence that the circulating autoantibody repertoire in TLR-deficient mice can influence 
dendritic cell activation and cytokine secretion, we have not established a molecular 
mechanism for this, nor have we documented how it translates to clinical disease activity. 
Because we suspect that immune complexes of autoantibodies and endogenous nucleic 
acids induce IFN-I production, we can utilize existing genetic models to establish a 
mechanism of disease pathogenesis. Genetic ablation of Fc gamma receptors in TLR9+/+ 
or TLR9 /_ mice can be achieved by breeding with Fcergltml mice (118), and the 
requirement for FcR signaling in mediating exacerbated disease can then be determined. 
AM14-sdTg mice may also provide insights into the requirement for IgG immune 
complexes in disease. Comparison of conventional AM 14 transgenic mice with AM 14- 
sdTg mice, which should have the same repertoire of autoantibody specificity, should 
allow us to determine what role class-switching to IgG isotypes plays in disease 
pathogenesis. Finally, combining TLR9-deficiency with IFN-I-deficiency in IFNAR-l '' 
mice (92) will allow us to identify the potential role of IFN-I in disease pathogenesis.
Another mechanism for increased disease severity in TLR9-deficient mice could 
be the failed clearance of apoptotic debris. The ability of IgM antibody to promote 
phagocytosis of apoptotic cells has been recently reported (205), and it is possible that 
anti-DNA antibodies fulfill a physiologic role in promoting the clearance of exposed 
DNA on fragments of dead and dying cells. The absence of anti-DNA antibodies in 
TLR9-deficient serum could then lead to an increase in circulating nucleic acid antigens 
derived from apoptotic cells, thereby facilitating TLR-mediated recognition of these
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antigens and promoting generalized inflammation. In a series of preliminary 
experiments, we have yet to identify any defect in phagocytosis of apoptotic cells in 
TLR97 mice or an impairment of TLR97 serum in promoting phagocytosis. More 
studies are planned to further evaluate this potential mechanism, such as quantification of 
circulating DNA in TLR97 serum, and identification of apoptotic cells in situ within 
secondary lymphoid organs.
As discussed in chapter 4, the nature of the interferon-stimulatory factor in serum 
from TLR9-deficient mice remains an enigma. Because of the high probability that 
autoantibodies are central to pDC stimulation, an initial first step will be to purify IgG 
fractions from serum, and ascertain whether interferon-stimulatory capacity is retained. 
Digestion of serum samples with RNase or DNase will also reveal whether pre-formed 
nucleic acid complexes are required for stimulation, or whether nascent complexes are 
formed during culture conditions. Additionally, stimulation with serum from TLR7- 
deficient mice will reveal what role the autoantibody repertoire has in promoting IFN-I 
secretion. At the level of the responding cells, it is clear that TLR9 expression is not 
required for IFN-I production. We suspect that TLR7-mediated recognition of RNA 
antigens is the mechanism of pDC activation, and that the IFN-I response will be 
abrogated in TLR7-deficient DCs. It is also possible that either TLR7 or TLR9 can 
promote IFN-I production, and we therefore plan to generate mice doubly-deficient for 
both of these receptors. Analysis of DC stimulation as well as clinical disease and 
autoantibody production in these mice will be highly informative.
Finally, several groups have recently reported the existence of novel innate 
sensors of cytosolic RNA and DNA that can induce IFN-I production by a TLR-
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independent mechanism (60-63), and that this pathway may be activated by endogenous 
DNA under appropriate conditions (166). It will thus be important to determine whether 
IFN-a. production induced by TLR9-deficient serum, or the exacerbated clinical disease 
in TLR9-deficient mice can be attributed to these TLR-independent pathways of immune 
activation. Analysis of clinical disease and IFN-I production in mice deficient for 
MyD88, the shared adaptor protein required for signaling through TLR7 and TLR9, will 
allow us to identify the relative contribution of TLR-dependent and -independent sensors 
of endogenous nucleic acid antigens. It is possible that the study of these TLR- 
independent activation pathways will reveal another dimension in the pathogenesis of 
SLE. If so, this could uncover yet another mechanism whereby innate immune signals 
instruct and regulate the activity of the adaptive immune system in health and disease.
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Figure 47. B cells at the center of immune activation cycles in SLE.
(1) Endogenous DNA- and RNA-containing antigens released by apoptotic and 
necrotic cells activate TLRs within autoreactive B cells, allowing differentiation to 
anti-nuclear antibody-secreting cells. Autoantibodies produced by these cells (blue 
arrows) can have direct pathogenic effects, releasing additional endogenous TLR 
ligands and promoting autoreactive B cell activation (B cell autonomous activation 
cycle). (2) Autoantibody immune complexes activate pDCs, inducing production of 
IFN-I (red arrows). IFN-I then acts upon B cells to promote antibody secretion (B 
cell-pDC activation cycle). (3) IFN-I induces maturation of monocytes or immature 
DCs into effective antigen presenting cells. Autoantibody immune complexes can also 
facilitate myeloid DC activation. (4) Mature dendritic cells activate cognate T cells 
(purple arrows) to produce autoreactive effector T cells, and IFN-I promotes T cell 
polarization to inflammatory TR1 effectors. Activated T cells may have direct 
cytotoxic effects on host tissues (dashed arrow). (5) Activated helper T cells provide 
additional stimulation to autoreactive B cells (purple arrows) for efficient antibody 
production (B cell-DC-T cell activation cycle). B cells can also reciprocally present 
antigen to cognate T cells (B cell-T cell activation cycle). (6) Cytokines such as BAFF 
produced by activated dendritic cells (green arrow) promote autoreactive B cell 
survival and antibody secretion (B cell-DC activation cycle).
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